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Drug response is a complex trait that shows significant interpatient variability. It has been 
suggested that response rates to major therapeutic classes of drugs range from 25 to 60 
percent [1]. To a certain extent this variability may be explained by genetic variation. The 
concept of interindividual differences in drug response was proposed as early as 1909 
[2]. However, current clinical practice hardly considers genetic variation a relevant factor 
during the processes of drug prescribing and dispensing. Pharmacogenetics is the study 
of variations in DNA sequence as related to drug response [3]. The ultimate goal of 
pharmacogenetics is to predict and thereby improve drug response in the individual patient. 
After the completion of the Human Genome Project in 2003, genomics has become a 
mainstay of biomedical research and pharmacogenetics has been forecasted to be one of 
the first clinical applications arising from the new knowledge [4]. Indeed, the research 
efforts in the field of pharmacogenetics expressed as the number of publications listed 
on PubMed have steadily increased until leveling out in 2009 at 1100-1200 publication 
per year (Figure 1.1) [5].
By contrast, the clinical use of pharmacogenetic testing did not meet the initial high 
expectations and has lagged considerably behind, despite the significant body of evidence 
supporting its usefulness. As a result of the unmet promises many clinicians have become 
somewhat disillusioned regarding pharmacogenetics in recent years. Indeed, expectations 
of the effect of a single polymorphism on drug response were unrealistically high [6]. Still, 
pharmacogenetics holds the promise of advancing drug therapy. 
The aim of this thesis is to identify the reasons for the slow clinical translation of 
pharmacogenetics and to explore and expand possible solutions to address these obstacles.
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Figure 1.1 Hits on PubMed using the search string “pharmacogenetics OR pharmacogenomics”.
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Basic principles of pharmacogenetics
A gene is a part of the DNA that codes for a type of protein or for a RNA chain that has a 
specific function in the organism. There are two alleles per autosomal gene (one paternal 
and one maternal) with one allele on each of the two chromosomes of a chromosome 
pair [7]. Together the two alleles form the genotype. Heterozygotes have two different 
alleles, and homozygotes have two of the same alleles. Genetic variation can consist of 
deletions, insertions, inversions, and copy number variation [8]. Most sequence variations 
are single nucleotide polymorphisms (SNPs), a single DNA base pair substitution that 
may result in a different gene product. As a result of this genetic variation many genes 
have multiple variants. The most common allele in a population is referred to as the wild 
type. Some of the variant alleles code for non-functional or decreased functional proteins. 
Allele frequencies can vary greatly in different ethnic populations. Phenotype refers to 
the trait resulting from the protein product encoded by the gene.
Outline of the thesis
This thesis is divided into four parts. The first part aims at identifying obstacles and possible 
solutions for the clinical implementation of pharmacogenetics. In the second part, issues 
related to the quality control of pharmacogenetic testing are discussed. In the third part the 
influence of genetic variation on the response to sulfonylureas (SUs), a class of commonly 
used oral antidiabetic drugs used in the treatment of Type 2 diabetes mellitus (T2DM) 
patients, is used as a case model to investigate the possibilities for pharmacogenetics in 
primary care. The fourth part contains the general discussion and summary. 
In Chapter 2 possible obstacles for the clinical implementation of pharmacogenetics are 
investigated and solutions to overcome these obstacles are identified. In the next chapter 
one of the identified solutions, the development of clinical guidelines to aid the use of 
pharmacogenetic tests, is investigated in detail (Chapter 3). Chapter 4 describes the 
results of a pilot experiment to investigate the technical feasibility of pharmacogenetic 
screening in primary care. In this chapter also the potential impact of the pharmacogenetic 
guidelines described in Chapter 3 is investigated. 
The application of pharmacogenetics in clinical practice may result in the adjustment of 
treatment of individual patients. Therefore, genotyping of patients in a routine clinical 
setting requires robust and reliable genotyping methods and good quality control is of great 
importance. Chapter 5 discusses the use of plasmid-derived samples as quality controls. A 
second issue related to quality control of pharmacogenetic tests is the exclusion of SNPs 
because of poor genotyping. Several studies have reported difficulties in genotyping 
rs757210, a SNP in the gene coding for hepatocyte nuclear factor 1β. Chapter 6 describes 
our experiments to find alternative methods to genotype this SNP. 
1 general introduction
The third part of this thesis is devoted to the investigation of the influence of genetic 
variation on the response to SUs. SUs are part of the mainstay of treatment with oral 
antidiabetic drugs. We selected SU treatment as a case model to investigate the potential 
role of pharmacogenetics in primary care for three reasons. First, most T2DM patients are 
treated in primary care. Secondly, there is significant interpatient variability in response 
to SUs, with approximately 10-20% of the patients experiencing primary failure. Thirdly, 
SUs are metabolized by the polymorphic enzyme CYP2C9. This enzyme also plays an 
important role in the metabolism of many other drugs frequently used in primary care. 
Chapter 7 describes the application of the classic candidate gene approach to investigate 
the effect of SNPs in CYP2C9 on the response to SUs. In Chapter 8 a different approach 
is applied. In 2007, multiple T2DM risk alleles have been identified from genome-wide 
association studies. From the identified T2DM risk alleles a panel of 20 consistently 
replicated SNPs appears of which the majority has been associated with the process 
of insulin release from the pancreatic beta-cells. We hypothesized that this panel of 20 
SNPs not only confers to an increased risk for T2DM but also influences response to SU 
treatment. Finally the results from the presented studies are put into perspective and a 
future outlook is described in Chapter 9.
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Pharmacogenomics is one of the first clinical applications of the postgenomic era. It 
promises personalized medicine rather than the established “one size fits all” approach to 
drugs and dosages. The expected reduction in trial and error should ultimately lead to more 
efficient and safer drug therapy. In recent years, commercially available pharmacogenomic 
tests have been approved by the Food and Drug Administration (FDA), but their 
application in patient care remains very limited. More generally, the implementation 
of pharmacogenomics in routine clinical practice presents significant challenges. This 
article presents specific clinical examples of such challenges and discusses how obstacles 




In 2003 the International Human Genome Sequencing Consortium declared that 
the Human Genome Project had been completed, raising expectations of clinical 
application in the near future. Pharmacogenomics (PGx) (here used synonymously with 
pharmacogenetics [Box 2.1]), promising the end of “one size fits all” drugs and of trial and 
error in pharmacotherapy, is often predicted to be one of the first such applications [1]. 
The concept of interindividual differences in drug response was proposed as early as 
1909 by Garrod in his book The Inborn Errors of Metabolism [2]. Today, the concept of 
PGx, namely that variation in drug response is related to genetic variation, is widely 
recognized. Two commercially available PGx tests that support the personalization of 
drug treatment have already received FDA approval. The tests detect variations in the 
genes coding for enzymes involved in drug metabolism: cytochrome P450 CYP2C19 and 
CYP2D6 (Roche AmpliChip, http://www.roche.com/), and UDP-glucuronosyltransferase 
(Invader UGT1AI Molecular Assay; Third Wave Technologies, http://www.twt.com/). 
Examples of these and other PGx tests actually being used in patient care are sparse, 
however. Recent surveys in Germany and Australia reported that only a small number of 
laboratories offer PGx testing for clinical use [3,4]. Current and potential future uses of 
PGx tests are summarized in Table 2.1.
This article focuses on challenges in the translation of PGx to clinical practice. Six challenges 
associated with consecutive phases in the translation process are discussed (Figure 2.1). 
Each of the identified challenges is exemplified by situations from clinical practice, and 
possible approaches to overcome them are discussed.
2 challenges for translating pharmacogenetics
BOX 2.1 
A matter of definitions
In many publications the terms pharmacogenetics (PGt) and pharmacogenomics 
(PGx) are used interchangeably while others distinguish between the two concepts 
[54–56]. We prefer to use the single term PGx with the following definition: “the 
individualization of drug therapy through medication selection or dose adjustment 
based upon direct (e.g., genotyping) or indirect (e.g., phenotyping) assessment of 
a person's genetic constitution for drug response.” This definition includes tests 
operating at protein, metabolite, or other biomarker levels whenever these factors 
are affected by genetic variation (i.e., single nucleotide polymorphisms, insertions, 
deletions, microsatellites, variance in copy number, etc). Both germline (i.e., heritable 
mutations) as well as somatic mutations (i.e., nonheritable mutations in, for example, 
tumor specimens) are considered. Therefore, immunohistochemical tests such as that 
for HER2/neu are considered a PGx test in the context of this article.
Players in the field
In the challenges presented in Figure 2.1, several “players” can be identified [5], 
including the biotechnology and analytical industry, the pharmaceutical industry, research 
institutions, funding agencies, regulatory agencies, clinicians, and patients. These players 
each have substantial roles, both individually and in collaboration, in developing and 
implementing clinical applications of PGx.
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Table 2.1 Use of PGx in clinical practice
Current Future
Primarily diagnostic; retrospective Prevention of toxicity and treatment optimization; prospective
Specific test in individual Population-wide screening 
Focus on adverse drug events Focus on therapy selection 










Providing scientific evidence for 
improvement in patient care by 
PGx testing
Selecting clinically relevant 
PGx tests
Providing data on diagnostic test
criteria of PGx testing 
Providing information on 
cost-effectiveness and 
cost-consequences of PGx testing
Improving acceptance of PGx 
testing
Developing guidelines directing the
clinical use of PGx test results
As an early step in this process, the biotechnology and analytical industry must develop 
fast, reliable, and affordable assays for routine PGx measurement. The reaction of the 
pharmaceutical industry to the concept of PGx has been reserved, possibly because of 
the potential for market segmentation and an end to the era of blockbuster drugs (Box 
2.2) [5]. Nonetheless, a 2001 report stated that by applying genomics technologies, the 
investments to develop a drug could be reduced by as much as $300 million and two 
years [6]. Further, the influence of the pharmaceutical industry on the translation of PGx 
to the clinic, although considerable, should not be overestimated. Manufacturers can be 
expected to pursue development of PGx tests only for new compounds and not for drugs 
already marketed. The latter would most likely be of interest to research institutions, for 
example academic medical centers.
Indeed, most of our PGx knowledge comes from clinical studies initiated by research 
institutions. The importance of adequately designed original studies on associations 
between genetic variation and clinical drug response needs to be recognized by funding 
agencies, including health insurers and governmental agencies [7]. In recent years, many 
172 challenges for translating pharmacogenetics
BOX 2.2 
PGx need not be financially unattractive from a drug manufacturer’s 
point of view
The potentially smaller market for a drug could be compensated by (1) an increased 
rate of adoption of the drug; (2) the identification of patients who otherwise would not 
have been candidates for the drug; (3) increased compliance with improved efficacy; 
and (4) the possibility of premium pricing [57]. This process can be illustrated with 
preliminary calculations of the use of the tumor necrosis factor alpha-blocking drug 
adalimumab used in the treatment of rheumatoid arthritis.
The prevalence of rheumatoid arthritis in adults in The Netherlands is 1%, resulting 
in approximately 160,000 potential users of adalimumab. The estimated cost 
for the treatment of all these patients with adalimumab during one year is about 
€1,900,000,000. To limit the costs, the use of adalimumab has been restricted to 
treatment of patients with moderate to severe rheumatoid arthritis failing to respond 
on disease-modifying antirheumatic drugs or methotrexate. As a result, only 3,440 
patients, or 2.15% of the potential 160,000, used the drug in 2005. When a certain 
PGx test enables predicting the response to adalimumab, there would be no legitimate 
reason to withhold the drug from the predicted responders; and if the prevalence of 
the responsive genotype were to exceed 2.15% in the rheumatoid arthritis patient 
population the revenues of the manufacturer would increase.
projects have been funded, and even prospective studies on dose recommendations are 
now being performed. In addition, these agencies will have to be convinced to reimburse 
routine PGx testing, which will require extensive information on cost-effectiveness and 
cost-consequences of PGx testing.
Regulatory agencies, such as the European Agency for the Evaluation of Medicinal 
Products and the FDA could play a role by recommending or requiring PGx testing 
for certain drugs, which would obviously provide a strong stimulus. In 2004 and 2005 
the FDA approved label changes of 6-mercaptopurine and irinotecan to include PGx 
information; recommendations for other drugs, such as warfarin, may follow [8,9]. In the 
case of irinotecan, however, results not fully supporting the dose adjustment included in 
the label change have been reported [10]. To date, mandatory testing is mentioned only 
in the package insert of trastuzumab [11]. The FDA has issued a guidance for industry 
on the subject of PGx and is encouraging voluntary data submission [12]. More recently 
the FDA and the European Agency for the Evaluation of Medicinal Products have issued 
a joint procedure for the voluntary submission of PGx data [13].
Following the increase of evidence of clinical relevance and number of available tests, 
physicians and clinical pharmacists need to become informed about the usefulness and 
also the limitations of PGx tests in patient care. Patients and patient advocacy groups also 
can have significant influence on PGx implementation.
CHALLENGES FOR IMPLEMENTATION OF PGx
Providing scientific evidence for improvement in patient care by PGx testing
On 16 August 2006, a search we did of the medical literature with the MeSH term 
“pharmacogenetics” on PubMed resulted in 3,347 hits, of which 1,487 —almost 45%—
were review articles. The relative paucity of original research articles is not the only 
problem. Many original articles involve a small, specific study population, administration of 
single doses, use of healthy volunteers instead of patients, or use of a different translation 
from genotype to phenotype. Moreover, most positive association studies lack validation 
of findings in an independent patient population.
A classic application of PGx, often used as an example of its potential clinical consequences, 
involves the variable effect of the antidepressant nortriptyline (NT) due to differences 
in the gene encoding cytochrome P450 family member CYP2D6. The plasma levels of 
NT may vary almost 10-fold depending on the number of functional CYP2D6 alleles. 
However, the scientific literature reveals a lack of solid evidence that, in the case of NT, 
the CYP2D6 polymorphisms actually lead to significant clinical consequences, such as 
increased toxicity or decreased drug efficacy.
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The Pharmacogenetics Working Party of the Royal Dutch Society for the Advancement of 
Pharmacy is working to implement PGx into their automated medication control database, 
which is to be used in computerized physician and pharmacist order entry systems (http://
farmacogenetica.knmp.nl/). Table 2.2 summarizes their recently conducted systematic 
literature search for evidence to define NT dose recommendations for different CYP2D6 
genotype-predicted phenotypes (search terms available upon request).
Only nine scientific articles concerning the interaction between CYP2D6 and NT, 
encompassing a total study population of 193 participants, could be retrieved. Among 
these participants there were only 15 poor metabolizers and 12 ultrarapid metabolizers 
(UM). Furthermore, the studies frequently were single-dose experiments with healthy 
volunteers or were limited to specific populations, such as Korean inhabitants or geriatric 
patients. Most study end points were pharmacokinetic, confirming that CYP2D6 genotype 
has an impact on NT pharmacokinetics. However, no drug efficacy or toxicity data 
were reported. Therefore, even for what is considered a classic example of PGx, solid 
scientific evidence for clinical relevance is still lacking. In a recent article Kirchheiner et 
al. [14] provide an overview of how better-designed studies are needed for the clinical 
breakthrough of PGx and how this breakthrough could be realized by a more systematic 
inclusion of PGx in drug development.
Selecting clinically relevant PGx tests
Research in the field of PGx should be focused on the development of diagnostic tests for 
clinically important problems. Not every association study leads to a potentially useful PGx 
test, and financial and technical resources may be wasted if the relevance of more readily 
measurable values is not excluded first [15]. For example, the 5-hydroxytryptamine 3 
receptor antagonists used to prevent nausea and vomiting are known to be metabolized by 
CYP2D6. Kim et al. showed genotype-dependent pharmacokinetics in healthy volunteers for 
tropisetron [16], suggesting a hypothesis that cancer patients who are UM are undertreated 
by a standard dose of tropisetron. This hypothesis was studied by Kaiser and colleagues in 
270 cancer patients. Patients with a high number of functional CYP2D6 alleles experienced 
more nausea and episodes of vomiting [17]. A similar result was found in patients receiving 4 
mg of ondansetron to prevent postoperative nausea and vomiting [18]. These findings clearly 
show the influence of UM phenotype on both pharmacokinetics and clinical effectiveness of 
5-hydroxytryptamine 3 receptor antagonists. However, due to the low prevalence of UM 
genotype in people of northern European descent, the “number needed to genotype” (i.e., 
the number of patients needed to genotype in order to prevent one patient from unnecessary 
nausea and vomiting) appeared to be 50. This number is probably too high to implement 
this PGx test into routine clinical practice and, more importantly, easier methods such as 
dose titration or the use of an alternative antiemetic regimen are already available to prevent 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































nausea [19]. PGx studies should be encouraged in fields where the likelihood of a clinically 
relevant effect is high and its potential usefulness is evident in clinical practice (Table 2.3).
Providing data on diagnostic test criteria of PGx testing
To be clinically useful, a PGx test must predict the outcome of drug treatment. Complex 
pathways are involved in the action and metabolism of most drugs, and nongenetic 
influences also contribute to drug response [15]. Therefore, PGx testing for single 
polymorphisms may account for only part of the variability in drug response. The 
diagnostic test criteria sensitivity, specificity, and predictive value are applicable to tests 
for which response is determined as a dichotomous variable. However, drug response 
cannot always be considered an all-or-none phenomenon. In these situations the relative 
contribution of the genotype to the variability in response (the percentage explained 
variance, R2) provides additional information. Diagnostic test criteria of PGx tests are not 
commonly reported, but are important for clinical implementation. Table 2.4 summarizes 
the characteristics of selected PGx tests.
It can be observed that the diagnostic test criteria for PGx tests are comparable to those 
of clinically available non-PGx tests (also shown in Table 2.4). Thus, while some consider 
current PGx tests as having inadequate value for clinical application, tests with comparable 
diagnostic test criteria are currently being used in patient care. The need for well-defined 
PGx test criteria has been previously discussed [20,21]. We maintain that demonstration 
of potential clinical usefulness requires the reporting of diagnostic test criteria in PGx 
association studies.
Providing information on cost-effectiveness and cost-consequences of PGx 
testing
Although funding agencies including health insurers have funded many PGx research 
projects in recent years, their willingness to reimburse routine PGx testing will require 
information on cost-effectiveness and cost-consequences. In 2004, Phillips performed a 
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Table 2.3 High likelihood of clinical relevance of PGx test
Drug characteristics
Narrow therapeutic index (i.e., high chance of toxicity)
Difficulty predicting response or adverse effect
Large interindividual variability in response
Consistent PK-PD relationship
Long-term treatment






























































































































































































































































































































































































































































































































































































































































































































































































































































systematic literature review on cost-effectiveness of PGx testing [22]. Only 11 published 
true cost-effectiveness analyses (CEAs) could be retrieved. Seven studies found a PGx-
based strategy to be cost-effective, two showed equivocal results, and two concluded that 
a PGx-based strategy was not cost-effective. Despite the publication of additional CEAs 
of PGx, there is a need for more information [23–26]. The performance of such CEAs 
is problematic for two reasons. First, there are limited data on the rate at which PGx 
testing actually prevents adverse drug reactions. Second, PGx test prices are dropping 
continuously. Even without data from a comprehensive CEA, some simple calculations 
can be made and preliminary conclusions can be drawn on potential cost-effectiveness 
of PGx testing (Box 2.3).
The example in Box 2.3 indicates that screening for dihydropyrimidine dehydrogenase 
(DPD) deficiency in all 5-fluorouracil (5FU)-treated patients is not cost-effective, mainly 
due to the low incidence of DPD deficiency and the high cost of the phenotypic assay. 
24
BOX 2.3 
Estimated potential cost-effectiveness of DPD screening
The cytotoxic drug 5FU is widely used, for example in colorectal cancer. Severe 
neutropenia is associated with deficiency of the enzyme DPD, which metabolizes 
5FU [58]. The deficiency of DPD is thought to be caused by germline mutations in 
the gene encoding DPD.
A possible strategy would be to test all 5FU-treated patients, and we estimate the 
cost consequences for the Dutch situation as follows. About 7,000 patients per 
year are treated with 5FU. A phenotypic test measuring DPD activity in peripheral 
mononuclear cells is available, and normal values for enzyme activity in both wild-type 
and heterozygotes are known, but are relatively difficult to distinguish. The incidence 
of DPD deficiency is about 3% and, therefore, 210 patients of the 7,000 5FU-treated 
patients may be detected by this test [59].
In a meta-analysis on 5FU-related toxicity it was reported that the incidence of 5FU-
related death is about 0.5%, and in 50% of the cases toxicity was explained by deficiency 
of the enzyme DPD [60]. The cost of the DPD assay is €850, which would result in 
an estimated cost of nearly €6 million to test all 7,000 patients for DPD status. This 
testing would save 17 patients per year, at a cost of €350,000 per saved life, which 
may be unrealistically high. Moreover, even then, 17 other patients will die from 
5FU-related toxicity anyway, because their toxicity is not related to DPD deficiency. 
Although this example is evaluated in a Dutch setting the data and conclusion can be 
applied to other settings.
It might become cost-effective if the cost of the assay decreases. Circumstances that 
favor the cost-effectiveness of PGx testing include high prevalence of the relevant allelic 
variant in the target population, good correlation between genotype and phenotype, 
satisfactory diagnostic test criteria, phenotype associated with significant morbidity or 
mortality if left untreated, and significant reduction in adverse drug reactions reduction 
by PGx testing [27].
Although the necessity of CEAs for every new clinical technique is debatable, and several 
innovations have found their way to application without proof of their cost-effectiveness 
[28,29], more research on the cost-effectiveness and cost-consequences of PGx testing 
will nonetheless stimulate its further implementation into clinical practice.
Developing guidelines directing the clinical use of PGx test results
PGx studies published to date usually report that carriers of a specified genotype in a 
particular patient population have an increased likelihood of a desired (or undesired) 
outcome of drug treatment. Such studies have not, however, resulted in the distillation 
of practical prescribing recommendations based on genotype. In particular, very little 
data are available on effective and safe dose adjustment for the different metabolizer 
phenotypes, although a 2001 consensus paper on deriving CYP2D6 phenotype-
related dose recommendations for antidepressants from pharmacokinetic study data 
represents an early step [30]. Coumarins used in the treatment and prevention of venous 
and thromboembolic disorders constitute one case in which the application of dose 
recommendations is relatively far advanced. Coumarins (e.g., warfarin, phenprocoumon, 
acenocoumarol) are primarily metabolized by CYP2C9, and treatment outcome is known 
to be associated with CYP2C9 genotype [31–39]. More recently, the gene coding for 
the vitamin K epoxide reductase subunit 1 (VKORC1) was found to contribute to the 
variability in response observed in warfarin users [40].
The effect of CYP2C9 and VKORC1 genotype combined with patient height explained 
up to 55% of variance in warfarin dose [41]. Two prospective (pilot) studies concluded 
that the use of an algorithm including CYP2C9 genotype for warfarin dosing is feasible 
[42,43], and prospective research is ongoing in the UK. Therefore, prospectively validated 
coumarin dosing algorithms that include PGx information might become available in the 
near future. In more recent developments, Wessels et al. have developed a clinical scoring 
system based on seven factors, including four genetic polymorphisms, to predict efficacy 
of methotrexate monotherapy in rheumatoid arthritis patients. They provide a tool that 
translates the outcome of the model into individual treatment recommendations [44]. De 
Leon et al. have published clinical guidelines for using CYP2D6 and CYP2C19 genotypes 
in the prescription of antidepressants or antipsychotics [45]. Further translational research 
aimed specifically at the practical application of PGx in clinical situations is warranted.
252 challenges for translating pharmacogenetics
Improving acceptance of PGx testing
A newly introduced drug or technology is normally first applied by a small group of 
clinicians. In time it may become standard treatment incorporated into guidelines and 
consequently into wider clinical use. The time from introduction to acceptance of new 
methods may vary widely, as illustrated by a comparison of the implementation of 
Calvert’s formula with that of HER2/neu testing. Carboplatin is currently dosed using 
the formula of Calvert, published in 1989, for area-under-the-curve targeted dosing [46]. 
Attention was called to Calvert’s formula several times but it was not until 1996 that it 
was reported by the American Hospital Formulary Service, a widely used source of drug 
information [47,48]. Assuming that uptake into guidelines to some extent represents 
clinical acceptance, this time course shows that it took no less than seven years for Calvert’s 
formula to be accepted. This relatively slow acceptance is further exemplified by the limited 
use of the formula in clinical trials with carboplatin during the early 1990s (Figure 2.2).
A contrasting example is the implementation of testing of breast cancers for HER2/neu 
overexpression with immunohistochemistry or fluorescence in situ hybridization to select 
Figure 2.2 The use of the Calvert formula in clinical trials from 1989 to 1998. A PubMed search for 
the dosing of carboplatin in clinical trials was performed for the period 1989–1998. For each year 
the first ten results of PubMed were screened for the use of the Calvert formula. Bars represent the 
percentage of results in which the Calvert formula was used to dose carboplatin (A), the Calvert 



















patients with metastasized breast cancer eligible for treatment with trastuzumab. In the late 
1980s and early 1990s, several studies demonstrated that breast cancers with HER2/neu 
overexpression showed poor prognosis [49–53]. In 1998 trastuzumab, a monoclonal drug 
directed against the HER2 protein, was launched on the US market. One year later, testing 
for HER2/neu overexpression was included in the American Hospital Formulary Service 
trastuzumab monograph. Testing for HER2/neu overexpression has become standard 
practice for guiding drug therapy for metastatic breast cancer. In contrast to the lengthy 
time line for acceptance of Calvert’s formula, the short time line of acceptance of testing 
for HER2/neu overexpression indicates that fast uptake is possible. The two examples 
differ in many respects (e.g., one results in a dose adjustment while the other results in 
the decision whether or not to prescribe the drug). Nonetheless, two differences might 
be observed to present potential opportunities for improved clinical uptake of PGx. First, 
the use of testing for HER2/neu overexpression was required by the regulatory agencies 
upon market introduction of trastuzumab. With regard to PGx testing, this requirement 
suggests that obligatory testing prior to drug prescribing might give a strong stimulus 
to the clinical uptake of PGx. Second, HER2/neu testing was actively advocated by the 
pharmaceutical company manufacturing the drug and by patient advocacy organizations. 
Similarly active support for the use of clinically established PGx tests by pharmaceutical 
companies or patient advocacy organizations might be expected to improve clinical uptake 
of PGx testing.
CONCLUSIONS
Because variation in drug responses is, at least to some extent, related to genetic variation, 
PGx testing has the potential to result in safer and more effective use of drugs by permitting 
individualized therapy. In recent years FDA-approved PGx tests have become available, 
but the use of PGx testing has remained limited, largely by a lack of scientific evidence 
for improved patient care by PGx testing. Providing this scientific evidence presents a 
significant challenge. The development of novel tests should be aimed at solving important 
clinical problems. To demonstrate potential for clinical use, PGx studies should report 
diagnostic test criteria. For PGx tests shown to improve patient care, guidelines directing 
the clinical use of PGx test results should be developed. Information on cost-effectiveness 
and cost-consequences of PGx testing should be provided to facilitate reimbursement 
by insurance companies. Finally, uptake in clinical practice will be given a stimulus if 
regulatory agencies recommend testing prior to prescribing the drug, and if pharmaceutical 
companies or patient groups advocate for use of the test. If the outlined challenges can 
be met, the incorporation of PGx in routine clinical practice may prove an achievable 
goal in the near future.
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Despite initial enthusiasm [1–3], the use of pharmacogenetics has remained limited to 
investigation in only a few clinical fields such as oncology and psychiatry [4–8]. The main 
reason is the paucity of scientific evidence to show that pharmacogenetic testing leads to 
improved clinical outcomes [9,10]. Moreover, for most pharmacogenetic tests (such as tests 
for genetic variants of cytochrome P450 enzymes) a detailed knowledge of pharmacology is 
a prerequisite for application in clinical practice, and both physicians and pharmacists might 
find it difficult to interpret the clinical value of pharmacogenetic test results. Guidelines 
that link the result of a pharmacogenetic test to therapeutic recommendations might help 
to overcome these problems, but such guidelines are only sparsely available. In 2001, an 
early step was taken to develop such guidelines for the therapeutic use of antidepressants, 
and these included CYP2D6-related dose recommendations drawn from pharmacokinetic 
study data [11]. However, the use of such recommendations in routine clinical practice 
remains difficult, because they are currently outside the ambit of the clinical environment 
and are not accessible during the decision-making process by physicians and pharmacists, 
namely the prescription and dispensing of drugs.
It was for these reasons that the Royal Dutch Association for the Advancement of Pharmacy 
established the Pharmacogenetics Working Group (PWG) in 2005. In this 15-member 
multidisciplinary working group, clinical pharmacists, physicians, clinical pharmacologists, 
clinical chemists, epidemiologists, and toxicologists are represented. The objective of the 
PWG is to develop pharmacogenetics-based therapeutic (dose) recommendations on 
the basis of a systematic review of literature, and to assist the drug prescribers as well 
as the pharmacists by integrating the recommendations into computerized systems for 
drug prescription and automated medication surveillance. The recommendations do not 
indicate patients who are eligible for genotyping, but merely aim to optimize drug use 
in the small but ever-increasing group of patients whose genotypes are known.
In the Netherlands, computerized drug prescription and automated medication surveil-
lance are well organized, and the majority of general practitioners as well as nearly all the 
community and hospital pharmacists use such a system [12]. Most of these automated 
medication systems use the G-standard, an extensive electronic drug database [13]. 
The therapeutic (dose) recommendations composed by the PWG are incorporated 
into the G-standard, thereby directly linking the pharmacogenetics-based therapeutic 
(dose) recommendations to the decision-making process. The first recommendations 
were released with the October 2006 edition of the G-standard. To our knowledge, 
the PWG initiative is the first to integrate pharmacogenetic test results and therapeutic 
(dose) recommendations into automated medication surveillance systems to be applied 
nationwide. In this article, we describe the procedures followed by the PWG for structured 
pharmacogenetic data collection, assessment, and subsequent synthesis of therapeutic 
(dose) recommendations. Furthermore, we report the first 26 defined recommendations 
included in the G-standard.
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STRUCTURED ASSESSMENT OF GENE-DRUG INTERACTIONS
Scope
The scope of the PWG comprises the compilation of therapeutic (dose) recommendations 
on the basis of gene–drug interactions. It was decided to commence with the 
polymorphisms that affect pharmacokinetics. A list of polymorphic enzymes involved 
in phases I and II of the metabolic process, including an overview of drug substrates, 
was compiled. The criteria for inclusion were: (i) that the enzyme is known to play an 
important role in the metabolic process in vivo, and (ii) that data relating to the gene–drug 
interaction are available in the published literature. The following sources were used for 
assessing whether these criteria were fulfilled:
•	 PubMed (http://www.ncbi.nlm.nih.gov)
•	 Website (http://medicine.iupui.edu/flockhart/table.htm, http://www.genemedrx.com, 
http://www.druginteractioninfo.org, http://www.themedicalletter.com)
•	 Drug interaction textbook [14]
•	 Pharmacogenetics textbook [15]
Data collection
For each drug, a systematic search of PubMed and Frisbee (a bibliography of Dutch 
medical literature) [16] was carried out. The articles included in the reference lists were 
individually screened for additional material or papers. Wherever information relating 
to gene–drug interaction was present in the European Public Assessment Report, the 
manufacturer was asked to provide further details. Review articles, studies involving non-
human subjects and in vitro experiments were excluded.
Data assessment
For data assessment, a method earlier described was adapted [13]. Two core parameters 
were defined:
•	 Level of evidence of the gene–drug interaction. This indicates the quality of the evidence 
found in literature for the gene–drug interaction, and was scored on a five-point scale 
with a range from 0 (lowest evidence) to 4 (highest evidence) (Table 3.1) [17].
•	 Clinical relevance of the potential adverse drug event, decreased therapeutic response, 
or other clinical effect resulting from the gene–drug interaction.
The clinical relevance was scored on a seven-point scale derived from the National 
Cancer Institute’s Common Toxicity Criteria [18]. A clinical or pharmacokinetic effect 
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that was not statistically significant was classified as AA (lowest impact), whereas death, 
for example, was classified as F (highest impact) (Table 3.2). At every level of this point 
scale, new events are added after assessment by the PWG.
Status report and therapeutic (dose) recommendation 
For each of the assessed gene–drug interactions, a status report was prepared that presented 
an overview of key findings from selected articles from the published literature, along with 
the scores representing level of evidence and clinical relevance. Based on these scores, each 
gene–drug interaction was coded with the highest scored level of evidence and clinical 
relevance. After a final assessment of the information presented in the status report, a 
decision was made whether or not a therapeutic (dose) recommendation was required. 
These recommendations could include (i) a dose adjustment, (ii) advice on therapeutic 
strategy (e.g., the advice for therapeutic drug monitoring or a warning for increased risk 
of adverse drug event or diminished therapeutic efficacy), or (iii) the recommendation 
to select an alternative drug. In order to clarify how the PWG had arrived at the final 
therapeutic (dose) recommendation, a concise rationale was provided.
A specific procedure was followed in the preparation of the status report. After data 
collection, the level of evidence and clinical relevance of each article were independently 
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Table 3.1 Assigned levels of evidence
Criteria for assigning levels of evidence
4 Published controlled studies of good qualitya relating to phenotyped and/or genotyped patients or 
healthy volunteers, and having relevant pharmacokinetic or clinical endpoints
3 Published controlled studies of moderate qualityb relating to phenotyped and/or genotyped patients or 
healthy volunteers, and having relevant pharmacokinetic or clinical endpoints
2 Published case reports, well documented, and having relevant pharmacokinetic or clinical endpoints. 
Well documented case series
1 Published incomplete case reports
Product information
0 Data on file
- No evidence
aThe study is deemed to be of “good quality” if:
(i) the use of concomitant medication with a possible influence on the phenotype is reported in the manuscript.
(ii) other confounders are reported (e.g., smoking status).
(iii) the reported data are based on steady-state kinetics.
(iv) the results are corrected for dose variability.
bWherever one or more of these “good quality” criteria were missing, the quality of the study was considered 
to be “moderate.”
scored by two PWG members. In order to prevent interobserver variation, a seven-
member subgroup of the PWG discussed the scores of each selected paper and composed 
a preliminary status report. This preliminary report was then evaluated by the complete 
PWG during one of its three-monthly meetings, resulting in the final consensus-based 
status report and inclusion into the G-standard.
Calculation of dose adjustments
The calculation of dose adjustments was based on four rules:
•	 Pharmacokinetic data only from papers with a level of evidence of 3 or 4 were used.
•	 Data from selected papers reporting both statistically significant and not statistically 
significant differences were used. Results showing differences that were not statistically 
significant were considered as having been caused by limited sample size per genotype. 
Dose recommendations were calculated only if statistically significant data were 
available, so as to rule out the possibility of making dosage calculations from data 
generated purely by chance.
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Table 3.2 Classification of clinical relevance
Classification of clinical relevance
AA Clinical effect (NS)
Kinetic effect (NS)
A Minor clinical effect (S): QTc prolongation (<450 ms ♀, <470 ms ♂), INR increase <4.5
Kinetic effect (S)
B Clinical effect (S): short-lived discomfort (<48 h) without permanent injury, for example, reduced 
decrease in resting heart rate, reduction in exercise tachycardia, diminished pain relief from oxycodone 
and ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, 
sleep disturbance, etc.)
C Clinical effect (S): long-standing discomfort (48–168 h) without permanent injury, for example, increase 
risk of failure of therapy with tricyclic antidepressants or atypical antipsychotic drugs: extrapyramidal 
side effects, parkinsonism: ADE resulting from increased bioavailability of tricyclic antidepressants, 
metoprolol, propafenone (central effects, e.g., dizziness).
D Clinical effect (S): long-standing effect (>168 h), permanent symptom or invalidating injury, for 
example, failure of prophylaxis of atrial fibrillation; deep vein thrombosis
E Clinical effect (S): Increased risk of failure of lifesaving therapy; expected bone marrow depression
F Clinical effect (S): death; arrhythmia; unexpected bone marrow depression
ADE, adverse drug event; INR, international normalized ratio; NS, not statistically significant difference; S, 
statistically significant difference.
•	 Dose calculations were based on the sum of parent drug and active metabolites for 
atomoxetine (4-hydroxyatomoxetine), clomipramine (desmethylclomipramine), 
imipramine (desipramine), nortriptyline (10-hydroxynortriptyline), propafenone 
(5-hydroxypropafenone), risperidone (9-hydroxy-risperidone), and venlafaxine 
(O-desmethylvenlafaxine).
•	 For prodrugs, pharmacokinetics of the active metabolite were used (e.g., morphine 
when codeine is used for analgesia).
We assumed that currently used standard doses are representative for extensive 
metabolizers. For calculating dose adjustments for the CYP2D6 PM phenotype (DPM), 
we started by making a dose adjustment calculation from each selected paper from the 
published literature, using the formula below:
DPM (%) = (AUCEM / AUCPM) x 100%
After calculating dose adjustments from the data in each individual paper, a final dose 
recommendation was calculated as the population size-weighted mean of the individual 
dose adjustments:
N = number of subjects with corresponding phenotype in article a, b, c, … x
Dose recommendations of drugs for other genotypes and phenotypes were calculated using 
analogous equations, except in the case of prodrugs (e.g., codeine for analgesia) and drugs 
with metabolites whose contribution to the clinical effect is unknown (e.g., tamoxifen).
Consequences for automated medication systems
On the basis of the information collated in the status report, the PWG classified the 
gene–drug combination according to whether or not there was interaction between 
gene and drug (interaction: yes/no) and whether or not any alerts that were generated 
had to be tagged for action (action: yes/no). Wherever action is required, the alert with 
the therapeutic (dose) recommendation appears on the screen during prescription and 
dispensing (Figure 3.1). Where no action is required, the alert is only logged in the system. 
Alerts will be generated only if a certain gene–drug combination occurs. Therefore, the 
recording of a patient’s genotype in the computerized drug prescription or automated 
medication surveillance system is a prerequisite for the generation of an alert. The 
classifications and their consequences for the computerized drug prescription and 
automated medication surveillance system have been described earlier [13]. Four 




N= number of subjects with corresponding phenotype in article a,b,c,……x 
 
(N(a) x DPM(a)) + (N(b) x DPM(b)) + (N(c) x DPM(c)) + … + (N(x) x DPM(x)) 
N(a) + N(b) + N(c) + ... + N(x) 
DPM (%) = 
text, a pharmacy counter text, a hospital text, and a background text. Each of these is 
specifically designed to meet the requirements of its user. After a prescription has been 
issued by a physician (prescriber text), the prescription is transferred to the pharmacy either 
electronically or physically (by the patient). In the Netherlands, the prescription is then 
processed electronically by a pharmacy assistant (pharmacy counter text in a pharmacy, 
hospital text in a hospital setting), and the prescribed drug is dispensed. Prescriptions 
are checked for medication errors by the pharmacist (background text in community 
pharmacy, hospital text in hospital).
Composed therapeutic (dose) recommendations
To date, we have used this method of assessment for 85 genotype/phenotype–drug 
combinations comprising 26 drugs (Table 3.3, please note that the table in this thesis 
contains the information for 53 drugs from the updated 2011 Cinical Pharmacology & 
Therapeutics paper). The assessed drugs were substrates for CYP2D6 (n = 21), CYP2C19 
(n = 1), CYP2C9 (n = 3), and UGT1A1 (n = 1). After assessment of the literature, 
393 development of pharmacogenetic guidelines
Figure 3.1 Typical alert generated by automated medication surveillance after prescription of 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































therapeutic (dose) recommendations were composed for 17 of the 26 drugs. It was decided 
that for four of the drugs (clozapine, duloxetine, flupenthixol, and olanzapine) no gene–
drug interaction was present and therefore no therapeutic (dose) recommendation was 
required. For aripiprazole, tamoxifen, acenocoumarol, phenprocoumon, and voriconazole, 
although a gene–drug interaction was present, no therapeutic (dose) recommendation 
was made.
Overview and caveats
We have developed a method to interpret the results of structured assessment of 
gene–drug interactions, and translate them into therapeutic recommendations. These 
recommendations have been included in the G-standard since October 2006, and are 
applied in clinical practice for patients whose genotype is known. The availability of these 
guidelines as part of most computerized drug prescription and automated medication 
surveillance systems in the Netherlands will facilitate the use of pharmacogenetic 
information in therapeutic decision-making. Recommendations relating to other drugs 
such as sulfonylureas, angiotensin II receptor blockers, and proton pump inhibitors, are 
currently under evaluation and will be released along with future three-monthly updates.
Many of the studies that were assessed did not have pharmacogenetics as their primary 
objective, and this resulted in underpowered studies. Even where pharmacogenetics was 
the primary study objective, the assessed endpoints were mostly pharmacokinetic; also, 
the results related to single-dose experiments in healthy volunteers and was therefore 
not representative of daily clinical practice. A third limitation was the frequent use of 
specific study populations such as Asians, involving the investigation of genotypes which 
occur only rarely in Caucasian populations. In particular, there is a dearth of data relating 
to intermediate and ultrarapid metabolizers. Because we did not allow extrapolation 
of dose recommendations if a phenotype was not present in the studied population, 
only a few dose recommendations could be calculated for ultrarapid and intermediate 
metabolizers. The number of research papers per gene–drug combination retrieved during 
our searches and eligible for assessment was lower than we had expected, varying from 
0 to 21. For nortriptyline, a widely used example for demonstrating the possible impact 
of pharmacogenetics, only 10 original papers were found eligible for assessment. These 
findings demonstrate that there remains a need for more studies to provide data on the 
clinical consequences of pharmacogenetics. These studies should be adequately designed 
with regard to sample size and clinically relevant endpoints [19]. Also, initiatives such as 
the cataloging of pharmacogenetic information, introduced by the Pharmacogenomics 
and Pharmacogenetics Knowledge Base (http://www.pharmgkb.org/), are a valuable 
approach to providing research studies with adequate power to demonstrate the clinical 
relevance of pharmacogenetics.
553 development of pharmacogenetic guidelines
Currently there is only limited evidence to justify prospective pharmacogenetic testing or 
population-wide screening. The justification for such testing and screening will depend 
upon the availability of sufficient data demonstrating that pharmacogenetic testing actually 
improves clinical outcome and is cost-effective [20]. Producing such evidence presents 
a significant challenge. Long-term monitoring of the clinical outcome of the PWG dose 
recommendations might provide such data. However, there are indications that patients 
with non-wild-type genotypes are more often prone to an aberrant drug response. 
Therefore, we chose to formulate therapeutic recommendations for the situation where 
the patient’s genotype is known. Currently, the infrastructure for genotyping is available 
only in a limited number of centers and needs to be expanded or made accessible for 
other centers [4,21].
Obviously, tests for single polymorphisms that affect pharmacokinetics may account 
for only part of the variability in drug response, and the pharmacogenetic tests that 
are currently available cannot replace other methods for dose individualization such as 
therapeutic drug monitoring [22,23]. We have described only genetic polymorphisms 
that affect the pharmacokinetics of a drug. The available literature on polymorphisms that 
affect pharmacodynamics, and the implications of these effects, is limited and sometimes 
contradictory [24,25].
In summary, our initiative to develop pharmacogenetics-based therapeutic (dose) 
recommendations and to make them accessible during electronic drug prescription and 
automated medication surveillance represents an important step forward toward the 
application of pharmacogenetic information in daily patient care.
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ABSTRACT
Purpose: To investigate the feasibility of pharmacy initiated pharmacogenetic screening in 
primary care with respect to patient willingness to participate, quality of DNA collection 
with saliva kits, genotyping, and dispensing data retrieved from the pharmacy.
Methods: Polypharmacy patients, age > 60 years that used at least 1 drug with ATC code 
N06AA01-N06AX19 (anti-depressants), A02BC01–A02BC05 (proton pump inhibitors), 
N05AA01-N05AH04 (anti-psychotics) or C07AB02 (metoprolol) in the preceding 2 
years were randomly selected. DNA was collected with saliva kits and genotyped for 
CYP2D6 and CYP2C19 with the AmpliChip. Pharmacy dispensing records were retrieved 
and screened for drugs interacting with the patient’s CYP2D6 and CYP2C19 genotype by 
using the evidence-based pharmacogenetic guidelines from the Dutch Pharmacogenetics 
Working Group.
Results: Out of the 93 invited patients, 54 patients (58.1%) provided informed consent. 
9 saliva samples (16.7%) contained too little DNA. Call rates for CYP2D6 and CYP2C19 
were 93.3% and 100% respectively. The frequencies of genotype-predicted-phenotype 
were 2.4%, 38.1%, 54.8%, and 4.8% for CYP2D6 poor-metabolizers (PM), intermediate-
metabolizers (IM), extensive-metabolizers (EM), and ultrarapid-metabolizers respectively. 
For CYP2C19 genotype-predicted-phenotype frequencies were 2.2%, 15.6%, and 82.2% 
for PM, IM, and EM, respectively. 
Conclusions: This study shows that pharmacy initiated pharmacogenetic screening is 




Pharmacogenetics promises an exciting approach to a more individualized drug therapy 
ultimately leading to a more efficient and safer application of drugs. To date, many efforts 
within the field of pharmacogenetics have been aimed at the improvement of drug therapy 
with “high risk” medications such as within the field of oncology. By contrast, multiple 
pharmacogenetic interventions for drug therapies with less high risk might also prove 
beneficial [1]. Yet the clinical use of genotyping prior to drug prescription and dispensing 
is not widely practiced [2].
Currently, pharmacogenetic information is accumulating rapidly and it was reported 
that based on the available pharmacogenetic information it is possible to generate 
advice for nearly 100 drugs for a patient with a completely sequenced genome [3]. In 
addition, Philips et al. reported that 16 out of 27 (59%) of the drugs most commonly 
associated with adverse drug events (ADEs) were metabolized by a polymorphic gene 
[4]. A subsequent study published by Grice et al. investigated the frequency of use 
of these 16 pharmacogenetic ADE-associated drugs in a primary care setting [5]. It 
was reported that 28.6% of the patients took more than one of the pharmacogenetic 
ADE-associated drugs indicating a high potential for pharmacogenetics to make drug 
therapy safer. A disadvantage of this study was that it did not include drugs for which 
pharmacogenetic testing is recommended to enhance efficacy instead of to avoid ADEs. 
In a study aimed at gaining insight into the feasibility of informing physicians reporting 
ADEs to the Netherlands Pharmacovigilance Centre about possible pharmacogenetic 
involvement and genotyping their patient Van Puijenbroek et al. reported that 39.5% of 
the reporting health care professionals actually initiated genotyping [6]. This illustrates 
that incorporating pharmacogenetic information in drug prescribing could increase 
safety of drug therapy. 
More recently, two large (inter)national initiatives aimed at providing pharmacogenetics 
based guidelines and recommendations concerning drug prescribing have been published 
[7,8]. The Clinical Pharmacogenetics Implementation Consortium (CPIC) recently 
published its first guideline [9] and has the goal to provide peer-reviewed, evidence-based, 
freely accessible guidelines for gene/drug pairs. CPIC published a list of 29 gene/drug pairs 
that were ranked highest in a survey of American Society for Clinical Pharmacology and 
Therapeutics members in 2010 [7]. The Dutch Pharmacogenetics Working group recently 
published updated evidence-based guidelines with pharmacogenetics recommendations 
concerning 53 drugs [8]. From the list of 53 drugs of the Dutch Pharmacogenetics 
Working group, the list of highest-ranked priority gene/drug pairs from CPIC and 
the article by Grice et al., it can be observed that many drugs used in primary care are 
to some extend influenced by pharmacogenetics, again illustrating a potential role for 
pharmacogenetics in primary care.
4 pharmacy initiated pharmacogenetic screening
The aim of the current study is to test the feasibility of pharmacy initiated pharmacogenetic 
screening in primary care with respect to patient willingness to participate, quality of 
DNA collection with saliva kits, genotyping, and quality of dispensing data retrieved 
from the pharmacy records.
METHODS
Study setting
In the Netherlands the vast majority of the population obtains their medication from only 
one community pharmacy, enabling collection of complete medication histories [10]. The 
pharmacy keeps an electronic patient record that covers all dispensing data. Polypharmacy 
patients were recruited from a community pharmacy located in the city of Leiden, the 
Netherlands. Patients were selected from the pharmacy records if they used at least one 
drug that is metabolized by CYP2D6 or CYP2C19 and at least four additional drugs in the 
preceding 2 years. Drugs were selected on their Anatomical Therapeutic Chemical (ATC) 
classification code [http://www.whocc.no/atc_ddd_index/]. To identify eligible ATC codes 
textbooks, an academic website [http://medicine.iupui.edu/flockhart/table.htm] and a review 
article by Kirchheiner et al. were used [11-13]. Codes eligible for inclusion comprised 
N06AA01 - N06AX19 (anti-depressants), A02BC01 – A02BC05 (proton pump inhibitors), 
N05AA01 - N05AH04 (anti-psychotics) and ATC-code C07AB02 (metoprolol). Patients 
had to be 60 year or older at the start of the study. This age was chosen for the practical 
reason that elderly patients are more frequently at home simplifying saliva collection.
Sample collection 
Samples of 2 ml saliva were collected during a 30 min house visit. Samples were collected 
in the Oragene DNA self-Collection kit (DNA Genotek Inc Ottawa, Ontario, Canada). A 
sample of 125 patients was drawn from the selected patients by randomization with the aim 
to invite 100 patients by mail and finally obtain DNA samples from 50 patients. General 
practitioners were informed of our study prior to contacting the patient, and asked to exclude 
patients with terminal disease status. Patients selected for inclusion received a letter from the 
pharmacy explaining the background of the study and the study objectives. Approximately 1-2 
weeks after the letter was sent, patients were contacted by phone by one of the pharmacists 
participating in the study (EV). During this phone call patients were asked if they agreed to 
participate. If patients agreed, a 30 minute house visit was planned to collect informed consent 
and a saliva specimen. If the first attempt to contact a patient by phone was unsuccessful a 
maximum of three consecutive attempts were made. After that the patient was considered 
not willing to participate. The study was approved by the ethics committee of the Leiden 
University Medical Center. Informed consent was obtained from all participants. 
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Genotyping
DNA was extracted from saliva using the Oragene DNA self-Collection kit according 
to the manufacturer’s instruction at the Leiden University Medical Center (Leiden, 
The Netherlands). DNA concentrations were measured with nanodrop (Isogen, 
Maarssen, The Netherlands) and diluted with water to a concentration of 10 ng/μl. 
The DNA was tested for 29 known polymorphisms in the CYP2D6 gene, including 
gene duplication and gene deletion, as well as two major polymorphisms in the 
CYP2C19 gene. Genotyping was performed at the department of clinical chemistry 
of the Erasmus MC (Rotterdam, The Netherlands) by use of the AmpliChip CYP450 
test (Roche Molecular Systems, Alameda, California) according to the manufacturer’s 
instruction. A genotype-predicted-phenotype (phenotype) was assigned to each patient 
[8]. For CYP2D6 intermediate metabolizers (IMs) were defined as patients carrying 
two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, 
*2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or 
carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive 
(*3-*8, *11-*16, *19-*21, *38, *40, *42) allele. Poor metabolizers (PMs) were defined 
as patients carrying two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles. 
Ultra rapid metabolizers (UMs) were defined as patients carrying a gene duplication 
in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity 
(*9, *10, *17, *29, *36, *41) alleles. All other patients were considered extensive 
metabolizers (EMs). For CYP2C19 IMs were defined as patients with one active (*1) 
and one inactive (*2, *3) allele. PMs were defined as patients carrying two inactive 
alleles.
Medication analyses
Data were extracted from the pharmacy dispensing records. Drugs for topical application 
were excluded from the analysis. The number of unique prescribed drugs per patient was 
calculated as the number of unique ATC codes prescribed to each patient in the studied 
period of 2 years. For each unique prescribed drug it was checked if a recommendation was 
available in the guidelines of the Dutch Pharmacogenetics Working Group of the Royal 
Dutch Association for the Advancement of Pharmacy [8]. These evidence-based guidelines 
contain a comprehensive evaluation of pharmacogenetic gene-drug interactions involving 
53 drugs and 11 genes. To illustrate the potential impact of pharmacogenetics on primary 
care, the percentage of prescribed drugs with any pharmacogenetic recommendation 
was calculated for each patient and in detail for pharmacogenetic recommendations 
regarding CYP2D6 and CYP2C19. To evaluate if patients with a non-EM CYP2D6 or 
CYP2C19 status had been empirically switched to non CYP2D6 / CYP2C19 substrates, 
the percentage of CYP2D6/CYP2C19 substrates with a pharmacogenetic recommendation 
of the total number of prescribed drugs was compared between EMs and non-EMs.
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Statistical analysis
The Student’s t-test was used to evaluate differences in the percentage of prescribed 
CYP2D6 and CYP2C19 substrates, and the number of drugs with a recommendation 
in the guideline of the Dutch Pharmacogenetics Working Group between EMs and non-
EMs. A p-value < 0.05 was regarded as significant. Statistical analysis was conducted 
with the SPSS statistical package (version 17.0, SPSS, Chicago, IL, USA).
RESULTS
Patient response
Five hundred and seven patients representing approximately 5% of the total registered 
patient population, were prescribed at least one drug from the selected ATC-codes and 
at least four additional drugs (Figure 4.1). Out of these patients a random sample of 125 
patients was selected. Twenty two patients were excluded because they visited a general 
practitioner that did not participate in the study. A further ten patients were excluded 
because of terminal disease status as judged by their general practitioner. Out of the 93 
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n = 54 (58.1%)
Patients available for analysis
n = 45 (83.3%)
382 patients (75.3%) randomly excluded
32 patients (25.6%) excluded
• 22 visited a non-participating general practitioner
• 8 excluded because of terminal disease status
• 2 already deceased
39 patients (41.9%) did not consent
• 22 unwilling to participate
• 1 deceased
• 6 could not be contacted by telephone
• 10 patients did not participate for other reasons
e.g. vacation, hospitalization etc.
9 saliva samples (16.7%) contained too little DNA 
Selected patients
n = 125 (24.7%)
Invited patients
n = 93 (74.4%)
invited patients, 54 patients (58.1%) provided informed consent. Twenty two patients 
(23.7%) of the 93 invited patients refused to participate, and 17 patients (18.3%) could 
not be included for other reasons (Figure 4.1). The mean age of the included patients 
was 71 years (range 60-91 years). Ethnicity was not routinely recorded but all patients 
were of European ancestry as observed during sample collection (by EV). There were 
more females (61.1%) than males (38.9%) in the cohort. The percentage of invited males 
and females that agreed to participate was 54.1% and 65.6% respectively (p = 0.29).
Genotyping
Nine saliva samples contained too little DNA for genotyping with the AmpliChip (< 50 
ng). The call rate after a single run was 93.3% for CYP2D6 (three no-calls) and 100% for 
CYP2C19. As expected the most frequent alleles were the CYP2D6*1 and CYP2D6*2 with 
a frequency of 0.35 and 0.21 respectively. The other functional allele, CYP2D6*35 was 
found with a prevalence of 0.10. The CYP2D6*4 allele was the most frequent zero activity 
allele followed by the CYP2D6*5 and CYP2D6*3 allele (0.17, 0.02, 0.01 respectively). 
The inactive alleles CYP2D6*41, CYP2D6*9, and CYP2D6*10 had a prevalence of 
0.06, 0.04 and 0.02 respectively. Most of the patients (54.8%) were predicted to have 
the EM phenotype, followed by IM (38.1%), UM (4.8%) and PM (2.4%). Prevalence 
of the CYP2C19*1 and CYP2C19*2 allele was 0.90 and 0.10 respectively. No carriers of 
CYP2C19*3 allele were found. One patient was homozygous for the CYP2C19*2 allele and 
therefore categorized as PM. Seven patients were heterozygous carriers of the CYP2C19*2 
allele and therefore categorized as IM. All other patients were considered EMs.
Medication history
The mean number of unique prescribed drugs per patient was 15.2 (95% CI 13.4-17.1) 
in the studied two year period with an average of 4.6 (95% CI 4.0-5.2) prescriptions per 
unique prescribed drug. The percentage of CYP2D6 substrates with a pharmacogenetic 
recommendation of the total number of prescribed drugs was not different between 
CYP2D6 non-EMs, and patients with a predicted CYP2D6 EM-phenotype with 4.70% 
and 4.86% respectively (p = 0.95). For CYP2C19 similar results were found with 
8.53% and 9.26% of the prescribed drugs having a pharmacogenetic recommendation 
for non-EMs and EMs respectively (p = 0.74). For patients with a predicted CYP2D6 or 
CYP2C19 non-EM phenotype detailed information about prescriptions for drugs for which 
a CYP2D6 or CYP2C19 pharmacogenetic recommendation was available are provided 
in Table 4.1. The CYP2D6 PM did not use any drugs with a CYP2D6 pharmacogenetic 
recommendation. Of the CYP2D6 UMs one patient did not use any of the drugs with a 
CYP2D6 pharmacogenetic recommendation and one patient used codeine 10 mg three 
times daily and paroxetine 20 mg once daily. The codeine was limited to a single prescription 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































only. The latter patient was also predicted to be a CYP2C19 IM and used clopidogrel 75 
mg once daily and omeprazole 40 mg twice daily. The reduced metabolic capacity for 
CYP2C19 and the drug-drug interaction between clopidogrel and omeprazole both lead to 
reduced formation of the active metabolite of clopidogrel and subsequent increased risk for 
therapeutic failure [14,15]. The CYP2D6 IMs were often prescribed tramadol or codeine, 
drugs that both are expected to have a reduced analgesic effect in CYP2D6 IMs. Metoprolol 
was also often prescribed but according to the guidelines of the Dutch Pharmacogenetics 
Working Group only requires a dose adjustment when used for heart failure. The CYP2C19 
IMs and PM were mostly prescribed proton pump inhibitors that do not require a dose 
adjustment since decreased metabolism results in increased therapeutic efficacy. 
Since we were interested in the potential impact of pharmacogenetics on primary care the 
medication history of all patients was further evaluated for drugs metabolized by other 
enzymes than CYP2D6 and CYP2C19. On average patients used 2.3 (15.9%, 95% CI 
1.9-2.7) drugs for which a recommendation of the Dutch Pharmacogenetics Working 
Group was available. The most frequently prescribed drugs with a pharmacogenetic 
recommendation were the proton pump inhibitors followed by phenprocoumon and 
metoprolol (Table 4.2). The number of drugs with a therapeutic recommendation did 
not differ between EMs and non-EMs with 2.2 versus 2.5 drugs for CYP2D6 EMs and 
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Table 4.2 Frequency of patients with a prescription for a drug with a recommendation in the Dutch 
Pharmacogenetics Working Group guidelines [8]



















non-EMs respectively (p = 0.48) and 2.5 versus 1.8 drugs for CYP2C19 EMs and non-
EMs respectively (p = 0.24).
DISCUSSION
The available evidence of genetic variants with clinical relevance regarding both efficacy 
and toxicity of drug therapy is accumulating rapidly. Elaborating on this information, 
multiple initiatives to develop clear cut therapeutic guidelines translating available evidence 
to therapeutic recommendations have been initiated [7,8,16]. However, there is little 
information regarding the potential impact of these recommendations in primary care. This 
study indicates that a majority of patients is willing to participate in a pharmacogenetic 
screening study and that pharmacy initiated pharmacogenetic screening is feasible in a 
primary care setting. 
Of the invited patients 58.1% was willing to participate in our study. This is a relatively 
large percentage given the fact that screening was not directly related to a clinical problem. 
For patients presenting with an adverse drug event or lack of therapeutic effect, willingness 
to participate in pharmacogenetic screening may be even higher. Age has also been reported 
to be of influence on the attitude towards pharmacogenetic testing, with younger patients 
being more likely to be optimistic about the usefulness of pharmacogenetic testing [17]. 
Therefore, willingness to participate may be higher in a population younger than 60 
years. On the other hand, we collected DNA samples during a visit at the patients’ home. 
Collection by mail may result in lower response rates.
There were more females than males included in our study although there was no 
statistically significant difference in the willingness to participate between the sexes. Sex 
differences concerning pharmacogenetic testing have been reported, with female patients 
being more likely to have concerns regarding the possible negative consequences of 
pharmacogenetic testing and being less willing to participate than males [17,18]. However, 
the finding that more females were included in this study might simply be explained by 
the fact that from 65 years onward the female to male ratio is starting to increase due to 
higher life expectancy of females.
The reported allele, genotype and phenotype frequencies are comparable to previously 
reported results obtained with the AmpliChip [19] or other methods such as PCR- RFLP 
in comparable populations of mainly white subjects [20,21]. These results indicate that 
no selection bias has occurred and that our patient cohort is representative.
Our study is limited in that we used a dichotomous outcome parameter to categorize 
drugs as either “with” or “without” a pharmacogenetic recommendation in the Dutch 
Pharmacogenetics Working Group guidelines. All drugs for which according to the 
guidelines a gene-drug interaction is present and an action is required were put in 
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a single category. This is an oversimplification because the guidelines provide many 
different types of recommendations, e.g. advice to adjust the dose, be extra alert to 
diminished therapeutic efficacy or increased risk for an ADE. Also, the recommendation 
depends on the metabolism of the drug, e.g. does the drug have active metabolites or 
is it a prodrug? For example, codeine is used for both pain and cough. The analgesic 
effect requires the formation of morphine by CYP2D6. Therefore, CYP2D6 UMs will 
require a dose reduction for an equal pain reduction compared to EMs whereas no dose 
reduction is required for the effect on cough. Dose adjustments were not investigated in 
this feasibility study. In addition, patients that used at least one drug that is metabolized 
by CYP2D6 or CYP2C19 were selected for inclusion. As a result, this study does not 
provide quantitative estimates of the incidence of the use of drugs with a pharmacogenetic 
recommendation for CYP2D6 or CYP2C19 in the Dutch pharmacogenetic guidelines. 
This study was not designed to and therefore does not provide direct evidence that the use 
of pharmacogenetic recommendations results in improved efficacy or decreased toxicity. 
That requires further study.
In our study we identified some potential pitfalls for pharmacogenetic screening in 
primary care as performed in this study. First, for a number of patients the production 
of the required 2 ml saliva was difficult. Since the included patients used at least five 
different medications this might be explained by the use of anticholinergic medication or 
other drugs that cause a dry mouth. Indeed five of the nine patients that failed to provide 
sufficient DNA used this type of medication. 
Secondly, the no-call rate for the AmpliChip was 6.7% for CYP2D6. This is relatively high 
when compared to results reported by other groups. In a study with 158 breast cancer 
patients treated with tamoxifen Borges et al. report a no-call rate of 0.7%. Serrano et al. 
report a no-call rate of 1.6% in a of 182 Italian breast cancer patients treated with tamoxifen. 
Both studies used DNA extracted from whole blood for genotyping. However, in a large 
study of 4,532 psychiatric patients the no-call rate for CYP2D6 with the AmpliChip was 
6.0% after three rounds of testing [22]. In that study it was first attempted to genotype 
patients with DNA extracted from buccal swabs or saliva specimens. When saliva/buccal 
DNA failed to provide a genotype, blood DNA was tested. The no-call rate after primary 
genotyping was as high as 13%. According to the authors, this was mainly the result of 
DNA collection with buccal swabs since this DNA tends to be contaminated by bacterial 
DNA [22]. DNA extracted from saliva has been reported to be of high quality and a suitable 
alternative to blood DNA [23]. In our laboratory we compared genotyping results of an 
additional set of 24 DNA samples for which both blood and saliva were available. The 
no-call rate for saliva was 4% higher compared to the no-call rate for blood samples with 
3/24 and 2/24 for saliva vs. blood respectively. Although these results are inconclusive and 
further investigation is required, the results may indicate that DNA extracted from saliva 
results in slightly less successful genotyping with the AmpliChip.
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According to the guidelines of the Dutch Pharmacogenetics Working Group approximately 
5-10% of the drugs prescribed to patients with aberrant CYP2D6 or CYP2C19 metabolism 
require an action such as a dose adjustment or extra awareness for an ADE [8]. In our study 
there was no difference in the percentage of prescribed CYP2D6 and CYP2C19 substrates 
between EMs and non-EMs of CYP2D6 or CYP2C19. This suggests that physicians have 
not empirically identified patients with aberrant metabolism e.g. by switching patient with 
ADE to medications that were not substrate for CYP2D6 or CYP2C19. From Table 4.1 
it can also be observed that patients with a non-EM phenotype were prescribed regular 
drug dosages. The current data do not allow an in depth analysis of switching behavior 
since this requires a complete medication history, including the first prescription, and not 
just a cross-sectional period of two years. 
Of the total number of prescribed medications 15.9% had a pharmacogenetic therapeutic 
recommendation in the Dutch guidelines. This number is comparable to a previously 
published estimate that 15-20% of prescribed drugs are metabolized by genetically 
polymorphic enzymes [24]. However, our results should be interpreted with extreme 
caution since one of the inclusion criteria was the use of at least one drug metabolized 
by CYP2D6 or CYP2C19. Therefore, the number of drugs with a pharmacogenetic 
recommendation may be overestimated in our data.
In conclusion, this study shows that pharmacy initiated pharmacogenetic screening is 
feasible for a primary care setting.
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Objectives: Genetic variation in genes encoding for drug-metabolizing enzymes, drug 
targets and signaling pathways have proven to contribute significantly to differences in 
drug response. Pharmacogenetics is now expanding from clinical pharmacological research 
to its application in clinical practice. Genotyping of patients in a routine clinical setting 
requires robust and reliable genotyping methods. 
Materials & methods: A survey of pharmacogenetic association studies for quality control 
samples published from 2005 to 2007 in the two most prominent pharmacogenetic 
journals, and development of plasmid-derived external controls. 
Results: Surveying journals revealed that only a minority of papers report the use of 
quality controls, and no standard procedures are applied. We established 12 plasmid-
derived external controls and applied these in pharmacogenetic testing. 
Conclusion: There still is a need for quality control materials, especially for application 
in pharmacogenetic testing. We hope that our initiative to create plasmid-derived controls 
will help to facilitate quality in the pharmacogenetic genotyping tests applied in research, 




Pharmacogenetic testing prior to drug treatment is not a routine practice, and is largely 
confined to academic hospitals and specialized laboratories [1]. Several reasons for the 
relatively slow translation of pharmacogenetics to the clinic may be considered [2,3]. 
The most important reason is the lack of scientific evidence of improvement in patient 
care by pharmacogenetic testing. Also, the limited insight into cost consequences and 
cost–effectiveness of a pharmacogenetic strategy presents an obstacle for implementation. 
Other reasons include the limited number of studies reporting diagnostic test criteria 
such as sensitivity, specificity and predictive value of pharmacogenetic tests, the lack of 
guidelines that help clinicians to link the sometimes complex results of a pharmacogenetic 
test to therapeutic recommendations, and finally the limited acceptance of pharmacogenetic 
testing by clinicians. However, three US FDA approved pharmacogenomic tests have 
recently become available (Amplichip®, Roche [Basel, Switzerland] [101], Invader® 
UGT1A1 molecular assay, Third Wave Technologies [WI, USA] [102] and Verigene® 
system, Nanosphere [IL, USA] [103]). Moreover, the FDA has included pharmacogenetic 
test information to the labels of several older and new drugs such as 6-mercaptopurine, 
azathioprine, atomoxetine and irinotecan [4], and recently the first large, randomized, 
double-blind prospective study providing evidence that pharmacogenetics can improve 
patient care has been published [5]. These points illustrate that, though not as fast as 
once anticipated, pharmacogenetics has reached the clinic and implicates that more 
pharmacogenetic tests will be introduced in the near future. Clinical application of 
pharmacogenetics will result in adjustment of treatment for individual patients. For 
example, patients at a high risk for having an undesired drug reaction or therapeutic 
failure owing to polymorphisms in CYP2D6 might receive an adjusted dose or change 
of drug therapy. Therefore, pharmacogenetic tests for clinical use need to be even more 
robust and reliable than testing methods for investigational use. Since 1999, the Center 
for Disease Control and Prevention (CDC) has initiated studies to assess the status of 
quality assurance practices of laboratories performing genetic testing [6]. One of the 
core recommendations from these studies was to improve the availability of quality 
control materials with utmost urgency [6,7]. Several organizations, such as The National 
Academy of Clinical Biochemistry [104] and the FDA [105], provide guidelines or survey 
programs [106] for pharmacogenetic testing. One of the main aims of these organizations 
is to provide quality control material for genetic testing [7]. Indeed, Jarvis et al. inserted 
targeted sequences of the cystic fibrosis gene into a plasmid to use that as quality control 
in clinical molecular testing [8]. They propose to use this approach as quality control for 
genetic testing.
However, despite the existence of commercially available reference material (i.e., from 
Coriell [NJ, USA] [107]; Gentris [NC, USA] [108]; or GeT-RM cell lines collected 
by the CDC [109]) this does not seem to be widely used for pharmacogenetic testing.
5 plasmid-derived quality control samples
In order to evaluate the use of qualified controls for genotyping studies, we surveyed all 
association studies that were published in the two most prominent pharmacogenomics 
journals from 2005 to 2007, to assess how often and which controls are used as quality 
controls. We found that only a minority of studies reported the use of quality controls, and 
overall no standard procedures are used. We established plasmid controls for frequently 
determined alleles: TPMT*2,*3B/C; CYP2D6*3, *4, *6, *9, *41; CYP2C9*2, *3; 
CYP2C19*2, and *3 and argue for the use of plasmids as standard genotyping controls.
METHODS
Literature study 
In March 2008, we manually checked papers that have been published in the journals 
Pharmacogenomics and Pharmacogenetics and Genomics in 2005, 2006 and 2007. The 
materials and methods sections were searched for the use of genotyping quality controls. 
The retrieved papers in which samples were genotyped, were marked as using ‘no controls’, 
‘intern controls’ (own material) or ‘external controls’ (well-characterized material).
Materials 
Plasmid pGEM-Teasy was obtained from Promega (Leiden, the Netherlands). Primers 
and pyrosequence materials were obtained from Isogen (IJsselstein, the Netherlands). 
Sepharosebeads were bought from Amersham (Buckinghamshire, UK), Taqman® kits 
were bought from Applied Biosystems (Nieuwerkerk aan de IJssel, the Netherlands). PCR 
reagents and plasmid isolation kit was obtained from Qiagen (Breda, the Netherlands). 
Materials used to create the plasmid were obtained from previously collected and genotyped 
controls. Informed consent was obtained from all participants.
Generation & genotyping of plasmids 
In order to establish plasmid controls that can be used for several techniques, we choose 
primers approximately 500 nucleotides up and downstream of the SNP. See Table 5.1 for 
sizes of the different amplicons and the position of the SNP herein. All obtained plasmids 
were numbered and sequenced. All plasmids are created by ligation of a specific PCR 
product into pGEM-Teasy and transformation to competent cells. Primers are chosen 
approximately 500 nucleotides up- and down-stream of the specific SNP. Primer sequences 
are listed in Table 5.1. PCR conditions were as follows: activation of polymerase at 95°C 
for 15 min, 35 cycles of 95–55–72°C, each for 1 min, followed by a final extension of 
10 min at 72°C. Each PCR reaction consisted of 5 pmol of each primer, 6 µl hotstart 
mastermix, 10 ng of chromosomal DNA in a total volume of 12 µl. All products were 
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checked by agarose gel electrophoreses. Ligation reaction consisted of 4 µl PCR product, 
0.5 µl pGEM-Teasy, 0.5 µl ligase and 5 µl water. Incubation for at least 1 h at room 
temperature, prior to transformation to DH5α cells and plating at ampicillin, X-gal and 
isopropylthiogalactoside (IPTG) containing Luria Broth (LB) agar plates. After overnight 
incubation at 37°C, white colonies were picked, grown in LB broth and checked for 
insert. Next, plasmids were sequenced using conventional methods and genotype was 
confirmed by pyrosequencing (TPMT and CYP2D6), restriction analysis (CYP2C9) or 
Taqman analysis (CYP2C19) according to manufacturers’ protocol. Of note, heterozygous 
controls were obtained by mixing two plasmid controls.
RESULTS
Literature study 
In volumes 6 (1–8; 2005), volumes 7 (1–6; 2006) and volumes 8 (1–12; 2007) of 
Pharmacogenomics, and in volumes 15 (1–12; 2005), volumes 16 (1–12; 2006) and 
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Table 5.1 Primer names and sequences
Nr Name SNP Sequence 5’-3’ Size Position SNP
0363 TPMT*2 (G>C) forward TTCACTTTAGTACAGTAGCTAC 1150 525
0364 TPMT*2 reverse TCACCATGCTTCAGGAAGC
0365 TPMT*3B (G>A) forward ATTACACACTCGTCTGCACAC 1150 554
0366 TPMT*3B reverse GGTCTCAAACTCCTGGG
0367 TPMT*3C (A>G) forward ACAATTCAGAGTTCAGGAAATT 1150 570
0368 TPMT*3C reverse ATCACCTGAACCTGGGAGGC
0369 CYP2C19*2 (A>G) forward AAAAGCTTTGAAATCCCCAACTA 1090 552
0370 CYP2C19*2 reverse ATTCCTAACCAGCTGTCTCATC
0371 CYP2C19*3 (A>G) forward ACAGAAGTCATTTAACTGCTCTG 1092 558
0372 CYP2C19*3 reverse TTTGCATTTCTCCAATGACTTC
0373 CYP2C9*2 (C>T) forward GCCATCTGAGTGGCAAGTAT 1150 610
0374 CYP2C9*2 reverse AGAAACCCCAGAGAAGTCAG
0375 CYP2C9*3 (A>C) forward TCCATCCAGGTCAGTAACAG 1150 521
0376 CYP2C9*3 reverse AAGTTGACAGATTAACATCATC
0377 CYP2D6 (*6*4*3*9*41) forward CACCTGCACTAGGGAGGT 2330 *6: 519




5 plasmid-derived quality control samples
volumes 17 (1–12; 2007) of Pharmacogenetics and Genomics, a total of 547 papers were 
published and 135 of these involved studies in which samples were genotyped. From 
these, 116 (86%) did not use or mention genotyping quality control, 12 (9%) did use 
quality controls but did not define them, in three studies (2%) a representative sample 
was sequenced as an additional control, and four studies (3%) used a defined control 
which was a previously sequenced sample (n = 2) or a reference panel from The Centre 
d’Etude du Polymorphism Humain (CEPH) (n = 2).
Sequencing plasmids 




Gene SNP Synonym rs nr Plasmid nr Genotype
CYP2D6a 1707Tdel *6 rs5030655 40,41,42 1707Tdel
G1846A *4 rs3892097 1 1846A
2549Adel *3 rs4986774 2 2549Adel
2613-2615AGAdel *9 rs5030656 3,4 2613-2615AGAdel
G2988A *41 rs28371725 5 2988A
CYP2C9 C3608T *2 rs1799853 6 3608C
7 3608T
A42614C *3 rs1057910 9,10,11 42614A
12,13 42614C
CYP2C19 G19154A *2 rs4244285 18 19154G
20 19154A
G17948A *3 rs4986893 22,23,24 17948G
25,26,27,28 17948A
TPMT G238C *2 rs1800462 29 238G
30,31,32 238C
TPMT G460A *3B rs1800460 33,34,35,36 460G
43 460A
A719G *3C rs1142345 39 719A
37,38 719G
aAs a reference for CYP2D6 SNPs a plasmid control was used with the wild-type nucleotides at designated 
positions (available on request). 
Genotyping plasmids 
The genotypes of all plasmids are listed in Table 5.2, and the result of a representative 
genotyping assay is shown in Figure 5.1. Results of the genotyping assays for the other 
plasmids are available on request.
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Figure 5.1 Example of validation report of TPMT*2. Plasmids with insert (see sequence) are 
genotyped by pyrosequencing. Heterozygous genotype is the result of mixture of both homozygous 
plasmids 29 and 30. Pyrosequence primer was reverse orientated, therefore derived genotype is 
from complementary strain and should be reversed.
5 plasmid-derived quality control samples
Tekst figuur 1 
Plasmid 29  
Entry: TPMT*2 rs1800462 
Position 1: C/C (passed) 
Plasmid 30  
Entry: TPMT*2 rs1800462 
Position 1: G/G (passed) 
Plasmid 29 + 30 
Entry: TPMT*2 rs1800462 
Position 1: G/C (passed) 
1 TTCACTTTAG TACAGTAGCT ACTAGCCACA TGTGGCTATT TAAATGTAAA 
    51 CTAAATAAAA TGTAAAATTC AGTTCCTCAA TCACGAGGAA CCAATGTGGC 
   101 TAATGCCTAT TTTATTGGAC AGCGACAGAT ATAGACATTT TCATCAATGC 
   151 AGAAAATTTT AATGGGCAGT GCTGATTTAG AGAAATTGAA AAGCATTTCC 
   201 TCTAGTCAAA TCAATTTGTA TTAAATCAGT ATTTTGTTAT ATATCTATAA 
   251 TTACATTCCA ACTGTTTCAT ACATAAAAAA AGATATATAT AATTTTCCAA 
   301 ATTTTTATTG TTTCCTGAAT TCATATAAGT CAGTTTTTCA GAATTTTTAT 
   351 AAGGTTTGAA AATAATATAG ATCTGCTTTC CTGCATGTTC TTTGAAACCC 
   401 TATGAACCTG AATTCATATA AATTCCTCTA AATTAAAGAA AATATATGCT 
   451 TACTCTAATA TAACCCTCTA TTTAGTCATT TGAAAACATA ATTTAAGTGT 
   501 AAATGTATGA TTTTATGCAG GTTTGCAGAC CGGGGACACA GTGTAGTTGG 
   551 TGTGGAAATC AGTGAACTTG GGATACAAGA ATTTTTTACA GAGCAGAATC 
   601 TTTCTTACTC AGAAGAACCA ATCACCGAAA TTCCTGGAAC CAAAGTWTTT 
   651 AAGGTTTGTT TTGATTTGGG TAAATAATTG TATCCATATC CCCACAAAAG 
   701 TTTTTCTCAG CGTGAGTATT ATGAGGATAC CATTCATGTG TCCGATGGTT 
   751 CCTATTTAGC ACGCAGATTC ACTGTAGATA CTATATAGTA TAAGAAGCAA 
   801 GGGCTTAAAA ATATAGGTGA TAGCTACCTA AATAGGTATA GACATATGTA 
   851 TATAAAAGCT GAGGTCAAAG CCTCTCTGTA CTCAAGCTTT TAGGCTTGTT 
   901 TTATTTTTAT TAACACGCAT TTTCTGAGAA CCCATCATGT GCCAGACCCT 
   951 GCCTAAGACA TTGAAGAGAT AAAGATAACA CAGCACACCC CCCTCACTCC 
  1001 CACCCCTAAA GAATCTCTTA GTTTAGGAGA GAAGAGAAAC AGGGACAAAG 
  1051 CTATTTGTAA TGCATGGAGC TAAGTGTAAA GACACAGGGT ATTAAGGGAA 




This study indicates that the use of external quality standards for genotyping assays is rare 
and not standardized. We found that in 2005, 2006 and 2007, 86% of papers in which 
samples were genotyped, and published in both the surveyed journals, did not use or 
define quality controls. We surveyed 20 other association studies, in randomly selected 
journals such as Rheumatism and Arthritis, Cancer and others, and found that one study 
mentioned the use of controls, but did not define them, and only one study was using 
CEPH DNA as controls [9]. Two studies declared that they sequenced a few samples to 
confirm the genotype. This indicates that the lack of using well-defined quality controls is 
a general observation in pharmacogenetic publications. In general, as a quality assurance, 
most studies duplicate 5–10% of the samples. This may serve as an internal control, 
for instance to exclude sample exchanging, but can not be regarded as an independent 
quality control sample to assure the validity of the pharmacogenetic test. We propose that 
independent external quality control samples are required to be included in (pharmaco)
genetic testing, as was previously suggested by Jarvis et al. [8].
By cloning the SNP of interest in a plasmid we created a set of plasmids that can be used 
for different pharmacogenetic assays. We cloned the most important genotypes, which are 
used for diagnostic testing in a plasmid and sequenced the insert. In addition, we tested 
these plasmids by pyrosequencing and/or Taqman analysis and found 100% concordance. 
However, we are aware that this is only the proof of principle and external validation by 
an independent laboratory is required.
At present we have cloned TPMT*2,*3B/C; CYP2D6*3, *4, *6, *9, *41; CYP2C9*2, 
*3; and CYP2C19*2, *3. In order to guarantee reliable genotyping results, independent 
of the assay or hospital, we argue for the use of these plasmids as external controls for 
genotyping testing. This selection of plasmids covers the most clinically relevant SNPs of 
TPMT, CYP2C9, CYP2C19 and CYP2D6 for pharmacogenetic testing in Caucasians at 
present. One should be aware that the exclusion of a SNP does not automatically identify 
a patient as wild-type for that gene, since not all mutations are covered in the assay.
The work described in this manuscript represents a new application for plasmid-
derived control and expands their use to the field of pharmacogenetics. This should 
enable pharmacogeneticists to use standard genotype controls for diagnostic testing. 
Pharmacogenetic testing for diagnostic reasons demands good-quality controls. In 
the USA, the CDC initiated studies to assess the status of quality assurance practices 
of laboratories performing genetic testing, and to develop recommendations for 
improvement in genetic testing [6,7]. Quality-control materials are essential for validating 
new tests, monitoring test performance and for detecting errors in the testing process; 
therefore, one of the issues with utmost urgency is, as acknowledged by the CDC, to 
improve the availability of quality-control materials. In concordance with laboratories 
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in the Netherlands, quality control materials in the USA are obtained through a number 
of sources, such as commercially available cell lines or DNA (i.e., CEPH from Coriell 
[107]), previously tested patient materials and inter-laboratory exchanges. However, 
despite the availability of the desired appropriate quality control materials, these 
resources are still not adequate for all genetic testing, especially for pharmacogenetic 
testing. For example in Europe, Eurogentest (Leuven, Belgium) [110] has started its 
activities in 2005 (funded by the European Commission). The aims of Eurogentest are 
to harmonize and improve the overall quality for existing genetic services. The raising 
of Eurogentest was the direct result of the lack of structure and harmonization at the 
European level; diverse quality schemes and lack of reference systems. There are close 
collaborations with a European project to develop reference materials, the Certified 
Reference Materials for Molecular Genetic testing project (CRMGEN [111]). Despite 
the call of CRMGEN for samples with interesting mutations to be banked, their reference 
material database exists of the common disorders like cystic fibrosis, Factor V Leiden, 
Huntington disease and more (a reference material summary sheet can be downloaded 
at their website [111]) but did not yet contain pharmacogenetic-related genes. Thus, 
also in Europe there are initiatives to develop and make available reference materials for 
genetic tests, although they are restricted to disease-related mutations at present, and not 
for use in pharmacogenetic testing. From these initiatives we can conclude that there 
still is a need for quality-control materials, especially for application in pharmacogenetic 
testing. We hope that our initiative to create plasmid-derived controls will help to 
facilitate quality in the pharmacogenetic genotyping tests applied in research, as well 
as in routine patient care.
EXECUTIVE SUMMARY
•	 Pharmacogenetics is now expanding from clinical pharmacological research to its 
application in clinical practice.
•	 Clinical application of pharmacogenetics will result in adjustment of treatment of 
individual patients. Therefore, quality assurance for clinically applied test is even 
more important than for investigational tests. This can be achieved by the use of 
standardized quality controls.
•	 Screening of the materials and methods sections of papers published in 2005–2007 
in Pharmacogenomics or Pharmacogenetics and Genomics revealed that only in a 
minority of papers the genotyping of quality controls is reported, and no standard 
procedures are applied.
•	 We developed plasmid-derived external controls for TPMT*2, *3B/C; CYP2D6*3, *4, 
*6, *9, *41; CYP2C9*2, *3; and CYP2C19*2, *3, and applied these in clinical testing.
1095 plasmid-derived quality control samples
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•	 The development of plasmid-derived external controls for pharmacogenetic testing 
represents a new application and expands the use of plasmid-derived controls to the 
field of pharmacogenetics.
•	 Plasmid-derived quality controls enable the general use of standardized external quality 
controls in pharmacogenetic testing.
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ABSTRACT
Background: Several studies report difficulties in genotyping HNF1β  rs757210 using 
TaqMan probes. This is possibly due to the tri-allelic nature of this SNP. The aim of the 
present research was to develop alternative methods for genotyping rs757210. 
Material & Methods: Pyrosequencing and High Resolution Melting analysis of small 
amplicons (HRM) were developed and tested in panels of type 2 diabetes mellitus 
patients (n = 258) and healthy blood donors (n = 183). Results were confirmed by 
Sanger sequencing.
Results: With pyrosequencing, allele frequencies for the A, G and C allele of 0.42, 0.56, 
0.02, and 0.37, 0.62, 0.01 were established in the panel of type 2 diabetes mellitus 
patients and healthy blood donors, respectively. Similar results were found using the 
more routinely available HRM method. Results for pyrosequencing and HRM were in 
99.6% concordance. 
Conclusion: Pyrosequencing and HRM can be used to genotype the tri-allelic SNP 
rs757210 in the HNF1β gene and have the advantage over the commercially available 




Rs757210 is located in the gene that codes for hepatocyte nuclear factor 1β (HNF1β). 
HNF1β is a transcription factor and alterations in this gene are associated with congenital 
anomalies of the kidney and urinary tract, as well as an increased risk for developing type 
2 diabetes mellitus (T2DM) [1-12]. Rs757210 is an intronic A/G SNP with a reported 
minor allele frequency of 0.43 (HapMap-CEU, accessed 03-12-2010). Genotyping of 
rs757210 with commercially available TaqMan probes was found problematic in multiple 
studies. Stancakova et al. reported genotyping results of 20 risk alleles for T2DM using 
TaqMan probes in a large cohort of non-diabetic men. HNF1β rs757210 had to be 
excluded from the analyses because of failure to achieve Hardy-Weinberg equilibrium 
(HWE) [13]. In an investigation of the influence of T2DM risk alleles on the risk for 
the development of diabetes after renal transplantation, Ghisdal et al. reported a low call 
rate for rs757210 compared to a call rate of > 99% for the 10 other genotyped SNPs 
[14]. Again, rs757210 was the only SNP that deviated from HWE. Holmkvist et al. 
report that genotyping rs757210 with matrix-assisted laser desorption/ionization-time-
of-flight mass spectroscopy (MALDI-TOF) was successful in subjects from the Malmö 
Preventive Project whereas genotyping rs757210 with a TaqMan assay failed in subjects 
from the Botnia study. These authors noted that the SNP is tri-allelic what is considered 
the reason for problematic genotyping [15]. In our own experience, repeated genotyping 
of rs757210 with a TaqMan assay also failed to meet the pre-defined quality criteria of 
a call rate ≥ 95% in a recent study on the effect of T2DM associated risk alleles on the 
response to sulfonylureas in T2DM patients [16].
The finding that rs757210 is tri-allelic has been reported previously [1,15] but has received 
limited attention in the literature. Furthermore, the NCBI SNP database [http://www.
ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=757210, accessed 27-06-2011] also does 
not mention that rs757210 is tri-allelic. 
The aim of the present research was to develop alternative methods for genotyping 
rs757210. First we developed a pyrosequencing method, and since this methodology 
is not always available, also the feasibility of a high resolution melting method of small 
amplicons (HRM) to genotype rs757210 was investigated.
RESULTS
Pyrosequencing 
Pyrosequencing confirmed rs757210 as being tri-allelic. Using the given nucleotide 
dispensation order we identified the rare variant C allele, with an allele frequency of 0.02 
(95% confidence interval (CI) 0.01-0.03) in a cohort of 258 T2DM patients (Figure 6.1). 
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Allele frequencies for the A and G allele were 0.42 (95% CI 0.37-0.46) and 0.56 (95% 
CI 0.52-0.61), respectively. No homozygous carriers of the allele C were found. Results 
were in Hardy-Weinberg equilibrium (p = 0.30). To ascertain that the pyrosequencing 
results were valid, genotypes of the 8 patients carrying a copy of the variant C-allele and 13 
(5%) other randomly chosen samples were confirmed by conventional Sanger sequencing. 
Results were in 100% concordance (data not shown). Subsequently, genotype frequencies 
of 0.37 (95% CI 0.32-0.42), 0.62 (95% CI 0.56-0.67), and 0.01 (0.002-0.03) for the 
A, G, C allele respectively, were established in a cohort of 183 healthy blood donors. 
No statistically significant differences were observed between the TDM population and 
healthy blood donors for any of the alleles (Table 6.1). 
High Resolution Melting
Figure 6.2 depicts the typical melting curves of the 6 different HNF1β genotypes. Since 
no patient with the CC genotype was included, the CC melting curve was obtained from 
genomic plasmid control. HRM results were obtained for all of the 258 TDM patients. 
Results were in 99.6% concordance with the pyrosequencing results confirming the 
feasibility of this method.
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Figure 6.1 Pyrograms for HNF1β rs757210. Panels depict typical pyrograms obtained for HNF1β 
rs757210 for patients with AA genotype (panel A); AG genotype (panel B); GG genotype (panel C); 
CG genotype (panel D); AC genotype (panel E).
MATERIALS AND METHODS
DNA samples and isolation
A total of 258 DNA samples was obtained from a panel of T2DM patients. Panel 
ascertainment and sample collection have been described in detail previously [17]. Briefly, 
patients that had at least one prescription of the oral antidiabetic drugs tolbutamide, 
glibenclamide, glimepiride or gliclazide between January 1992 and June 2008, were at 
least 18 years of age and without insulin use at the time of first sulfonylurea prescription 
were included. Patients were recruited from four university affiliated primary care centers 
located in the vicinity of Leiden, The Netherlands. Patients received a written invitation 
by mail from their general practitioner. All patients provided informed consent and the 
study was approved by the institutional ethics committee. DNA was extracted from saliva 
specimens using Oragene kits (Westburg, Veenendaal, The Netherlands). To compare 
allele frequencies between T2DM patients and healthy volunteers an additional set of 183 
anonymized DNA samples was obtained from a panel of residual blood samples obtained 
from healthy blood donors (Sanquin, Leiden, The Netherlands). DNA was extracted 
with the Magnapure Compact instrument (Roche, Almere, The Netherlands) according 
to the manufacturers’ protocol. 
Pyrosequencing
First a pyrosequencing method was developed. Oligonucleotides were obtained from 
Eurogentec (Maastricht, The Netherlands). Primer sequences for polymerase chain 
reaction (PCR) and pyrosequence reactions are listed in Table 6.2. HotStar PCR mastermix 
and pyrosequencing reagents were obtained from Qiagen (Hilden, Germany) and PCR 
reactions were performed on the MyCycler (Biorad, Veenendaal, The Netherlands). The 
PCR reactions consisted of 10 ng DNA and 5 pmol of each primer in a total volume of 
12µl. Cycle conditions were, initial enzyme activation for 15 minutes at 95°C, followed by 
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Table 6.1 Allele frequencies of HNF1β rs757210 alleles in 258 type 2 diabetes mellitus patients and 
183 healthy blood donors determined with pyrosequencing
Type 2 diabetes mellitus patients (n = 258) Healthy blood donors (n = 183)
Allele Mean 95% CI Mean 95% CI p-value
A 0.42 0.37-0.46 0.37 0.32-0.42 0.19
G 0.56 0.52-0.61 0.62 0.56-0.67 0.17
C 0.02 0.01-0.03 0.01 0.002-0.03 0.82
95% CI, 95% confidence interval.
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Figure 6.2 Typical melting peaks for the 6 different HNF1β rs757210 genotypes obtained with High 
Resolution Melting of the small amplicons. Lines represent results for AA (•);GG (•);AG (•); CG (•); AC 
(•), genotypes respectively, obtained from type 2 diabetes mellitus patients or plasmid controls, and 
CC (•) genotype obtained from genomic plasmid control.
Panel A Mixture of samples from type 2 diabetes mellitus patients and genomic plasmid controls. 
Panel C Typical melting peaks obtained from genomic plasmid controls. 
Panel B Typical melting peaks obtained from type 2 diabetes mellitus patients. 
35 cycles of 95°C-55°C-72°C each for 30 seconds, and a final extension of 10 minutes at 
72°C. Samples were genotyped on the Pyrosequencer 96 MA (Biotage, Uppsala, Sweden). 
The pyrosequence reactions were performed according to the manufacturers’ protocol. 
Sequence to analyze was C/A/GTGTCCAGGCT and nucleotide dispensation order was 
TCAGCTGTCA. As a quality control 5% of the samples were genotyped in duplicate 
and no inconsistencies were observed. To ascertain that pyrosequencing results were 
valid, genotypes from more than 5% of patients were confirmed with Sanger sequencing, 
including all patients with the rare third allele.
High Resolution Melting of small amplicons
Secondly, the DNA samples from 258 T2DM patients were genotyped based on melting 
plots obtained by HRM of small amplicons. Results were compared to the results of 
pyrosequencing. Oligonucleotides used for small amplicon (+ 40 bp) genotyping were 
chosen adjacent to the SNP. Internal oligonucleotide calibrators were used to improve small 
amplicon genotyping. Oligonucleotide sequences are listed in Table 6.2. Amplification 
was performed in a 10 µl reaction volume in a HRM suitable 96-well plate (Thermofast 
® 96 Skirted, ABgene, Westburg, Leusden, The Netherlands). The reactions included 
HotStar PCR mastermix (Qiagen, Hilden, Germany), 5 pmol primers, 1x LC-Green® 
Plus (Bioke, Leiden, The Netherlands), 0.05 mM internal oligonucleotide Calibrator 
(IDT, Coralville, USA) and 20 ng DNA. Reactions were overlaid with mineral oil 
(Sigma-Aldrich, Zwijndrecht, The Netherlands). PCR conditions was as follows: 15 
minutes at 95°C, followed by 40 cycles of 95°C (10 sec)-55°C (20 sec)-72°C (30 sec) 
and a final extension of 5 minutes at 72°C followed by 1 minute at 95°C. Finally, the 
samples were cooled down to room temperature. High resolution melting was performed 
on the Lightscanner® (HR-96, Idaho Technology, Salt Lake City, USA). Melting was 
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Table 6.2 Primers for PCR and pyrosequencing of HNF1β rs757210
Name Purpose Modification Orientation Sequence 5’-3’
783 PCR forward CAGCTGCGAGAGTGTCTC
784 PCR 5’-Biotine reverse CTCCATGTGAGAAGTATAGC
785 Pyrosequencing forward AGCCTGCAGGCTGGGCTC
804 Plasmid forward TGAACACTGTTCAGCCTGC
805 Plasmid reverse TCTAAATGCAGTTACTTGAGG
806 HRM forward AAGCCTGACAGGCTGGGCTC
807 HRM reverse TTGGGGCAGGAGCCTGGAC
done from 50°C to 98°C with ramp rate of 0.1°C/sec. Melting curves were analyzed with 
Lightscanner® Software using Call-IT 2.0. Again, 5% of the samples were genotyped in 
duplicate and no inconsistencies were observed.
Genotype controls 
HRM requires the use of well characterised controls. Therefore plasmid controls with 
a 639 bp insert of the HNF1β gene, with the three variants of the SNP at position 
240 were created. Preparation has been described in detail previously [18]. In short, 
plasmid controls were made by ligation of HNF1β PCR product into pGEM-T easy 
vector (Promega, Leiden, The Netherlands) and plasmid DNA was isolated by standard 
procedures. Genotypes of the plasmid controls were determined by conventional 
sequencing on the ABI 3130 analyser using BigDye® Terminator v3.1 Cycle Sequencing 
Kit From Applied Biosystems (Applied Biosystem, Nieuwerkerk aan de IJssel, The 
Netherlands). 
Statistical analysis
The data were analyzed using the SPSS statistical package (version 17.0, SPSS, Chicago, 
IL, USA). Possible deviation from Hardy–Weinberg equilibrium was tested by the χ2 test. 
A p-value < 0.05 was considered a deviation. Difference in allele frequencies between 
patients with T2DM and healthy blood donors were tested with an unpaired Student’s 
t-test. A p-value < 0.05 was regarded as statistically significant.
DISCUSSION
In this study, we showed the feasibility and accuracy of pyrosequencing and HRM to 
genotype the tri-allelic rs757210 in the HNF1β gene. With the pyrosequencing method 
the presence of the rare variant C allele was confirmed and the allele frequencies were 
established in T2DM patients and healthy blood donors. To the best of our knowledge, 
this is the first study to report pyrosequencing and HRM as useful alternatives methods 
to TaqMan to genotype rs757210 with the latter method having the disadvantage to fail 
to determine the rare C-allele variant.
The presence of the tri-allelic nature of rs757210 was noted by Winckler et al. recently 
[1]. Holmkvist et al. established genotype frequencies in a Swedish population of 
2293 healthy individuals of whom 132 developed type 2 diabetes [15]. Reported allele 
frequencies were 0.36, 0.61, and 0.03 for the A, G, and C allele respectively. These 
results are comparable to the pyrosequencing results reported in this article. However, 
genotyping by Holmkvist et al. was performed by MALDI-TOF. These techniques are 
not standard for most laboratories. For this reason we extended our investigations to 
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test the feasibility of HRM of small amplicons to detect these variants. HRM of small 
amplicons is an attractive genotyping method because it is fast, relatively cheap (no 
labelled primers are required), no sample processing is required after amplification 
and most new generation real-time machines, present in many laboratories performing 
genotyping studies, are equipped with this possibility making it more accessible for 
other investigators [19,20]. 
The problems of genotyping rs757210 with the commercially available TaqMan assays 
probably originate from the fact that the assay was designed without knowledge of the 
tri-allelic nature of the SNP. Both pyrosequencing and HRM are more flexible concerning 
probe design and therefore better suited to genotype this SNP. 
A possible limitation of our study is that no homozygous carriers of the C allele were 
included. Therefore we were unable to test the suitability of the pyrosequencing and 
HRM method to genotype subjects with this genotype. Based on the frequency of the 
C allele, 0.04% of the population is expected to be homozygous carrier of the C allele 
and as a result very large cohorts are required to include them. Also, both methods were 
perfectly capable of identifying heterozygous carriers.
Carriers of the A allele of rs757210 have an increased risk to develop T2DM (OR 1.12 
p = 5*10-6) [1,13]. Models that use HNF1β genotype and other genetic markers can 
explain approximately 5-10% of T2DM heritability [21]. In our cohort no statistically 
significant difference in allele frequencies was observed between patients with T2DM and 
healthy blood donors. This is most likely due to the limited sample size of our study. Post-
hoc power analysis revealed that the power tot detect a statistically significant difference 
of 0.05 in allele frequency with an α of 0.05, was 48.8%. 
HNF1β is an important gene. Besides its contribution to T2DM risk prediction it 
might also provide opportunities for new therapeutic interventions and management 
i.e. pharmacogenetics. Currently there are insufficient data to support the latter, but the 
knowledge of the pharmacogenetics of oral anti-diabetic drugs has increased significantly in 
recent years [22-24]. Combined with the ever increasing incidence of T2DM worldwide, 
these developments might anticipate a greater clinical role for genotyping HNF1β and 
other genetic variants, and endorse the relevance of easily available genotyping methods 
such as our pyrosequencing or HRM method. 
Conclusion
In conclusion, we have shown that pyrosequencing and HRM can both be successfully 
applied to genotype the tri-allelic SNP rs757210 in the HNF1β gene.
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Aims: Sulfonylureas are mainly metabolized by the enzyme CYP2C9. Two allelic variants, 
CYP2C9*2 and CYP2C9*3, result in decreased metabolic capacity and have been 
associated with elevated sulfonylurea serum levels. However, most of the available data 
originates from pharmacokinetic analyses performed in healthy individuals. In this study, 
the effect of CYP2C9*2 and CYP2C9*3 alleles on prescribed dose and time-to-stable 
dose of sulfonylureas was investigated. 
Materials & methods: A group of 207 incident sulfonylurea users treated in four 
university affiliated primary care centers were identified. The effect of the CYP2C9*2 
and CYP2C9*3 alleles on prescribed dose and time-to-stable dose was then assessed. 
Results: No significant effects of the CYP2C9*2 and CYP2C9*3 alleles were found. 
However, a trend towards a lower stable glimepiride dose for carriers of the CYP2C9*3 
allele was observed. 
Conclusion: Genotyping for the CYP2C9*2 and CYP2C9*3 alleles currently appears 
to have no clinical implications for dosing of sulfonylureas in primary care patients with 




Sulfonylureas (SUs) are part of the mainstay of treatment of type 2 diabetes mellitus 
(T2DM) with oral antidiabetic drugs. They act by closing the pancreatic β-cell potassium 
channels, stimulating insulin secretion [1]. SUs are initiated at a low dose and titrated 
up to the optimal dose with intervals of 2–4 weeks until the glycemic target is achieved. 
Undertreatment will increase the risk of long-term microvascular and macrovascular 
complications, whereas overtreatment will lead to hypoglycemia, a well recognized adverse 
event that limits rapid dose escalation and is reported to be fatal in 1.4–10% of cases [2].
The enzyme CYP2C9 plays an important role in the pharmacokinetics of SUs. Two 
allelic variants, CYP2C9*2 and CYP2C9*3, result in decreased metabolic capacity. Both 
alleles are relatively common in Caucasians [101]. Most of the available data regarding 
the effect of CYP2C9 polymorphisms on SU treatment originate from pharmacokinetic 
analyses performed in healthy individuals [3–9]. Only four studies have assessed the 
effect of CYP2C9 polymorphisms in T2DM patients. Presence of the CYP2C9*3 
allele was associated with hypoglycemia [10,11]. Furthermore, the CYP2C9*3 allele is 
associated with the absence of tolbutamide dose escalation and carriers of the CYP2C9*2 
or CYP2C9*3 allele are less likely to fail on SU monotherapy [12,13]. However, none 
of these studies have assessed the effect of the CYP2C9 genotype on the time required 
for SU dose titration. Therefore, the aim of this study was to investigate the effect of 
CYP2C9*2 and CYP2C9*3 alleles on prescribed dose and time-to-stable dose of SUs in 
T2DM patients in a primary care setting.
MATERIALS AND METHODS
Study setting 
In The Netherlands patients are listed with one family physician (FP) who is consulted 
for all healthcare problems and indicates whether referral to secondary care is appropriate. 
The FP keeps an electronic patient record (EPR) that covers all medical information, 
including prescription data concerning the patient. T2DM patients are treated according 
to the T2DM guideline of the Dutch College of General Practitioners [14]. 
Study population
Patients were recruited from four university affiliated primary care centers located in 
the vicinity of Leiden, The Netherlands. Approximately 37,000 patients were enlisted. 
Retrospective clinical and prescription data were retrieved from the EPR. Patients 
were eligible for the study if they had received at least one prescription of tolbutamide, 
glibenclamide, glimepiride or gliclazide after 1992, were at least 18 years of age and 
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were without insulin use at the time of first SU prescription and had at least 270 days 
of follow-up registered in the EPR. To ascertain that a SU prescription was the first, a 
period of at least 6 months without SU prescriptions prior to that prescription recorded 
in the EPR was required.
Sample collection
Eligible patients received a written invitation by mail from their FP. After consent, a 
saliva collection kit (DNA Genotek, ON, Canada) was mailed. The ethics committee 
of the Leiden University Medical Center approved the study and informed consent was 
obtained from all participants. 
Genotyping
Genotyping of CYP2C9*2 (rs1799853) and CYP2C9*3 (rs1057910) was performed by a 
TaqMan® allelic discrimination assay (Applied Biosystems, CA, USA), independently and 
without knowledge of the patient data. Assays were used according to the manufacturer’s 
instructions and performed on 10 ng genomic DNA. Fluorescence detection and genotype 
calling were performed using an ABI Prism® 7750 Sequence Detection System (Applied 
Biosystems).
Definition of effect of CYP2C9*2 and CYP2C9*3 alleles on SU dose and 
time-to-stable dose
The primary end point of our study was the effect of the CYP2C9*2 and CYP2C9*3 
alleles on the stable SU dose. This was defined as the first period of 270 consecutive 
days or more without SU dose adjustment, or initiation or adjustment of therapy with 
another SUs, insulin or metformin. Dose was normalized to allow for the pooling of 
different SUs by dividing the prescribed daily dose with the standard daily dose used by 
the Dutch Healthcare Insurance Board (10 mg glibenclamide; 1000 mg tolbutamide; 
160 mg gliclazide; 2 mg glimepiride) [15]. The period of 270 days or more was chosen 
because prescriptions in The Netherlands are limited to a maximum of 90 days, and 270 
days or more equals three consecutive prescriptions.
The secondary end points of our study were the effect of CYP2C9*2 and CYP2C9*3 alleles 
on the time to the first stable SU dose, and the effect of the CYP2C9*2 and CYP2C9*3 
alleles on the number of dose adjustments during the first year of SU treatment. Finally, 
the effect of the CYP2C9*2 and CYP2C9*3 alleles on the change in fasting glucose levels 




A difference in stable dose of 0.33 was considered to be clinically relevant. According to 
the T2DM guidelines of the Dutch College of General Practitioners this equals a difference 
in titration time of approximately 4 weeks. In the power analysis, we calculated that 120 
patients were to be included in order to test for statistical difference at a two-sided 5% 
significance level with at least 80% power.
The data were analyzed using the SPSS statistical package (version 16.0, SPSS, IL, USA). 
Possible deviation from Hardy–Weinberg equilibrium was tested by the χ2 test. Differences 
in stable SU dose, number of dose adjustments, and fasting glucose levels were analyzed 
with Kruskal–Wallis nonparametric tests and multivariate linear regression analysis. All 
demographic and clinical variables were tested univariately against stable SU dose. The 
variables with a p-value of less than 0.1 were selected for multivariate analysis. In addition, 
age, gender and genotype were included in the multivariate analysis regardless of their 
univariate p-value.
Associations between the CYP2C9*2 and CYP2C9*3 alleles and time-to-stable dose were 
evaluated using Kaplan–Meier survival analysis techniques.
RESULTS
Figure 7.1 depicts the study population. In total, 207 T2DM patients were available for 
data analysis. Table 7.1 presents the patient characteristics. The mean age at the time of 
first SU prescription was 61.5 years and 52.2% of the study population were men. Mean 
follow-up was 6.0 years, reflecting that most patients (74.4%) were included after 1st 
January 2000. The majority of patients started with tolbutamide (42.5%) or glimepiride 
(39.6%). Patients received an average of 26 SU prescriptions with a median duration 
of 90 days per prescription. In total, 30.4% of the patients used metformin when they 
started SU treatment. The population was in Hardy–Weinberg equilibrium (χ2 = 5.50; 
p = 0.14), indicating a low likelihood of selection bias or errors in genotyping.
Table 7.2 summarizes the effect of the CYP2C9*2 and CYP2C9*3 alleles on the SU dose. 
The mean starting dose was 0.62. As expected, no differences in mean starting dose were 
observed between the genotype groups. Of the 207 T2DM patients, 152 (73.4%) achieved 
stable dose. There were no statistically significant differences in the percentage of patients 
that achieved stable dose between carriers of the CYP2C9*2 (70.7%) and/or CYP2C9*3 
(77.5%) allele compared with homozygous carriers of the CYP2C9*1 (79.4%) allele (p 
= 0.48). For mean stable glimepiride dose, a trend towards a lower dose for carriers of 
a CYP2C9*3 allele in comparison to homozygous carriers of the CYP2C9*1 allele was 
observed (1.01 vs. 0.61; p = 0.07).
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To identify possible associations between demographic and clinical variables and stable 
SU dose, univariate regression analysis was performed. The SU starting dose and the 
use of metformin were associated with the mean stable SU dose (Table 7.3). To adjust 
for the effects of metformin and initial SU dose, a multivariate regression analysis with 
CYP2C9 genotype, age and sex was performed. In summary, the results remained similar 
to the data as presented in Table 7.2.
Since SUs are titrated to the optimal dose, an analysis of the time-to-stable SU dose 
and CYP2C9 genotype was performed. Median time-to-stable dose was 56, 50 and 48 
days for homozygous carriers of the CYP2C9*1 allele, carriers of the CYP2C9*2 allele 
or the CYP2C9*3 allele, respectively. The Kaplan–Meier curves for time-to-stable dose 
130
Figure 7.1 Flowchart of the study population. FP, family physician; SU, sulfonylurea.














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































demonstrated no significant differences between carriers of the CYP2C9*1, CYP2C9*2 or 
CYP2C9*3 alleles (p = 0.58) (Figure 7.2). For all CYP2C9 genotypes, approximately 35% 
of the patients achieved stability without any dose adjustment from the first prescription. 
The mean number of dose adjustments in the first year of SU therapy was 1.02 (range: 
0–6) for all patients, and did not differ between the genotype groups with 0.95 dose 
adjustments for homozygous carriers of the CYP2C9*1 allele, 1.22 dose adjustments for 
carriers of the CYP2C9*2 allele and 1.06 dose adjustments for carriers of the CYP2C9*3 
allele (p = 0.24).
In addition, differences in fasting glucose levels were assessed for the CYP2C9 genotypes. 
For 75 patients (49.3%), fasting glucose level measurements were available in the period 
90 days prior to the first SU prescription and during stable SU dose. Fasting glucose 
levels decreased with 2.8, 2.6 and 2.4 mmol/l for homozygous carriers of the CYP2C9*1 
allele, carriers of the CYP2C9*2 allele, and carriers of the CYP2C9*3 allele, respectively 
(p = 0.89).
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Table 7.3 Analysis of multiple factors relevant for stable sulfonylurea dose in type 2 diabetes 




95% CI p-value Difference 
in change 
95% CI p-value
Constant 0.912 0.307–1.516 0.003
Male vs. female 
gender
-0.190 -0.355– -0.025 0.024 -0.15 -0.32–0.02 0.083
The effect of age 
(per year increase)
-0.005 -0.013–0.004 0.280 -0.005 -0.014–0.003 0.218
Metformin use 
vs. no metformin 
use at stable 
sulfonylurea dose
0.142 -0.038–0.321 0.120 0.177 -0.01–0.361 0.060
Carrier of CYP2C9*2 
allele vs. wild-type
0.001 -0.209–0.211 0.992 0.041 -0.171–0.254 0.701
Carrier of CYP2C9*3 
allele vs. wild-type
-0.088 -0.307–0.130 0.425 -0.129 -0.352–0.094 0.254
First sulfonylurea 
dose
0.583 0.266–0.899 0.000 0.569 0.253–0.885 0.000
aThis considers the change in stable sulfonylurea dose (expressed as the prescribed daily dose divided by 
the standard daily dose used by the Dutch Healthcare Insurance Board).
DISCUSSION
In this retrospective study of 207 primary care patients with T2DM, no statistically 
significant effect of the CYP2C9*2 and CYP2C9*3 alleles on the prescribed stable dose 
or time-to-stable dose of SUs was found. However, a trend towards a lower stable dose 
for carriers of the CYP2C9*3 allele was observed, in the subgroup of patients treated 
with glimepiride. Since no difference in stable dose or time-to-stable dose between 
the different genotypes was observed, we hypothesized that carriers of the CYP2C9*2 
and CYP2C9*3 alleles might have a larger decrease in fasting glucose levels. There was 
however, no significant difference in decrease in fasting glucose levels during stable dose 
between carriers of the CYP2C9*2 or CYP2C9*3 alleles and homozygous carriers of the 
CYP2C9*1 allele in the relatively small subgroup of patients with fasting glucose level 
measurements available.
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Figure 7.2 Kaplan-Meier survival plots of time to the first stable dose of sulfonylurea in type 2 
diabetes mellitus patients in primary care stratified by CYP2C9 genotype.
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Our study has some limitations. In general, observational studies may potentially be 
affected by bias. The FPs were unaware of the genotype, thereby excluding this information 
bias. In our study, no data was available for patients who had switched to another family 
practice or who died in the period after 1992. As a consequence, we cannot completely 
rule out the possibility of selection bias. However, our population was in Hardy–Weinberg 
equilibrium, suggesting that no selection bias on genotype occurred. Moreover, a 
nonresponse analysis on age, gender, type of first prescribed SU, metformin use and FP 
revealed no differences between participants and patients who did not consent to our 
study, indicating that no selection bias on any of these parameters occurred.
The analysis of time-to-stable dose assumes that FPs adhere to the T2DM guideline of 
the Dutch College of General Practitioners. In general, adherence to guidelines by Dutch 
FPs is good [16]. If FPs do not adhere to the guideline, they can initiate treatment with a 
different dose or follow different titration intervals. In both situations this could introduce 
an error to our analyses of time-to-stable dose. However, there is no reason to assume 
that this error is not divided randomly over the different genotype groups. Therefore it 
does not affect the comparison of time-to-stable dose between the genotype groups but 
can only affect the absolute results of the time-to-stable dose analyses.
The CYP2C9 genotype is known to have a significant effect on the pharmacokinetics of 
SUs in healthy volunteers [3–7,9]. Less information is available regarding the effect of the 
CYP2C9 genotype in T2DM patients. Two retrospective studies assessed the effect of the 
CYP2C9*2 and CYP2C9*3 alleles on treatment outcomes with SUs. Becker et al. found 
that carriers of the CYP2C9*3 allele treated with tolbutamide received significantly lower 
doses on the arbitrarily chosen 10th prescription compared with patients with the wild-type 
genotype, No such effect was found for any of the other assessed SUs [12]. In addition, 
Zhou et al. observed a trend towards a 5% dose increase for patients with none or one 
copy versus no dose increase in carriers of two copies of the CYP2C9*2 or CYP2C9*3 
alleles in patients who were mainly treated with gliclazide monotherapy [13]. We report 
similar findings towards a lower stable SU dose for patients with a CYP2C9*3 allele for 
a population of whom approximately 40% of the patients is treated with glimepiride. 
These findings indicate that the CYP2C9*3 allele influences the treatment of T2DM 
patients with SUs. However, although inconclusive, our study suggests that the effect is 
probably small and we therefore feel that there is currently insufficient evidence to support 
the genotyping of CYP2C9 prior to prescribing SUs to an individual.
The pathogenesis of T2DM is not yet fully understood. Current theories include defects 
in insulin-mediated glucose uptake in muscle, dysregulation of the adipocyte as a secretory 
organ, dysfunction of the pancreatic β-cell and impaired insulin action in the liver [17]. 
Several studies including linkage analysis, candidate gene approaches and genome-wide 
association studies have identified 20 common genetic variants associated with T2DM 
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reflecting the disease’s multifaceted genetic background [18]. Probably as a consequence 
of this heterogeneity, interpatient variability of drug response remains largely unexplained. 
It is possible that the multifaceted genetic background of T2DM surpasses the effect 
of the CYP2C9 genotype on SU response. Therefore, there may be subpopulations of 
T2DM patients in which the effect of the CYP2C9*2 and CYP2C9*3 alleles may be of 
clinical relevance. 
Conclusion
In conclusion, no association between the CYP2C9*2 or CYP2C9*3 alleles and time-to-
stable dose was found in T2DM patients in primary care, whereas carriers of a CYP2C9*3 
allele showed a trend towards a lower stable glimepiride dose. However, there are many 
other factors influencing SU treatment outcome. Therefore, the effect of the CYP2C9*2 
and CYP2C9*3 alleles currently has no clinical implications to dosing of SUs in T2DM 
patients.
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Objective: After the identification of type 2 diabetes mellitus (T2DM) risk alleles from 
genome-wide association studies, models have been developed to identify subjects at high 
risk to develop T2DM. We hypothesize that a panel of 20 repeatedly associated T2DM 
risk alleles influences response to sulfonylureas (SUs).
Methods: Two hundred and seven incident SU (tolbutamide, glibenclamide, glimepiride, 
gliclazide) users with T2DM were recruited from four primary care centers. A genetic 
risk score per patient was calculated based on the number of risk-alleles. With this score, 
patients were categorized into three predefined genetic risk groups. The effect of the 
genetic risk group on the achievement of stable SU dose, prescribed stable SU dose, and 
time to stable SU dose was analyzed.
Results: Carriers of more than 17 T2DM risk alleles had a 1.7-fold reduced likelihood 
to achieve stable SU dose (p = 0.044). No significant effect of the number of T2DM 
risk alleles on prescribed dose was found. Carriers of more than 17 T2DM risk alleles 
showed a marginally significant increased time to stable dose (hazard ratio: 0.81; 95% 
confidence interval 0.75–1.01, p = 0.058).
Conclusion: T2DM risk alleles are associated with response to SUs in primary care 
T2DM patients. This suggests that individualization of T2DM treatment according to 




The incidence of type 2 diabetes mellitus (T2DM) is increasing at an alarming rate. 
Worldwide, the number of patients is expected to increase from 171 million in 2000 to 
366 million in 2030 [1]. The therapeutic goal of treating T2DM patients is to prevent 
or delay long-term microvascular and macrovascular complications by achieving the best 
possible glycemic control.
Sulfonylureas (SUs) are part of the mainstay of treatment with oral antidiabetic drugs. 
Tolbutamide, glibenclamide (glyburide), gliclazide, and glimepiride are the most 
commonly used representatives of this group. These drugs act by closing the pancreatic 
β-cell potassium channels, stimulating insulin secretion [2]. SUs are initiated at a low 
dose and escalated to the optimal dose with intervals of 2–4 weeks until the glycemic 
target (HbA1c < 7%) is achieved. However, there is significant interpatient variability 
in response to SUs, with approximately 10–20% of the patients experiencing primary 
failure (decrease in fasting glucose level < 1.1 mmol/l) and a similar percentage having 
an above average response (mean reduction HbA1c 1.5–2%) [3–5].
With the completion of multiple genome-wide association studies (GWAS) the knowledge 
of the complex genetic background of T2DM has increased. These studies report 
associations between genetic variants and the risk for the development of T2DM. A panel 
of 20 T2DM associated single nucleotide polymorphisms (SNPs) comprising 19 genes 
out of the GWAS data appears, that has been replicated in several studies [6–17]. These 
SNPs are used in models with the ultimate goal to identify subjects at high risk to develop 
T2DM. Although marginally, the addition of genetic information to clinical T2DM risk 
factors increased the ability to predict future diabetes [18–24].
From the panel of 20 T2DM risk-associated SNPs, the majority is involved in the process 
of insulin release from the pancreatic β-cells (Table 8.1). As SUs act by stimulating insulin 
secretion, response to SU treatment may also be influenced by these genetic variants. 
Indeed, two of the 19 T2DM risk-associated genes, encoding KCNJ11 and TCF7L2, have 
been previously correlated with variation in SU response [4]. Furthermore, in subjects 
analyzed for genetic variation in the genes TCF7L2, PPARG, FTO, KCNJ11, NOTCH2, 
WFS1, CDKAL1, IGF2BP2, SLC30A8, JAZF1, HHEX, it was reported that subjects 
with 12 or more T2DM risk alleles did not increase their insulin secretion to compensate 
for the increased insulin resistance as efficiently as those with 8 or less risk alleles [19]. 
Therefore, patients with a greater number of risk alleles may show less response to SU 
treatment and individualization of T2DM treatment according to genetic profile may be 
an opportunity to improve clinical outcome.
We hypothesize that the genetic variants associated with the development of T2DM are also 
associated with response to SU treatment. Therefore, we investigated the effect of T2DM 
risk alleles on the response to SU treatment in T2DM patients in a primary care setting.
8 genetic risk factors for t2DM anD sU response
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Table 8.1 Selected single nucleotide polymorphisms associated with type 2 diabetes mellitus
Gene rs number Chromosome Risk 
allele
Year Mechanism References
NOTCH2 rs10923931 1 T 2008 Unknown [9,19-24]
THADA rs7578597 2 T 2008 Unknown [9,19-24]
IGF2BP2 rs4402960 3 T 2007 β-cell 
dysfunction
[8,9,11-13,18-24]
PPARG rs1801282 3 C 2000 Insulin 
sensitivity
[8,9,11-13,19-24]
ADAMTS9 rs4607103 3 C 2008 Unknown [9,19-24]
WFS1 rs10010131 4 G 2007 Unknown [9,13,18-20,22,24]
CDKAL1 rs7754840 6 C 2007 β-cell 
dysfunction
[7-9,11-13,18-24]
JAZF1 rs864745 7 A 2008 β-cell 
dysfunction
[9,19-24]
SLC30A8 rs13266634 8 C 2007 β-cell 
dysfunction
[7-9,11-14,18-24]
CDKN2A/CDKN2B rs10811661 9 T 2007 β-cell 
dysfunction
[8,9,11-13,18-24]
rs564398 9 A [8,18,20,24]
TCF7L2 rs7903146 10 T 2006 β-cell 
dysfunction
[7-9,11-14,18-24]
HHEX/IDE rs1111875 10 G 2007 β-cell 
dysfunction
[7-9,11-14,18-24]
CDC123/CAMK1D rs12779790 10 G 2008 Unknown [9,19-24]
KCNJ11 rs5219 11 T 2003 β-cell 
dysfunction
[8,9,11-13,19-24]
KCNQ1 rs2237892 11 C 2008 β-cell 
dysfunction
[10,17,24]




TSPAN8/LGR5 rs7961581 12 C 2008 Unknown [9,19-24]
FTO rs8050136 16 A 2007 Obesity [8,9,11,13,19-22,24]





In the Netherlands the general practitioner (GP) plays a central role in the provision of 
health care. Patients are listed with one GP who is consulted for all healthcare problems 
and indicates whether a referral to secondary care is appropriate. Typically, the GP keeps an 
electronic patient record (EPR) that covers all medical information concerning the patient 
including prescription information and reports from laboratories and specialists. GP’s 
have adopted the practice guideline T2DM of the Dutch College of General Practitioners 
[25]. Tailoring the treatment to the individual patient is an important part of the therapy. 
Cohort ascertainment
A total of 207 T2DM patients from four university-affiliated primary care centers (17 
GPs) located in the vicinity of Leiden, the Netherlands were recruited. The ascertainment 
of the cohort has been described in detail previously [26]. In brief, patients that had at 
least one prescription of tolbutamide, glibenclamide, glimepiride, or gliclazide between 
January 1992 and June 2008, were at least 18 years of age and without insulin use at 
the time of first SU prescription, and had at least 270 days of follow-up registered in the 
EPR, were included. Ethnicity was not routinely recorded in the EPR but most patients 
in the Netherlands are from European ancestry. Patients received a written invitation by 
mail from their GP. Of the 472 invited patients, 222 (47%) agreed to participate (see 
Figure 8.1). After consent, a saliva collection kit (DNA Genotek Inc., Ottawa, Ontario, 
Canada) was mailed. The study was approved by the ethics committee of the Leiden 
University Medical Center.
Genotyping
We selected a panel of 20 SNPs in 19 genes that have been associated with the development 
of T2DM in at least three GWAS and were consistently replicated in later studies aimed 
at estimating the predictive value of these SNPs on the development of T2DM [6–24]. 
The selected SNPs are listed in Table 8.1. DNA was isolated from the saliva according 
to the protocol provided by the manufacturer (DNA Genotek Inc.). Taqman genotyping 
assays for 19 SNPs were designed by and obtained from Applied Biosystems (Applied 
Biosystems, Nieuwerkerk aan den IJssel, the Netherlands). SNP rs757210 could not be 
designed as a Taqman genotyping assay and therefore was genotyped by pyrosequencing 
(Isogen Life Science, Maarssen, the Netherlands). Taqman genotyping assays were 
performed on the LightCycler 480 II Real-Time PCR System (Roche Diagnostics, 
Almere, the Netherlands) according to standard procedures. Genotyping was performed 
without knowledge of the clinical data. We obtained an average genotyping success rate 
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of more than 95%. As a quality control 5% of the samples were genotyped in duplicate 
for all assays and no inconsistencies were observed. Five patients were excluded for quality 
reasons (genotype call rate ≥ 80%). All SNPs were in Hardy–Weinberg equilibrium (p 
> 0.05), with the exception of rs2237892 (p = 0.011). This is most probably ascribed 
to the very low minor allele frequency of rs2237892, which was 0.025 in our study and 
comparable with previously reported minor allele frequencies of 0.056–0.075 (http://
www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2237892) accessed 5 October 
2010. 
Definition of effect
For each patient a cumulative genetic risk score was calculated based on the number of 
present risk alleles. Each person could have 0, 1, or 2 of them for each SNP, resulting in a 
theoretical individual cumulative risk score between 0 and 40. This approach assumes an 
equal and additive effect of each allele on the risk of T2DM. To allow categorization of 
patients, we predefined three genetic risk groups on the basis of the frequency distribution 
of risk alleles. We defined a low genetic risk group and a high genetic risk group as the 
quintiles with the lowest and highest number of T2DM risk alleles, respectively. All other 
patients (three quintiles) were categorized in the intermediate risk group.
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Figure 8.1 Flowchart of the study population. 
The primary endpoint of our study is the effect of the genetic risk group on achieving 
stable SU dose. Stable SU dose was defined as the first period of more than or equal 
to 270 consecutive days without SU dose adjustment, or initiation or adjustment of 
therapy with other SUs, insulin or metformin. If therapy with insulin was initiated 
patients were censored. The period of more than or equal to 270 days was chosen because 
prescriptions in the Netherlands are limited to a maximum of 90 days and more than or 
equal to 270 days equals three consecutive prescriptions. Stable SU dose was calculated 
as normalized dose by dividing the prescribed daily dose with the standard daily dose 
used by the Pharmaceutical Aid Committee of the Dutch Health Care Insurance Board 
(10 mg glibenclamide; 1,000 mg tolbutamide; 160 mg gliclazide; 2 mg glimepiride). 
Secondary endpoints of our study are the stable SU dose and the time required for dose 
escalation (time to stable SU dose).
Statistical analysis
The data were analyzed using the SPSS statistical package (version 16.0, SPSS, Chicago, 
Illinois, USA). Deviation from Hardy–Weinberg equilibrium was tested by the χ2 test. 
Achievement of stable SU dose was analyzed with the χ2 test and multivariate logistic 
regression analysis. Differences in mean stable SU dose between genetic risk groups 
were analyzed using the Kruskal–Wallis test and multivariate linear regression analysis. 
Associations between the genetic risk groups and time to stable SU dose were evaluated 
using the Cox survival regression analysis. Before multivariate analysis, all demographic 
and clinical variables were tested univariately against the selected outcome. Variables with 
a p-value of 0.1 or less, age, and sex were selected for multivariate analysis. All multivariate 
analyses were corrected for age and sex.
RESULTS
Data from 202 T2DM patients were available. The range of the calculated genetic risk 
score was 10–26. The quintiles with the lowest (≤ 17) and highest (≥ 21) number of 
T2DM risk alleles consisted of 59 patients and 62 patients, respectively (Figure 8.1). Table 
8.2 presents the characteristics of the 202 patients. There were no differences between 
the different genetic risk groups observed in any of the patient characteristics except for 
age. Patients in the high-risk group were younger at the time of first SU prescription 
compared with patients in the low-risk and intermediate-risk group, respectively (p 
= 0.001). Mean follow-up was 5.9 years, reflecting that most patients (75.2%) were 
included after 2000. Our patients received an average of 26 SU prescriptions during 
the follow-up period with a median duration of 90 days per prescription.
The results of achieving stable SU dose and the T2DM genetic risk groups are presented 









































































































































































































































































































































































































































































































































































in Figure 8.3. Of the patients, 148 (73.3%) achieved stable SU dose. The percentage 
of patients achieving stable SU dose was lower in the high-risk group compared with 
the intermediate-risk and low-risk groups (61.3 vs. 74.1 vs. 84.7%, respectively, p = 
0.004). In the multivariate logistic regression analysis age at first SU prescription, the 
concomitant use of metformin, and the T2DM genetic risk group were independently 
significantly associated with achieving stable SU dose (Table 8.3). The regression model 
explained 28.7% of the variation in achievement of stable dose. Data show that patients 
with a higher T2DM risk had a 1.7-fold reduced likelihood to achieve stable SU dose 
(p = 0.044).
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Figure 8.2 Distribution of type 2 diabetes mellitus risk alleles and subsequent classification in 
risk groups. Patients were categorized in three genetic risk groups. Low-risk group; quintile with 
the lowest (≤ 17) number of type 2 diabetes mellitus risk alleles. High-risk group; quintile with the 
highest (≥ 21) number of type 2 diabetes mellitus risk alleles. Remaining patients were categorized 
in the intermediate-risk group (18-20 type 2 diabetes mellitus risk alleles).
Next, the mean SU starting dose was analyzed. The mean SU starting dose for all patients 
was 0.61 (95% CI 0.58–0.65). As expected, no differences in SU starting dose were 
found between the different genetic risk groups. No differences in mean stable SU dose 
were found between the different T2DM genetic risk groups [low-risk group 0.90, 95% 
CI 0.75–1.05 vs. intermediate-risk group 0.84, 95% CI 0.74–0.94 vs. high-risk group 
0.95, 95% CI 0.72–1.17, p = 0.97]. In multivariate linear regression, only the effect 
of the SU starting dose and sex were independently significant associated with stable 
SU dose, whereas the genetic risk group for T2DM was not associated with stable SU 
dose.
As SUs are escalated to the optimal dose, the effect of the genetic risk group on time to 
stable SU dose was evaluated. Carriers of the high-risk genetic profile (≥ 21 risk alleles) 
had a two-fold and five-fold longer time to stable dose compared with patients with the 
intermediate risk (18–20 risk alleles) and low-risk profile (≤ 17 risk alleles) (median time 
to stable SU dose 160 vs. 59 vs. 31 days, respectively, p = 0.007). In a multivariate Cox 
regression analysis including the factors such as age on first SU prescription, sex, and 
the concomitant use of metformin, patients with a higher number of risk alleles showed 
a marginally significant increased time to stable SU dose (hazard ratio: 0.81; 95% CI 
0.75–1.01, p = 0.058) (Figure 8.4).
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Figure 8.3 Percentage of type 2 diabetes mellitus patients that reached stable sulfonylurea dose. 
Low-risk group; patients with 17 or less risk alleles. Intermediate-risk group: patients with 18-20 risk 
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To the best of our knowledge, this is the first study exploring the relationship between 
response to treatment with SUs and T2DM risk alleles. In this retrospective cohort study 
of 202 T2DM patients, patients with more than 17 risk alleles have a 1.7-fold reduced 
likelihood to achieve a stable SU dose. These patients also show a marginally significant 
increased time to achieve stable SU dose compared with carriers of less than 17 risk alleles. 
However, the number of T2DM risk alleles does not seem to affect the average stable SU 
dose used. Therefore, our data suggest that patients with a higher number of T2DM risk 
alleles have a decreased and delayed response to SU treatment.
Drug response is determined by both pharmacokinetics and pharmacodynamics of a drug. 
Several groups have investigated genetic variation in genes affecting the pharmacokinetics 
of SU response. Two variants in CYP2C9, CYP2C9*2 and CYP2C9*3, have been 
associated with a decreased SU metabolism in healthy volunteers [27]. Five studies assessed 
the effect of these polymorphisms in T2DM patients. Presence of the CYP2C9*3 allele 
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Figure 8.4 Multivariate Cox regression analysis plots of time to the first stable dose of sulfonylureas 
in type 2 diabetes mellitus patients in primary care. 
Low-risk group (   ); patients with 17 or less risk alleles. Intermediate-risk group (- - - -); patients 
with 18-20 risk alleles. High-risk group (– – –); patients with at least 21 risk alleles.
was associated with an increased risk for hypoglycemia [28,29]. Tolbutamide users with 
a CYP2C9*2 or CYP2C9*3 allele have been shown to have a significantly lower dose 
escalation compared with homozygous carriers of the CYP2C9*1 allele [30]. In a large 
cohort of 1,073 incident SU users with T2DM Zhou et al. [31] found that carriers of the 
CYP2C9*2 or CYP2C9*3 allele were less likely to fail on SU monotherapy. In a recent 
study we found no statistically significant effect of the CYP2C9*2 or CYP2C9*3 allele 
on the prescribed stable dose [26].
Variation in genes associated with the pharmacodynamics of SUs in T2DM patients has 
received considerably less attention. Genetic variants associated with SU response have 
been described for some monogenic forms of diabetes [32–34]. For polygenic T2DM, 
variants in the genes KCNJ11, TCF7L2, ABCC8, IRS1, and NOS1AP have been associated 
with SU response [35–38]. Of these, only the genes KCNJ11 and TCF7L2 were reported 
to contribute to an increased risk for T2DM in published GWAS. KCNJ11 encodes the 
Kir6.2 subunit, one of the two subunits that form the ATP-sensitive potassium channel 
involved in insulin release. Carriership of the E23K variant of the KCNJ11 gene has been 
associated with failure to SU therapy, but there are some conflicting results [39–41]. 
Variants in the TCF7L2 gene have also been associated with SU response. In a study 
with 901 incident SU users, patients with the TT genotype for rs7903146 were 1.73 
times less likely to be treated to lower a target HbA1c of 7% in the first 3–12 months of 
treatment compared with patients with the CC genotype [42]. For a variant in linkage 
with rs7903146 an even larger effect (odds ratio = 1.95) was reported. In this study, none 
of the individual risk alleles were significantly associated with the achievement of stable 
dose (see Table 8.4), risk allele frequency and association with achievement of stable SU 
dose of the individual SNPs). This is most likely due to the limited sample size of our 
study and the probable small effect size of the individual risk alleles.
Our study has some limitations. No data were available for patients that switched to 
another GP or who died after 1992. Therefore, we cannot completely rule out the 
possibility of selection bias, although this is conceptually very unlikely. A nonresponse 
analysis with age, sex, type of first prescribed SU, metformin use, and GP showed no 
differences between participants and patients who did not consent to our study, suggesting 
that no selection bias has occurred on any of these parameters.
We selected stable SU dose as the primary endpoint of our analysis. Ideally macrovascular 
(e.g. diabetes-related death or myocardial infarction) or microvascular events (e.g. 
retinopathy or renal failure) would have been used. Alternatively, biomarkers related to 
these events, such as HbA1c or fasting plasma glucose (FPG) might have been used. 
However, as data concerning these parameters were not routinely recorded in the EPR, 
data were too sparse to be used in our analysis. Therefore, we selected stable SU dose as 
an alternative. Although, no SU pharmacogenetics studies have used stable SU dose as 
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endpoint, this parameter closely reflects actual clinical practice. The time to stable SU dose 
analysis assumes that GPs adhere to the T2DM guideline of the Dutch College of General 
Practitioners and titrate SU dose in response to glucose and HbA1c levels. We have three 
arguments that support our assumption. Firstly, mean FPG was 7.77 mmol/l (95% CI 
7.42–8.12, n = 95) for the subgroup of patients with a FPG measurement available during 
stable SU dose. Secondly, the adherence of GPs to guidelines is reported to be good in 
the Netherlands [43]. Finally, even if GPs do not adhere to the T2DM guideline, and bias 
would be introduced to our analysis, there is no reason to assume that the nonadherence 
of GPs is not divided randomly over the different genetic risk groups. Therefore, possible 
nonadherence does not affect the comparison of the time to stable dose between the different 
genetic risk groups but can only affect the absolute results of this analysis.
There are multiple known factors that predict a good response to SUs including baseline 
HbA1c, recently diagnosed diabetes, mild-to-moderate fasting hyperglycemia (< 
12.2–13.3 mmol/l), good β-cell function (high fasting C-peptide level), no history of 
insulin therapy, and absence of islet cell or glutamic acid decarboxylase antibodies [3]. 
However, for none of these factors sufficient data were available in our retrospective 
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Table 8.4 Risk allele frequency and association with achievement of stable SU dose of the individual 
SNPs




Association with achievement of 
stable dose (p-value, χ2)
Patients 
(n)
TCF7L2 rs7903146 T 0.359 0.188 199
KCNJ11 rs5219 T 0.418 0.338 202
HHEX/IDE rs1111875 G 0.616 0.506 202
SLC30A8 rs13266634 C 0.730 0.523 201











IGF2BP2 rs4402960 T 0.306 0.759 197
KCNQ1 rs2237892 C 0.027 0.665 199
PPARG rs1801282 C 0.890 0.567 202
FTO rs8050136 A 0.394 0.554 202
NOTCH2 rs10923931 T 0.108 0.755 202
WFS1 rs10010131 G 0.623 0.742 202
JAZF1 rs864745 A 0.538 0.813 202
THADA rs7578597 T 0.903 0.538 202
CDC123/CAMK1D rs12779790 G 0.185 0.242 195
TSPAN8/LGR5 rs7961581 C 0.279 0.244 202
ADAMTS9 rs4607103 C 0.752 0.319 199
HNF-1β (TCF2) rs757210 A 0.428 0.918 190
MTNR1B rs10830963 G 0.271 0.878 202
cohort study and we were unable to account for their effect. In addition, the available 
data on weight, a factor that is associated with the onset of T2DM, were too sparse to be 
included in the analysis as a covariate. As a consequence we cannot rule out that patients 
with a higher number of risk alleles also have a more severe form of T2DM that might 
confer to an a priori decreased probability to achieve stable SU dose. In our opinion, the 
only way to collect sufficient high quality data that cover all of these parameters would 
be to conduct a prospective observational study. Ideally such a study would include two 
treatment arms with pharmacological different drugs or placebo. Such a design would 
allow differentiating between the effect of T2DM risk alleles on disease progression and 
effect on treatment.
The results of different SUs were pooled in one analysis. Although SUs are generally 
reported to have equipotent glucose lowering effects when administered in maximally 
effective doses [3,5], it would be interesting to investigate if our hypothesis is valid for 
each of the individual SUs. However, due to the sample size of our study such a subgroup 
analysis was not possible.
We achieved a high success rate of genotyping with a call rate of more than 95% for all 
individual SNPs. After exclusion of five patients with a call rate of less than or equal to 
80, 0.9% of the genotype data were missing. Missing genotype data were replaced with 
a risk score of 0. To test the sensitivity of our analysis for this replacement, we reanalyzed 
the data using two alternative approaches. First, as for some SNPs the wild-type allele 
is the risk allele, missing data were replaced with the score of the wild-type allele. As a 
result, two patients were reclassified from the low-risk to the intermediate-risk group, 
and one patient was reclassified from the intermediate-risk group to the high-risk group. 
Secondly, we excluded all patients with any missing data, resulting in the exclusion of an 
additional 31 (15.3%) patients. Similar results on all end points were obtained with all 
approaches, except for the effect of the genetic risk score that lost statistical significance 
in multivariate analysis after exclusion of all patients with missing data. These sensitivity 
analyses indicate that our results are valid.
The analysis of the effect of the genetic risk score on SU response assumes that each 
risk allele has an equal and additive effect, both within and between loci. This is clearly 
a simplification of the mechanism leading to variation of SU response. However, this 
approach is used in all GWAS studies concerning prediction of T2DM. Until it is clear 
what the true effect size of individual risk alleles is, the additive genetic model is probably 
the most appropriate and consistent method to analyze T2DM genetic data.
We chose to compare the quintile with the lowest (≤ 17, n = 59, low-risk group) and 
highest (≥ 21, n = 62, high-risk group) number of T2DM risk alleles, whereas patients 
with 18–20 risk alleles were pooled in one group (n = 81, intermediate-risk group) 
(Figure 8.1). The use of quintiles was based on a study by Lyssenko et al. [19] and allows 
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potentially easy translation to the clinic by clear classification of T2DM patients. The 
cutoffs for the quintiles with the highest and lowest number of T2DM risk alleles fell 
within the group of patients with 21 and 17 risk alleles respectively. We categorized patients 
with 17 risk alleles to the low-risk group and 21 alleles to the high-risk group, resulting 
in a slightly larger number of patients in both categories than anticipated. To ascertain 
that our results are not solely due to study design, we also analyzed the genetic risk score 
as a continuous variable instead of the analysis of risk groups. Next to this genetic risk 
score (range 10–26), sex, age on first SU prescription, and the use of metformin were 
included in the multivariate analysis. Data showed similar results for both the effect size 
and direction for the genetic risk score (odds ratio 0.88, 95% CI 0.76–1.02, p = 0.11). 
This suggests that with increasing number of risk alleles, the chance of achieving stable 
SU dose decreases.
The concept of disease-related genes influencing response to treatment is not new. For 
example, variation in the gene coding for the 5-hydroxytryptamine 2A receptor has 
been associated with variation of clozapine response and increased susceptibility to 
schizophrenia [44,45]. Variation in the gene coding for the β-2-adrenergic receptor has 
been associated with airway responsiveness to β-2-receptor agonists and susceptibility 
to lower airway reactivity in patients with asthma [46,47]. Our results show that 
patients with a higher number of risk alleles were younger at the date of their first SU 
prescription. This may be the result of a more ‘aggressive’ form of T2DM. For many 
complex diseases such as T2DM, there may be multiple genetic backgrounds resulting 
in similar phenotypic disease, each requiring a different drug treatment. Our results 
support this concept, and support the use of disease-related genes in pharmacogenetic 
studies. We should emphasize, however, the fact that we have only begun to unravel the 
genetic determinants of drug response in T2DM and that although many of the genes 
are associated with β-cell function, the exact mechanism behind our finding remains 
unclear. Our results do provide some ‘proof of principle’ that the complex background 
of T2DM may ultimately result in the identification of different genetic subgroups of 
T2DM patients that require different pharmacotherapy. However, replication in an 
independent cohort and further elucidation of the causal mechanisms underlying SU 
response are warranted.
In conclusion, T2DM-associated risk alleles are associated with response to SU treatment 
in primary care T2DM patients. This suggests that individualization of T2DM treatment 
according to genetic profile may be an opportunity to improve clinical outcome.
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from Concept to Clinic
9.1
Adapted from: JJ Swen, JAM Wessels and H-J Guchelaar, 
Geneesmiddelenbulletin 2010;44:97-103.
INTRODUCTION
Pharmacogenetics is the study of variations in DNA sequence as related to drug response 
[1]. The ultimate goal of pharmacogenetics is to predict and thereby improve the drug 
response in the individual patient. After the completion of the Human Genome Project 
pharmacogenetics was often thought to be one of the first clinical applications resulting 
from the new knowledge of the human genome [2]. This chapter will present an overview 
of the developments within the field of pharmacogenetics in recent years, discuss barriers 
for clinical uptake, and finally will provide a future perspective of the implementation of 
pharmacogenetics in clinical practice.
Gene-drug interactions
Gene-drug interactions can be divided into three different types; gene-drug interactions 
affecting the pharmacokinetics of a drug, gene-drug interactions affecting the 
pharmacodynamics of a drug, and idiosyncratic gene-drug interactions. 
Pharmacokinetic gene-drug interactions
Initially the field of pharmacogenetics focused on drug metabolism [3]. Pharmacokinetics 
describes the processes to which a drug is exposed after administration. These processes 
are divided into absorption, distribution, metabolism (phase 1; biotransformation, phase 
2; conjugation), and excretion. Drug plasma concentration is a result of these processes. 
Each of these processes can be affected by genetic variation resulting in a different plasma 
concentration, drug exposure and subsequently possibly a difference in drug response [4]. 
The cytochrome P450 enzyme system is involved in the phase I metabolism of numerous 
drugs [5]. Genetic variation in genes coding for cytochrome P450 enzymes can affect 
the metabolic capacity of these enzymes. In general four different genotype inferred 
phenotypes are distinguished; ultrarapid metabolizers (UMs) with increased metabolic 
capacity, extensive metabolizers (EMs) with a normal metabolic capacity, intermediate 
metabolizers (IMs) with a decreased metabolic capacity, and poor metabolizers (PMs) 
with a strongly decreased metabolic capacity. Within each genotype inferred phenotype 
a significant variation in metabolic capacity remains [6]. UM status results in faster 
and increased formation of drug metabolites. As a result, efficacy can be decreased, or 
increased in the case of prodrugs. IM and PM status can result in adverse drug events 
due to increased plasma concentration or decreased efficacy in the case of prodrugs. The 
platelet aggregation inhibitor clopidogrel presents an example of a prodrug that requires 
metabolic activation. This reaction is catalyzed by the genetically polymorphic enzyme 
cytochrome P-450 CYP2C19. Several pharmacogenetic studies with clinically relevant 
endpoints have been reported (Box 9.1.1).
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During phase II metabolism an endogenous substrate (e.g. glucuronic acid, sulphate or 
glutathione) is incorporated in the drug molecule to facilitate excretion in the urine or 
bile. The N-acetylation of isoniazid by N-acetyltransferase is perhaps the most well-known 
example of genetic variability affecting phase II metabolism [3]. Other examples of genetic 
variation associated with phase II metabolism are thiopurine S-methyltransferase (TPMT), 
and UDP glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1). 
Transporter proteins play an important role in the absorption, distribution, and excretion 
phase of a wide variety of drugs. Drug plasma concentrations are particularly determined by 
drug transporters in the small intestine, liver, and kidney. For example, the P-glycoprotein 
encoded by the ABCB1 gene transports many drugs out of the cell into the urine or bile. 
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BOX 9.1.1 
Clopidogrel
From an analysis of nearly 1,500 patients with acute coronary symptoms who were 
treated with clopidogrel it was concluded that carriers of a reduced function CYP2C19 
allele had an increase of 53% in the composite primary efficacy outcome of the risk of 
death from cardiovascular causes, myocardial infarction, or stroke, as compared with 
noncarriers (hazard ratio 1.53, 95% CI 1.07-2.19) [7]. In a study of 259 patients 
who survived a first myocardial infarction it was reported that the primary composite 
endpoint of death, non-fatal myocardial infarction, or urgent revascularization occurred 
more frequently in carriers of the CYP2C19*2 allele (hazard ratio 5.38, 95% CI 2.32-
12.47) [8]. In a cohort of approximately 2,200 clopidogrel treated patients presenting 
with an acute myocardial infarction it was observed that patients carrying any two 
CYP2C19 loss-of-function alleles (CYP2C19*2, *3, *4, or *5) had a higher occurrence 
of the composite endpoint of death from any cause, nonfatal myocardial infarction, or 
stroke compared to patients with no loss-of-function alleles (hazard ratio 1.98, 95% 
CI 1.10-3.58) [9]. The observed association between reduced function CYP2C19 
alleles and increased likelihood of a cardiovascular event has been confirmed in a 
genomewide association study [10]. By contrast, the CYP2C19*17 allele results in an 
increased metabolic capacity of CYP2C19. In a cohort of 1,524 patients undergoing 
percutaneous coronary intervention after pretreatment with 600 mg clopidogrel it was 
observed that carriers of the CYP2C19*17 allele had an increased risk for bleeding 
(odds ratio 1.80, 95% CI 1.03-3.14) [11]. A limitation of most clopidogrel data is 
that they are obtained from observational studies or subgroup analyses of studies not 
primarily designed to investigate the effect of genetic variation in CYP2C19 rather 
than randomized controlled trials. 
Genetic variation in the ABCB1 gene results in variable expression of P-glycoprotein and 
variation in drug plasma concentrations [4,12]. For many other transporter proteins 
pharmacogenetic effects have been described [13,14].
Pharmacodynamic gene-drug interactions
Pharmacodynamics describes the effects of the drug on the body i.e. its biological effect 
mediated through interaction with a receptor, enzyme or ionchannel. Pharmacodynamic 
gene-drug interactions occur at this level and can influence drug response i.e. by 
genetic variation resulting in increased expression of a receptor. This is exemplified 
by the screening of breast cancers for HER2/neu overexpression to select patients 
eligible for treatment with trastuzumab (although strictly this is not an example of 
pharmacogenetics according to the EMA definition since no variations in DNA sequence 
is involved). Trastuzumab is a monoclonal drug directed against the HER2 protein 
that is expressed on the surface of tumor cells and mediates uncontrolled growth [15]. 
Trastuzumab is approved for the treatment of HER-2-positive breast cancer. A second 
example of a pharmacodynamic gene-drug interaction is the variation in response to the 
treatment with the oral anticoagulant warfarin as a result of genetic variation in the gene 
coding for vitamin K epoxide reductase (VKORC1), a key enzyme in the vitamin K 
cycle [16]. 
Idiosyncratic gene-drug interactions
Finally, there are idiosyncratic adverse drug reactions. Idiosyncrasy is an abnormal 
response that is unpredictable and thought to have an underlying genetic etiology. 
pharmacogenetic research has increasingly focused on these types of adverse drug 
reactions but was hampered by a lack of sufficient numbers of patients with well 
characterized phenotypes [17,18]. A classic example of idiosyncratic gene-drug 
interactions is glucose 6-phosphate dehydrogenase and response to primaquine (Box 
9.1.2). 
The association of HLA-B*5701 genotype with the hypersensitivity reaction to the 
antiretroviral drug abacavir presents a more recent example. For the latter gene-drug 
interaction the first randomized controlled pharmacogenetic trial was performed 
in 2008 [22]. 1,956 human immunodeficiency virus type 1 infected patients were 
randomly assigned to undergo prospective HLA-B*5701 screening, with exclusion of 
HLA-B*5701–positive patients from abacavir treatment (prospective-screening group), 
or to undergo a standard-of-care approach. Both immunologically confirmed (2.7% 
vs. 0%) and clinically diagnosed (7.8% vs. 3.4%) hypersensitivity reactions were more 
frequent in the control group than in the prospective-screening group. In response 
of these results registration authorities have revised the package insert of abacavir to 
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include the advice to screen for HLA-B*5701 prior to treatment initiation and to avoid 
prescription of abacavir to carriers of the HLA-B*5701 polymorphism, unless there is 
no therapeutic alternative.
OBSTACLES FOR THE IMPLEMENTATION OF PHARMACOGENETICS 
IN ROUTINE CLINICAL PRACTICE
Since the completion of the human genome project in 2003, genomics has become a 
mainstay of biomedical research and pharmacogenetics has been predicted to be one of 
the first clinical applications arising from the new knowledge [2,23,24]. Indeed, the 
research efforts in the field of pharmacogenetics expressed as the number of publications 
listed on PubMed have steadily increased during the last decade until leveling out in 
2009 at 1,100-1,200 publication per year (Figure 1.1, Chapter 1) [25]. By contrast, the 
clinical use of pharmacogenetic testing did not meet high expectations and has lagged 
considerably behind (Chapter 2). 
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BOX 9.1.2 
Historic perspective
The concept of interindividual differences in drug response was proposed as early as 1909 
by Garrod in his book The Inborn Errors of Metabolism [19]. But pharmacogenetics 
did not emerge as a distinct discipline until the late 1950s. For instance, it was then 
observed that a deficiency of glucose 6-phosphate dehydrogenase (G6PD) resulted 
in acute hemolytic crises in approximately 10% of the African-American soldiers but 
only a very small number of Caucasian soldiers who used primaquine as antimalarial 
drug [3]. G6PD deficiency was also suspected to account for favism - hemolysis after 
ingestion of Fava beans. Next, in 1956 Werner Kalow was the first to demonstrate 
interindividual variation in butyrylcholinesterase activity leading to clinical differences 
of patients in response to the muscle relaxant suxamethonium [20]. In 1977, Smith 
and his colleagues studied the antihypertensive effects of debrisoquine. Smith was 
the only among the study subjects to experience a very strong hypotensive reaction, 
and collapsed. When he recovered, he found out that the most important metabolite 
of debrisoquine was not detectable in his urine. In 1977 he published on the poor 
metabolizer and extensive metabolizer phenotypes of debrisoquine [21]. Since then 
many more SNPs in CYP2D6 as well as other cytochrome P-450 polymorphisms 
have been identified.
To better understand the reasons for the limited clinical use of pharmacogenetics one 
should take into account the consecutive phases and associated challenges on the road 
to clinical implementation of pharmacogenetics presented in Figure 2.1. This figure 
represents the parts of the “life cycle” of a pharmacogenetic biomarker. After the proof 
of principle, a pharmacogenetic biomarker is applied in small scale clinical research 
allowing evaluation of efficacy and cost-effectiveness. Following positive results, clinical 
adoption on an increasing scale will initiate. The first, and major, obstacle precluding 
clinical application of pharmacogenetics is the relative lack of scientific evidence that 
pharmacogenetics results in improvement in patient care [26]. Although the number of 
pharmacogenetic publications is large, approximately 45% of these publications consist 
of review articles and only a limited proportion is original research. The relative paucity 
of original research articles is not the only problem. Many original articles involve small, 
specific study populations, administration of single doses, use of healthy volunteers 
instead of patients, use of a different translation from genotype to phenotype, or were 
not designed to investigate pharmacogenetics. Moreover, most positive association 
studies lack validation of findings in an independent patient population. However, in 
recent years the number of well-designed pharmacogenetic studies increased. Many of 
these studies are genome wide association studies (GWAS) designed to investigate the 
association between genetic variability and drug efficacy or adverse drug reactions. GWAS 
have revolutionized genetic research as they allow the discovery of multiple gene variants 
with individually small effects. The underlying rationale for GWAS is the hypothesis that 
common diseases are attributable in part to common genetic variants present in more 
than 1-5% of the population [27]. The advantage of GWAS is that it eliminates the need 
to choose, a priori, candidate genes or variants. GWAS are highly suitable to identify 
genetic variants contributing to complex phenotypes (Figure 9.1.1). At the end of 2010 
1,212 published GWAS were listed at the National Human Genome Research Institute 
GWAS catalog [28]. The GWAS have identified hundreds of genetic variants associated 
with common diseases (type 2 diabetes mellitus (T2DM), inflammatory bowel disease, 
prostate cancer) as well as various individual traits (height, hair color, eye color) providing 
novel insights in the genetic architecture of complex traits in general. However, clinical 
application is limited since most SNPs only explain a small portion of genetic heritability 
[29]. For example despite extensive analyses by consortia that accrued cohorts of over 
20,000 subjects only 5-10% of T2DM heritability can be explained by genetic variants 
[30]. Since 2007 GWAS have increasingly been applied to the field of pharmacogenetics 
(Table 9.1.1). 
Drug response is a complex phenotype involving both known and unknown biological 
pathways. The GWAS approach enables novel and less obvious pharmacogenetic genes 
to be discovered, especially for genetic variation affecting drug pharmacodynamics which 
is more complex and often less well understood than drug pharmacokinetics. The GWAS 
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approach also seems promising in the discovery of genetic variants predicting drug response 
since drug response is generally a complex trait that is influenced by numerous genetic and 
environmental factors. There are some important differences between pharmacogenetic 
GWAS and GWAS for complex diseases (Figure 9.1.1).
First, for a GWAS of complex diseases such as T2DM it is unlikely to detect a common 
allele with a large effect size since such an allele would have been eliminated from the 
population due to natural selection. Yet some of the first pharmacogenetic GWAS 
have reported relatively large effect sizes that involved fewer genes compared to those 
detected in GWAS for complex disease [31]. This could be explained by the fact that 
for drug response no “natural-selection” occurs unless involved genes are also part of 
normal physiological processes. For adverse drug events the process of natural selection 
is embodied by the drug registration authorities that do not approve drugs that cause 
frequent toxicity (as would be the case for common alleles resulting in adverse drug 
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Figure 9.1.1 Feasibility of genome wide association studies to identify genetic variants by risk allele 
frequency and effect size (odds ratio). Genome wide association studies are especially suited to 
identify common variants of common disease. Figure adapted from [27,29]. Dashed circles indicate 
effect size vs. allele frequency for disease related genome wide association studies, boxes indicate 
pharmacogenetic genome wide association studies. PGt, pharmacogenetics.
events). However observed difference in effect size between GWAS for complex disease 
and pharmacogenetics might be biased by the fact that most pharmacogenetic GWAS 
have been of limited sample size (often < 500) compared to GWAS for complex disease 
(typical sample size 4,000). For drug response similar results have been obtained with 
a recent GWAS investigating glycemic response (HbA1c ≤ 7%) to metformin (n = 
3,920) [32]. A SNP (rs11212617) with an odds ratio of 1.35 for treatment success 
was reported. If more pharmacogenetic studies with larger sample sizes become 
available also more effect sizes similar to those in complex disease GWAS may be 
detected. 
A second difference is related to the definition of the studied phenotype. Because drug 
response is influenced by numerous genetic and environmental factors it often shows a 
continuous phenotypic distribution. It is suggested that selectively genotyping patients at 
the extremes of the response distribution provides nearly equivalent power to complete 
genotyping [33]. Heterogeneity in phenotype can also be introduced because drug 
response can not always be measured in a quantitative way.
A concern for pharmacogenetic GWAS is that currently commercially available 
genotyping arrays do not sufficiently capture the genetic variation that is already known 
to be important to common pharmacokinetic and pharmacodynamic pathways. In a 
recent evaluation of seven commercially available genotyping arrays it was estimated 
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Table 9.1.1 Published and replicated genome-wide association studies of drug response
Drug Outcome Patient population Significant genes Reference
Warfarin Efficacy All with drug VKORC1 CYP4F2 
CYP2C9
[76,77]
Acenocoumarol Efficacy All with drug VKORC1 CYP4F2 
CYP2C9 CYP2C18
[78]
Peginterferon α Efficacy Chronic hepatitis C infection IL28-β [79-81]
Clopidogrel Efficacy Percutaneous coronary intervention CYP2C19 [10]
Methotrexate Efficacy Pediatric patients with acute 
lymphoblastic leukemia
SLCO1B1 [82]
Simvastatin Toxicity Patients with myopathy and drug SLCO1B1 [83]
Flucloxacillin Toxicity Patients with liver injury and drug HLA-B*5701 [43]
Carbamazepine Toxicity Patients with hypersensitivity syndrome 
and drug
HLA-A*3101 [54]
Metformin Efficacy All with drug rs11212617 [32]
that coverage of 83 SNPs associated with 26 important pharmacogenes listed on 
PharmGKB coverage varied from 10-53% [34,35]. However, it is without doubt that 
GWAS offer tremendous possibilities for discovering new insights in the mechanisms 
of drug response. 
A second obstacle for clinical implementation is the lack of information on cost-
effectiveness and cost-consequences of pharmacogenetic testing. Cost-effectiveness has 
only been established for a very limited number of pharmacogenetic tests. The performance 
of cost-effectiveness analyses is problematic for two reasons. First, there are limited data 
on the rate at which pharmacogenetic testing actually prevents adverse drug reactions. 
Second, pharmacogenetic test prices are dropping continuously (Figure 9.1.2) [36]. A 
recent systematic review on cost-effectiveness of 20 pharmacogenetic studies found a lack of 
standardization regarding aspects such as the perspective of the analysis, factors included in 
the sensitivity analysis and the applied discount rates. In particular, an important limitation 
of several studies was related to the failure to provide a sufficient evidence-based rationale 
for an association between genotype and phenotype [37]. 
A third obstacle is that most pharmacogenetic tests (such as tests for genetic variants of 
cytochrome P450 enzymes) a detailed knowledge of pharmacology is a prerequisite for 
application in clinical practice, and both physicians and pharmacists might find it difficult 
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Figure 9.1.2 Cost of sequencing a human-sized genome. Reproduced from: Wetterstrand KA. DNA 

































































































to interpret the clinical value of pharmacogenetic test results. Guidelines that link the result 
of a pharmacogenetic test to therapeutic recommendations might help to overcome these 
problems, but such guidelines are only sparsely available (Chapter 2 and 3).
Other obstacles for clinical application of pharmacogenetics are unclear reimbursement 
status, and a lack of financial stimulus for the pharmaceutical industry to develop 
pharmacogenetic tests for drugs already marketed [26,38,39] (Chapter 2).
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BOX 9.1.3 
High likelihood of clinical relevance of pharmacogenetic testing
Pharmacogenetics can be useful in situations where the predictive ability of currently 
available biomarkers is low and the consequences, positive or negative, of a treatment 
are large. This can be exemplified by genotyping DPYD in patients treated with 
5-fluorouracil or its oral prodrug capecitabine. DPYD codes for the enzyme DPD 
which metabolizes these drugs. Germline polymorphisms in DPYD are associated with 
deficiency of the enzyme DPD which results in severe neutropenia [40].
A second useful application of pharmacogenetics may be in situations where controlling 
or adapting a therapy on the basis of a phenotype is not possible. This is exemplified by 
genotyping CYP3A5 in renal transplant patients prior to treatment with the calcineurin 
inhibitor tacrolimus. To prevent acute rejection, it is important to establish adequate 
tacrolimus plasma concentrations as early as possible. CYP3A5 is polymorphic and 
over ten different alleles have been identified [41]. The CYP3A5*3 allele, results in a 
non-functional CYP3A5 enzyme, and is the allele with highest gene frequency among 
Caucasians. In a randomized open label study with 280 renal transplant recipients 
treated with tacrolimus it was found that a larger proportion of patients receiving the 
genotype adapted dose had values within the targeted C0 at day 3 after treatment 
initiation (43.2% vs. 29.1%) [42].
A third example of a situation where pharmacogenetics can be useful is the lack of 
alternative drug treatments. Testing for HLA-B*5701 in patients infected with HIV 
sensitive to abacavir and a viral load requiring treatment present an example. 
Finally, pharmacogenetics can be useful in the elucidation and possibly prevention of 
idiosyncratic drug reactions such as the development of drug drug-induced liver injury 
due to flucloxacillin. Recently it was reported that approximately 85% of these cases 
can be explained by HLA-B*5701 status [43].
TRANSLATING PHARMACOGENETICS TO PRIMARY CARE
Quality control of pharmacogenetic testing
Pharmacogenetic testing prior to drug treatment is currently not a routine practice, and 
largely confined to academic hospitals and specialized laboratories. Clinical application of 
pharmacogenetics will result in adjustment of treatment of individual patients. Therefore 
quality control for clinically applied pharmacogenetic tests is even more important than 
for investigational pharmacogenetic tests. This can be achieved by the use of standardized 
quality controls. Yet after screening of the materials and methods sections of papers 
published in 2005-2007 in Pharmacogenomics or Pharmacogenetics and Genomics we found 
that only in a minority of papers the genotyping of quality controls is reported, and no 
standard procedures are applied (Chapter 5). Subsequently, we developed plasmid-
derived external controls for TPMT*2, *3B/C; CYP2D6*3, *4, *6, *9, *41; CYP2C9*2, 
*3; CYP2C19*2, *3 to enable the general use of standardized external quality controls 
in pharmacogenetic testing. The availability of good quality control materials is of key 
importance for the clinical implementation of pharmacogenetics. 
A second issue related to quality control is the exclusion of SNPs because of poor 
genotyping. In Chapter 6 we report that the exclusion of rs757210, a SNP in HNF1β, 
because of difficulties in genotyping with TaqMan probes might be related to the tri-
allelic nature of this SNP. Therefore we investigated the suitability of pyrosequencing 
and high-resolution melting as alternatives. These two chapters illustrate that ensuring 
the analytical validity of pharmacogenetic tests is essential. In addition they show that 
design of pharmacogenetic tests and operation of a pharmacogenetic laboratory are an 
evolving specialism in clinical laboratory medicine.
Pharmacogenetic dose recommendations in clinical practice
In 2005 the Royal Dutch Association for the Advancement of Pharmacy established 
the Pharmacogenetics Working Group (PWG) (Chapter 3). In this 15-member mul-
tidisciplinary working group, clinical pharmacists, physicians, clinical pharmacologists, 
clinical chemists, epidemiologists, and toxicologists are represented. The objective of the 
PWG is to develop pharmacogenetics-based therapeutic (dose) recommendations on the 
basis of a systematic review of literature, and to assist the drug prescribers as well as the 
pharmacists by integrating the recommendations into computerized systems for drug 
prescription and automated medication surveillance. The recommendations do not indicate 
patients who are eligible for genotyping, but merely aim to optimize drug use in the small 
but ever-increasing group of patients whose genotypes are known. Initially the project 
focused on genetic variations that affect pharmacokinetics, but this has been expanded 
to include genetic variations that affect pharmacodynamics for example the interaction 
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between genetic variation in the gene coding for factor V Leiden and estrogen-containing 
oral contraceptives. To date, the PWG has composed pharmacogenetic guidelines for 
53 drugs associated with 11 genes [44]. The guidelines issued since October 2006 
are available through most automated drug prescription, dispensing, and medication 
surveillance systems in The Netherlands making them accessible during the decision-
making process by physicians and pharmacists, namely the prescription and dispensing 
of drugs. A detailed description of the background of the project, methods used for data 
collection, data assessment, and preparation of gene–drug monographs are provided in 
Chapter 3. Recently, another project aimed at the creation of pharmacogenetic dosing 
guidelines was launched: the Clinical Pharmacogenetics Implementation Consortium 
(CPIC) [45]. The consortium was created in 2009 with the aim of facilitating the clinical 
implementation of pharmacogenetic testing by providing guidance to test users and has 
recently published its first guideline [46]. Created guidelines will be publicly available in 
the Pharmacogenomics Knowledge Base [34].
Despite the availability of pharmacogenetic guidelines there is little information 
regarding the potential impact of these guidelines in primary care. To test the feasibility 
of pharmacogenetic screening in primary care we conducted a pilot study among 93 
polypharmacy patients treated in primary care (Chapter 4). This study indicated that 
pharmacogenetic screening is feasible in a primary care setting with regard to patient 
willingness to participate, quality of DNA collection with saliva kits, genotyping, and 
dispensing data retrieved from pharmacy records. On average, included patients used 2.3 
drugs with a recommendation in the PWG guidelines. Moreover, general practitioners had 
not empirically switched PMs to drugs that were not substrate of the aberrant enzyme. 
These findings indicate potential clinical relevance of pharmacogenetic for a primary care 
setting. However, this was only a small pilot study with a highly selected patient population 
of polypharmacy patients aged > 60 not representing the average primary care patient.
FUTURE PERSPECTIVE
Throughout this thesis it is noted that the initial enthusiasm with what pharmacogenetics 
was received, sometimes even described as “hype”, has transformed into doubt and disbelief 
among some health care professionals in more recent years. In my opinion this is mainly 
due to the fact that pharmacogenetics has often been depicted as a “revolution” while in 
fact it is more an evolution, albeit a rapid evolution. Pharmacogenetic research is beginning 
to show consistent, reproducible results for an increasing number of genetic markers for 
drug response. In the upcoming years, we will see some important developments. 
The first development concerns dosing algorithms that include pharmacogenetic as 
well as more traditional clinical variables such as age, renal function and bodyweight. 
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Approximately 10 years ago, the majority of pharmacogenetic research was aimed 
at investigating the effect of a single polymorphism on treatment outcome. Often, 
the investigated polymorphism had been previously associated with an enzyme or 
transporter involved in the metabolic pathway of the drug under investigation. 
Nowadays, pharmacogenetic research has progressed from searching for associations 
between individual polymorphisms and treatment outcome, through combinations of 
multiple polymorphisms affecting pharmacokinetics and pharmacodynamics, to the use 
of pharmacogenetic models including polymorphisms as well as more traditional clinical 
variables for therapy individualization such as age, renal function and bodyweight. The 
inclusion of these traditional clinical variables is essential since drug response is a complex 
trait and individuals belonging to the same “pharmacogenetic class” sometimes still vary 
about 10-fold in metabolic ratio. Therefore pharmacogenetics alone can not explain all 
interindividual differences in drug response. The progress from individual polymorphisms 
to pharmacogenetic models is well exemplified by the coumarin warfarin. This drug is 
metabolized by the polymorphic enzyme CYP2C9. The CYP2C9 genotype by itself 
explained 5–18% of the variation in required warfarin dose [47]. It was already reported 
that genetic variability in VKORC1, a gene coding for vitamine K epoxide reductase, a 
key enzyme in the vitamine K cycle, could explain 15–37% of the variation in required 
warfarin dose [19,48-50]. Recently, dosing algorithms including genetic variants of 
VKORC1, CYP2C9 and clinical factors such as age, sex, height and bodyweight have 
been reported to explain up to 50% of variation in required warfarin dose [51]. Currently, 
such dosing algorithms are under development for acenocoumarol and phenprocoumon, 
the coumarins used in The Netherlands [52].
A second development is the application of pharmacogenetic knowledge to idiosyncratic 
drug reactions [17]. Multiple relatively rare adverse drug events such as flucloxacilline 
induced liver injury [43], Stevens-Johnson syndrome induced by carbamazepine [53,54], 
and the hypersensitivity reaction to abacavir have all been associated with specific HLA-B 
genotypes. For the latter, a prospective study showed that the hypersensitivity reaction 
can be prevented by screening patients prior to treatment with abacavir [22].
A third development is the availability of guidelines that link the result of a pharmacogenetic 
test to specific dose recommendations. No matter what level of evidence is required for 
implementation of pharmacogenetics in clinical practice, it will be essential to develop 
algorithms that aid physicians in their interpretation and use of pharmacogenetic data. 
In 2001, an early step was taken to develop such guidelines for the therapeutic use of 
antidepressants, and these included CYP2D6-related dose recommendations drawn from 
pharmacokinetic study data [55]. In the Netherlands the PWG established in 2005 by 
the Royal Dutch Association for the Advancement of Pharmacy published guidelines 
concerning 53 drugs and 11 genes [44]. In 2009, an international initiative to create 
pharmacogenetic guidelines was launched: the Clinical Pharmacogenetics Implementation 
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Consortium [45]. Recently CPIC published its first guideline that is publicly available 
in the Pharmacogenomics Knowledge Base [34,46]. There is an increasing call for 
new pharmacogenetic guidelines [56]. In addition to guidelines created by these 
consortia regulatory authorities such as the FDA and EMA are increasingly including 
pharmacogenetic information in drug labels. The FDA has a special genomics group that 
created a table of valid genomic biomarkers in the context of approved drug labels [57]. 
The table contains entries for over 20 drugs.
A fourth development is that genetic variation that has previously been associated with 
gene-drug interactions is increasingly being associated with disease and vice versa. This can 
be exemplified by the recently reported association between CYP2C19 poor metabolizer 
status and significantly lower levels of depressive symptoms [58]. A second example is the 
reported association of CYP2D6 ultrarapid metabolism with suicidal behavior [59,60]. 
An example of disease associated alleles with treatment outcome is provided in Chapter 8. 
In this chapter it is found that T2DM patients with a higher number of T2DM associated 
risk alleles also have an increased risk of non-response to treatment with sulfonylureas. 
A fifth development is the integration of gene–drug and drug–drug interactions. To date, 
drug–drug interactions have been considered characteristic only for the drugs involved. 
However, in the light of current knowledge of pharmacogenetics, this might no longer be 
valid. For example, the interaction between a CYP2D6 inhibitor and a CYP2D6 substrate 
requires different management for CYP2D6 IMs than for CYP2D6 PMs. Therefore, the 
combination of gene–drug and drug–drug interactions may have major implications for 
drug prescribing and dispensing. Research in this field is only starting to evolve [61].
A sixth development is the significant technological advancement and associated price 
drops of genotyping cost. Figure 9.1.2 shows the development of the cost of sequencing 
a single genome. The sudden price drop at the beginning of 2008 represents the time 
when the sequencing centers transitioned from Sanger-based to ‘next-generation’ 
DNA sequencing technologies [62]. With a strong market-based competition and new 
approaches under development prices may even drop further to as low as a few hundred 
Euros within the next decade, bringing it close to the price of computed tomography 
and magnetic resonance imaging [63].
As a result of these developments, I foresee that pharmacogenetics will increasingly set 
foot inside routine clinical practice in the next 10 years. Dosing algorithms, including 
pharmacogenetics combined with traditional clinical variables will increasingly be 
developed. At first, most pharmacogenetic test will be applied to specific patient 
populations were stakes are high, such as transplantation patients or cancer patients but 
over time a wider clinical adoption will initiate. Over time, information concerning the 
genetic status of a patient will increasingly be considered a regular clinical parameter 
like renal function and body mass index. The main driver for this development is 
174
the plummeting price of genotyping (Figure 9.1.2). The significant price drop will 
probably also limit the issue of cost-effectiveness since test costs are the major part of 
pharmacogenetics costs, and stimulate an increasing number of patients to purchase a 
direct-to-consumer genomewide profiling test. Although currently potential effects of 
this type of genetic testing are unknown [64], as a result clinicians may be increasingly 
confronted with patients with a known genotype. The increasing number of patients with 
a known genotype raises important issues and eliminates others. 
First of all, the increasing preemptive availability of a patient’s genotype will eliminate 
the hurdles associates with test logistics. A major issue that will remain is the 
discussion concerning the required evidence base for initial clinical implementation 
of pharmacogenetics. Some argue that pharmacogenetic interventions should not 
be implemented until they are proven superior over the existing standard of care by 
randomized clinical trials (RCTs) [65]. However, RCTs are very expensive and should 
be reserved for the most important medical interventions e.g. in the case of large public 
health burden. Many useful clinical applications of pharmacogenetics may never justify 
a RCT since the potential benefits of the test are simply too small. For example, the 
5-hydroxytryptamine 3 receptor antagonists used to prevent nausea and vomiting are 
known to be metabolized by CYP2D6. As a result, CYP2D6 UM may be undertreated 
with a standard drug dose. However, the patient’s clinician can easily increase the drug 
dose or switch to a different anti-emetic therapy in response of nausea. In this kind of 
situations, other levels of evidence such as one or two confirmatory studies reproducing 
evidence from the initial exploratory study combined with a strong biological rationale 
for a gene-drug interaction may be sufficient to justify clinical implementation of 
pharmacogenetic testing. A lower level of evidence may also be justified in situations 
where the genotype of a patient is already known. For example, if a patient has been 
previously genotyped and is reported to be a CYP2D6 PM should this patient be treated 
with the standard dose of haloperidol, a CYP2D6 substrate? There are multiple studies 
reporting lower dose requirements for CYP2D6 PMs [66-71]. Yet, no RCT has been 
published. Also there seems to be a different perception of the required evidence for 
clinical implementation of pharmacogenetic information compared to other, nongenetic 
clinically relevant information [56]. For example, the selective estrogen receptor modulator 
tamoxifen used for the treatment of estrogen receptor-positive breast cancer needs to be 
metabolically activated by CYP2D6 to its active component endoxifen that is 100 times 
more potent than the parent compound [72]. Both genetic variation resulting in reduced 
CYP2D6 activity and concomitant drugs that inhibit CYP2D6 activity are expected to 
result in a lower endoxifen concentration and consequent reduction in tamoxifen efficacy. 
Yet, it is generally accepted to avoid the use of strong CYP2D6 inhibitors (e.g. selective 
serotonin inhibitors) in patients treated with tamoxifen whilst there is no such acceptation 
regarding genotyping for CYP2D6.
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A second major issue is to what extent genomic diversity can explain variability in 
drug response. To date, many pharmacogeneticists have focused mainly on single 
polymorphisms ignoring the combined effect of multiple polymorphisms and even 
more importantly the effect of epigenomics on drug response. In the near future whole 
genome sequencing will become increasingly available. Also microRNAs (miRNAs), short 
noncoding RNAs that negatively regulate the expression of target genes, may become 
increasingly important. Differences in miRNA expression could be an important factor 
contributing to variability in drug response and utilizing them opens a new era in the 
field of predicting drug response that that we will begin to explore [73-75]. 
Successfully bridging the gap from research to bedside seems within reach in the field of 
pharmacogenetics. In many cases, the risks associated with pharmacogenetics are limited 
whilst potential benefits are substantial. Challenges remain, but we should expect routine 
pharmacogenetic tests entering the process of drug prescribing and dispensing within 
the next decade.
REFERENCES
1.  European Medicines Agency. EMA definition ICH 
Topic E15 Definitions for genomic biomarkers, 
pharmacogenomics, pharmacogenetics, genomic 
data and sample coding categories. <http://www.
ema.europa.eu/docs/en_GB/document_library/
Scientific_guideline/2009/09/WC500002880.
pdf > Accessed May 24 2011.
2.  Collins FS, McKusick VA. Implications of the 
Human Genome Project for medical science. 
JAMA 2001;285(5):540-544.
3.  Meyer UA. Pharmacogenetics - five decades of 
therapeutic lessons from genetic diversity. Nat 
Rev Genet 2004;5(9):669-676.
4.  Evans WE, McLeod HL. Pharmacogenomics--
drug disposition, drug targets, and side effects. 
N Engl J Med 2003;348(6):538-549.
5.  Evans WE, Relling MV. Pharmacogenomics: 
translating functional genomics into rational 
therapeutics. Science 1999;286(5439):487-491.
6.  Schenk PW, van Fessem MA, Verploegh-Van 
Rij S et al. Association of graded allele-specific 
changes in CYP2D6 function with imipramine 
dose requirement in a large group of depressed 
patients. Mol Psychiatry 2008;13(6):597-605.
7.  Mega JL, Close SL, Wiviott SD et al. Cyto-
chrome p-450 polymorphisms and response to 
clopidogrel. N Engl J Med 2009;360(4):354-
362.
8.  Collet JP, Hulot JS, Pena A et al. Cytochrome P450 
2C19 polymorphism in young patients treated 
with clopidogrel after myocardial infarction: a 
cohort study. Lancet 2009;373(9660):309-317.
9.  Simon T, Verstuyft C, Mary-Krause M et al. 
Genetic determinants of response to clopidogrel 
and cardiovascular events. N Engl J Med 2009; 
360(4):363-375.
10.  Shuldiner AR, O’Connell JR, Bliden KP et al. 
Association of cytochrome P450 2C19 genotype 
with the antiplatelet effect and clinical efficacy 
of clopidogrel therapy. JAMA 2009;302(8):849-
857.
11.  Sibbing D, Koch W, Gebhard D et al. Cytochrome 
2C19*17 allelic variant, platelet aggregation, 
bleeding events, and stent thrombosis in 
clopidogrel-treated patients with coronary stent 
placement. Circulation 2010;121(4):512-518.
12.  University of California San Francisco-US Food 
and Drug Administration Transportal <http://
bts.ucsf.edu/fdatransportal> Accessed 01 June 
2011.
176
13.  Zolk O, Fromm MF. Transporter-mediated drug 
uptake and efflux: important determinants of 
adverse drug reactions. Clin Pharmacol Ther 
2011;89(6):798-805.
14.  Yee SW, Chen L, Giacomini KM. Pharmacog-
enomics of membrane transporters: past, present 
and future. Pharmacogenomics 2010;11(4):475-
479.
15.  Slamon DJ, Clark GM, Wong SG, Levin 
WJ, Ullrich A, McGuire WL. Human breast 
cancer: correlation of relapse and survival with 
amplification of the HER-2/neu oncogene. 
Science 1987;235(4785):177-182.
16.  Rieder MJ, Reiner AP, Gage BF et al. Effect 
of VKORC1 haplotypes on transcriptional 
regulation and warfarin dose. N Engl J Med 
2005;352(22):2285-2293.
17.  Pirmohamed M. Pharmacogenetics of idiosyn-
cratic adverse drug reactions. Handb Exp Phar-
macol 2010;(196):477-491.
18.  Pirmohamed M, Aithal GP, Behr E, Daly A, 
Roden D. The phenotype standardization 
project: improving pharmacogenetic studies of 
serious adverse drug reactions. Clin Pharmacol 
Ther 2011;89(6):784-785.
19.  Garrod AE. Inborn errors of metabolism. Oxford 
Univ. Press London, UK; 1909.
20.  Kalow W, Maykut MO. The interaction between 
cholinesterases and a series of local anesthetics. 
J Pharmacol Exp Ther 1956;116(4):418-432.
21.  Mahgoub A, Idle JR, Dring LG, Lancaster 
R, Smith RL. Polymorphic hydroxylation of 
Debrisoquine in man. Lancet 1977;2(8038):584-
586.
22.  Mallal S, Phillips E, Carosi G et al. HLA-B*5701 
screening for hypersensitivity to abacavir. N Engl 
J Med 2008;358(6):568-579.
23.  Lander ES, Linton LM, Birren B et al. Initial 
sequencing and analysis of the human genome. 
Nature 2001;409(6822):860-921.
24.  Finishing the euchromatic sequence of the hu-
man genome. Nature 2004;431(7011):931-
945.
25.  PubMed. < http://www.ncbi.nlm.nih.gov/
pubmed/> Accessed 15 March 2011.
26.  Swen JJ, Huizinga TW, Gelderblom H et al. 
Translating pharmacogenomics: challenges on 
the road to the clinic. PLoS Med 2007;4(8):e209.
27.  Manolio TA, Collins FS, Cox NJ et al. Finding 
the missing heritability of complex diseases. 
Nature 2009;461(7265):747-753.
28.  National Human Genome Research Institute 
GWAS catalog <http://www.genome gov/
GWAStudies/> Accessed 21 June 2011.
29.  McCarthy MI, Abecasis GR, Cardon LR et al. 
Genome-wide association studies for complex 
traits: consensus, uncertainty and challenges. 
Nat Rev Genet 2008;9(5):356-369.
30.  Billings LK, Florez JC. The genetics of type 2 
diabetes: what have we learned from GWAS? 
Ann N Y Acad Sci 2010;1212:59-77.
31.  Daly AK. Genome-wide association studies in 
pharmacogenomics. Nat Rev Genet 2010;11(4): 
241-246.
32.  Zhou K, Bellenguez C, Spencer CC et al. 
Common variants near ATM are associated 
with glycemic response to metformin in type 2 
diabetes. Nat Genet 2011;43(2):117-120.
33.  Crowley JJ, Sullivan PF, McLeod HL. 
Pharmacogenomic genome-wide association 
studies: lessons learned thus far. Pharmacogenomics 
2009;10(2):161-163.
34.  The Pharmacogenomics Knowledge Base. 
<http://www.pharmgkb.org/>
35.  Peters EJ, McLeod HL. Ability of whole-
genome SNP arrays to capture ‘must have’ 
pharmacogenomic variants. Pharmacogenomics 
2008;9(11):1573-1577.
36.  Check HE. Genome sequencing: the third 
generation. Nature 2009;457(7231):768-769.
37.  Vegter S, Boersma C, Rozenbaum M, Wilffert 
B, Navis G, Postma MJ. Pharmacoeconomic 
evaluations of pharmacogenetic and genomic 
screening programmes: a systematic review 
on content and adherence to guidelines. 
Pharmacoeconomics 2008;26(7):569-587.
38.  Gurwitz D. Pharmacogenetics education: 10 
years of experience at Tel Aviv University. 
Pharmacogenomics 2010;11(5):647-649.
39.  Hopkins MM, Ibarreta D, Gaisser S et al. Putting 
pharmacogenetics into practice. Nat Biotechnol 
2006;24(4):403-410.
1779.1 discussion on translating pharmacogenetics
40.  Van Kuilenburg AB, Haasjes J, Richel DJ et 
al. Clinical implications of dihydropyrimidine 
dehydrogenase (DPD) deficiency in patients 
with severe 5-fluorouracil-associated toxicity: 
identification of new mutations in the DPD 
gene. Clin Cancer Res 2000;6(12):4705-4712.
41.  Home Page of the Human Cytochrome P450 
(CYP) Allele Nomenclature Committee. 
<http://www.cypalleles.ki.se/cyp3a5.htm> 
Accessed 14 June 2011.
42.  Thervet E, Loriot MA, Barbier S et al. 
Optimization of initial tacrolimus dose using 
pharmacogenetic testing. Clin Pharmacol Ther 
2010;87(6):721-726.
43.  Daly AK, Donaldson PT, Bhatnagar P et al. 
HLA-B*5701 genotype is a major determinant 
of drug-induced liver injury due to flucloxacillin. 
Nat Genet 2009;41(7):816-819.
44.  Swen JJ, Nijenhuis M, de Boer A et al. Pharmaco-
genetics: from bench to byte- an update of guide-
lines. Clin Pharmacol Ther 2011;89(5):662-673.
45.  Relling MV, Klein TE. CPIC: Clinical 
Pharmacogenetics Implementation Consortium 
of the Pharmacogenomics Research Network. 
Clin Pharmacol Ther 2011;89(3):464-467.
46.  Relling MV, Gardner EE, Sandborn WJ et al. 
Clinical Pharmacogenetics Implementation 
Consortium guidelines for thiopurine 
methyltransferase genotype and thiopurine 
dosing. Clin Pharmacol Ther 2011;89(3):387-
391.
47.  Tan GM, Wu E, Lam YY, Yan BP. Role of 
warfarin pharmacogenetic testing in clinical 
practice. Pharmacogenomics 2010;11(3):439-
448.
48.  D’Andrea G, D’Ambrosio RL, Di PP et al. 
A polymorphism in the VKORC1 gene is 
associated with an interindividual variability in 
the dose-anticoagulant effect of warfarin. Blood 
2005;105(2):645-649.
49.  Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, 
Stafford DW. Identification of the gene for 
vitamin K epoxide reductase. Nature 2004; 
427(6974):541-544.
50.  Rost S, Fregin A, Ivaskevicius V et al. Mutations 
in VKORC1 cause warfarin resistance and 
multiple coagulation factor deficiency type 2. 
Nature 2004;427(6974):537-541.
51.  Klein TE, Altman RB, Eriksson N et al. 
Estimation of the warfarin dose with clinical 
and pharmacogenetic data. N Engl J Med 2009; 
360(8):753-764.
52.  van Schie RM, Wadelius MI, Kamali F et 
al. Genotype-guided dosing of coumarin 
derivatives: the European pharmacogenetics of 
anticoagulant therapy (EU-PACT) trial design. 
Pharmacogenomics 2009;10(10):1687-1695.
53.  Chung WH, Hung SI, Hong HS et al. Medi-
cal genetics: a marker for Stevens-Johnson syn-
drome. Nature 2004;428(6982):486.
54.  McCormack M, Alfirevic A, Bourgeois S et 
al. HLA-A*3101 and carbamazepine-induced 
hypersensitivity reactions in Europeans. N Engl 
J Med 2011;364(12):1134-1143.
55.  Kirchheiner J, Brosen K, Dahl ML et al. 
CYP2D6 and CYP2C19 genotype-based dose 
recommendations for antidepressants: a first 
step towards subpopulation-specific dosages. 
Acta Psychiatr Scand 2001;104(3):173-192.
56.  Amstutz U, Carleton BC. Pharmacogenetic 
testing: time for clinical practice guidelines. Clin 
Pharmacol Ther 2011;89(6):924-927.
57.  US Food and Drug Administration. Table of 
Valid Genomic Biomarkers in the Context of 




58.  Sim SC, Nordin L, Andersson TM et al. 
Association between CYP2C19 polymorphism 
and depressive symptoms. Am J Med Genet B 
Neuropsychiatr Genet 2010;153B(6):1160-1166.
59.  Zackrisson AL, Lindblom B, Ahlner J. High 
frequency of occurrence of CYP2D6 gene 
duplication/multiduplication indicating 
ultrarapid metabolism among suicide cases. Clin 
Pharmacol Ther 2010;88(3):354-359.
60.  Stingl JC, Viviani R. CYP2D6 in the brain: 
impact on suicidality. Clin Pharmacol Ther 2011; 
89(3):352-353.
61.  Vormfelde SV, Brockmoller J, Bauer S et al. 
Relative impact of genotype and enzyme 
induction on the metabolic capacity of CYP2C9 
in healthy volunteers. Clin Pharmacol Ther 
2009;86(1):54-61.
62.  Metzker ML. Sequencing technologies - the next 
generation. Nat Rev Genet 2010;11(1):31-46.
178
63.  Lander ES. Initial impact of the sequencing of the 
human genome. Nature 2011;470(7333):187-
197.
64.  Bloss CS, Schork NJ, Topol EJ. Effect of direct-
to-consumer genomewide profiling to assess 
disease risk. N Engl J Med 2011;364(6):524-
534.
65.  Altman RB. Pharmacogenomics: “noninferiority” 
is sufficient for initial implementation. Clin 
Pharmacol Ther 2011;89(3):348-350.
66.  Brockmoller J, Kirchheiner J, Schmider J et 
al. The impact of the CYP2D6 polymorphism 
on haloperidol pharmacokinetics and on 
the outcome of haloperidol treatment. Clin 
Pharmacol Ther 2002;72(4):438-452.
67.  Panagiotidis G, Arthur HW, Lindh JD, Dahl 
ML, Sjoqvist F. Depot haloperidol treatment in 
outpatients with schizophrenia on monotherapy: 
impact of CYP2D6 polymorphism on 
pharmacokinetics and treatment outcome. Ther 
Drug Monit 2007;29(4):417-422.
68.  Yasui-Furukori N, Kondo T, Suzuki A et al. 
Effect of the CYP2D6 genotype on prolactin 
concentration in schizophrenic patients treated 
with haloperidol. Schizophr Res 2001;52(1-2): 
139-142.
69.  Desai M, Tanus-Santos JE, Li L et al. Pharma-
cokinetics and QT interval pharmacodynam-
ics of oral haloperidol in poor and extensive 
metabolizers of CYP2D6. Pharmacogenomics J 
2003;3(2):105-113.
70.  Llerena A, de la RA, Berecz R, Dorado P. 
Relationship between haloperidol plasma 
concentration, debrisoquine metabolic ratio, 
CYP2D6 and CYP2C9 genotypes in psychiatric 
patients. Pharmacopsychiatry 2004;37(2):69-73.
71.  Llerena A, Dahl ML, Ekqvist B, Bertilsson L. 
Haloperidol disposition is dependent on the 
debrisoquine hydroxylation phenotype: increased 
plasma levels of the reduced metabolite in poor 
metabolizers. Ther Drug Monit 1992;14(3):261-
264.
72.  Jin Y, Desta Z, Stearns V et al. CYP2D6 
genotype, antidepressant use, and tamoxifen 
metabolism during adjuvant breast cancer 
treatment. J Natl Cancer Inst 2005;97(1):30-39.
73.  Rukov JL, Vinther J, Shomron N. Pharmacog-
enomics genes show varying perceptibility to 
microRNA regulation. Pharmacogenet Genomics 
2011;21(5):251-262.
74.  Kacevska M, Ivanov M, Ingelman-Sundberg 
M. Perspectives on epigenetics and its relevance 
to adverse drug reactions. Clin Pharmacol Ther 
2011;89(6):902-907.
75.  Nakajima M, Yokoi T. MicroRNAs from biology 
to future pharmacotherapy: Regulation of cyto-
chrome P450s and nuclear receptors. Pharmacol 
Ther 2011;131(3):330-337.
76.  Cooper GM, Johnson JA, Langaee TY et al. A 
genome-wide scan for common genetic variants 
with a large influence on warfarin maintenance 
dose. Blood 2008;112(4):1022-1027.
77.  Takeuchi F, McGinnis R, Bourgeois S et al. 
A genome-wide association study confirms 
VKORC1, CYP2C9, and CYP4F2 as principal 
genetic determinants of warfarin dose. PLoS 
Genet 2009;5(3):e1000433.
78.  Teichert M, Eijgelsheim M, Rivadeneira F et 
al. A genome-wide association study of aceno-
coumarol maintenance dosage. Hum Mol Genet 
2009;18(19):3758-3768.
79.  Ge D, Fellay J, Thompson AJ et al. Genetic 
variation in IL28B predicts hepatitis C treat-
ment-induced viral clearance. Nature 2009; 
461(7262):399-401.
80.  Suppiah V, Moldovan M, Ahlenstiel G et al. 
IL28B is associated with response to chronic 
hepatitis C interferon-alpha and ribavirin 
therapy. Nat Genet 2009;41(10):1100-1104.
81.  Tanaka Y, Nishida N, Sugiyama M et al. 
Genome-wide association of IL28B with 
response to pegylated interferon-alpha and 
ribavirin therapy for chronic hepatitis C. Nat 
Genet 2009;41(10):1105-1109.
82.  Trevino LR, Shimasaki N, Yang W et al. 
Germline genetic variation in an organic 
anion transporter polypeptide associated with 
methotrexate pharmacokinetics and clinical 
effects. J Clin Oncol 2009;27(35):5972-5978.
83.  Link E, Parish S, Armitage J et al. SLCO1B1 
variants and statin-induced myopathy--a 
genomewide study. N Engl J Med 2008;359(8): 
789-799.
1799.1 discussion on translating pharmacogenetics
180
The Infl uence of 
Genetic Variation




Type 2 diabetes mellitus (T2DM) is a common metabolic disease with an estimated 
prevalence of 171 million in 2000. The incidence of T2DM is increasing at an alarming 
rate and global prevalence estimates are up to 366 million for 2030 [1]. The therapeutic 
treatment of T2DM is aimed at the prevention or delay of long term microvascular and 
macrovascular complications by achieving the best possible glycemic control. For decades, 
sulfonylureas (SUs) have been an important part of treatment with oral antidiabetic drugs. 
Tolbutamide, glibenclamide (glyburide), gliclazide, and glimepiride are the most commonly 
used representatives of this group. These drugs act primarily by promoting pancreatic 
insulin secretion. They close the pancreatic β-cell potassium channels. This causes membrane 
depolarization, which triggers calcium influx and release of intracellular calcium stores, which 
in results in exocytosis of insulin containing vesicles and subsequent insulin release [2]. SUs 
are initiated at a low dose and escalated to the optimal dose with intervals of 2-4 weeks until 
the glycemic target (HbA1c < 7%) is achieved. However, there is significant interpatient 
variability in response to SUs, with approximately 10-20% of the patients experiencing 
primary failure (decrease in fasting glucose level < 1.1 mmol/L) and a similar percentage 
having an above average response (mean reduction HbA1c 1.5-2%) [3-5].
The influence of CYP2C9
Sulfonylureas are extensively metabolized in the liver primarily by CYP2C9 [6]. CYP2C9 
genotype is known to have a significant effect on the pharmacokinetics of SU in healthy 
volunteers [7-12]. In a group of 207 incident sulfonylurea users treated in four university-
affiliated primary care centers we found no statistically significant effect of the CYP2C9*2 
and CYP2C9*3 alleles on the prescribed stable dose or time to stable SU dose (Chapter 
7). However, a trend towards a lower stable dose for carriers of the CYP2C9*3 allele was 
observed in the subgroup of patients treated with glimepiride. There also was no effect 
of the CYP2C9*2 and CYP2C9*3 alleles on decrease in fasting glucose levels for the 
relatively small subgroup of patients with fasting glucose level measurements available. 
Yet most studies on CYP2C9 and SUs in T2DM patients report some significant effect 
(Table 9.2.1). However, in general the reported effect size is small, and due to publication 
bias there might also be more studies with negative results that failed to be published. 
Moreover, results are sometimes not replicated as is exemplified by the two papers of 
Holstein. In their initial 2005 paper [13] they reported a significant overrepresentation 
of carriers of the CYP2C9*3 allele in a sample of 20 T2DM patients submitted to the 
emergency department with a severe hypoglycemia (symptomatic, requiring IV glucose, 
blood glucose measurement < 2.8 mmol/l) but no such finding was found in the 10-year 
follow up study [14]. Genotyping for the CYP2C9*2 and CYP2C9*3 allele currently seems 
to have no clinical implications for dosing of SU in primary care patients with T2DM.
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The influence of genetic risk factors for type 2 diabetes mellitus
Genetic variation in other genes than CYP2C9 might also contribute to interpatient 
variability in SU response. The pathogenesis of T2DM is not yet fully understood. Current 
theories include defects in insulin mediated glucose uptake in muscle, dysregulation of 
the adipocyte as a secretory organ, dysfunction of the pancreatic β-cell, and an impaired 
insulin action in the liver [15]. From 2007 onward an increasing number of genome 
wide association studies reporting associations between genetic variants and the risk for 
the development of T2DM have been published. These studies revealed the complex 
genetic background of T2DM that results in a single phenotypic disease. Probably as 
a consequence of this heterogeneity, interpatient variability of SU response cannot be 
explained by genetic variation in CYP2C9 alone. Compared to pharmacogenetics affecting 
SU pharmacokinetics, variation in genes associated with the pharmacodynamics of SUs 
in T2DM patients has received even less attention. Genetic variants associated with SU 
response have been described for some monogenic forms of diabetes [16-18]. For polygenic 
T2DM, variants in the genes KCNJ11, TCF7L2, ABCC8, IRS1, and NOS1AP have been 
associated with SU response [19-22]. Of these, only the genes KCNJ11 and TCF7L2 
were reported to contribute to an increased risk for T2DM in published GWAS. From 
the genome wide association studies a panel of 20 T2DM associated SNPs comprising 19 
genes appears, that has been replicated in several studies [23-33]. We hypothesized that 
the multiple genetic background of T2DM might influence drug response (Chapter 8). 
Since the majority of the reported T2DM associated SNPs is involved in the process of 
insulin release from the pancreatic β-cells and SUs act by stimulating insulin secretion we 
investigated if response to SU treatment is influenced by the genetic variants. We found 
that patients with more than 17 T2DM risk alleles had a 1.7-fold reduced likelihood to 
achieve stable SU dose. These patients also show a marginally significant increased time 
to achieve stable SU dose compared to carriers of less than 17 risk alleles. However, the 
number of T2DM risk alleles does not seem to affect the prescribed average stable SU 
dose. Therefore, our data suggest that patients with a higher number of T2DM risk alleles 
have a decreased and delayed response to SU treatment.
CONCLUSIONS AND IMPLICATIONS FOR FUTURE RESEARCH
Progression in the field of SU pharmacogenetic has been slow but significant. Our finding 
that patients with a higher number of T2DM risk alleles show a different response to SUs 
provides some “proof of principle” that the complex background of T2DM may ultimately 
result in the identification of different genetic subgroups of T2DM patients that require 
different pharmacotherapy. Yet we are only on the beginning of the understanding of 
what genetic variation determines response to SU and numerous challenges for future 
research remain. For example, the significant technological advancement in genotyping 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































and associated price drop has permitted genome wide association studies. Within the field 
of diabetes, the GWAS technique has been mainly used to focus at disease but recently the 
first GWAS for glycemic response to metformin was reported. Since GWAS is hypothesis 
generating and does not rely on prior knowledge about underlying mechanisms these 
studies are bound to unravel new mechanisms in drug action. Indeed, the study reported 
an association between a SNP not previously associated with response to metformin 
[34]. Unfortunately this SNP only explained 2.5% of the variance in metformin response 
limiting its utility for treatment decisions. A comparable low explanatory value was found 
in our risk allele model (4.2%, Chapter 8, Table 8.3). This highlights a major issue 
that can be anticipated in SU pharmacogenetics; effect sizes of individual SNPs will be 
modest to small. In order to identify common SNPs with small to modest effect sizes, 
large cohorts with well characterized patients and outcome measures will be required. 
This presents a significant challenge since to date most SU pharmacogenetic studies have 
been of limited sample size. Once SNPs that predict response have been identified from 
GWAS, underlying pharmacological pathways explaining the observed effects will have 
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In many patients drugs do not show the expected efficacy, whereas in other patients 
they cause toxic effects, sometimes even at low dose. Response rates to major classes of 
drugs range from 25 to 60 percent. For some patients, the reason for this variability may 
be explained by genetic variation. Pharmacogenetics is the study of variations in DNA 
sequence as related to drug response. The ultimate goal of pharmacogenetics is to predict 
and thereby improve drug response in the individual patient. The concept of interindividual 
differences in drug response was proposed as early as 1909. With the completion of 
the Human Genome Project in 2003 hope was raised that pharmacogenetics could be 
implemented in clinical practice in the near future. However, the expectations of the effect 
of a single nucleotide polymorphism (SNP) on drug response were unrealistically high and 
the clinical use of pharmacogenetic testing remained limited. Yet, the body of evidence 
supporting its usefulness is growing continuously. The research presented in this thesis 
aims to identify the reasons for the slow clinical translation of pharmacogenetics and to 
explore and expand possible solutions to address these obstacles. The thesis is divided 
into four parts. First, obstacles and possible solutions for the clinical implementation of 
pharmacogenetics are identified. In the second part, issues related to the quality control of 
pharmacogenetic testing are discussed. In the third part, the influence of genetic variation 
on the response to sulfonylureas (SUs), a class of commonly used oral antidiabetic drugs, 
is used as a case model to investigate the possibilities for pharmacogenetics in primary 
care. The fourth part contains the general discussion and a future outlook.
Clinical implementation of pharmacogenetics in primary care
In Chapter 2 six challenges associated with the different phases in the translation process of 
the clinical implementation of pharmacogenetics are identified and solutions to overcome 
these obstacles are discussed. It is concluded that the major reason for the limited clinical 
translation of pharmacogenetics is the relative lack of scientific evidence for improved 
patient care by pharmacogenetic testing. Providing this scientific evidence presents a 
significant challenge. Other challenges for the implementation of pharmacogenetic 
testing include the selection of clinically relevant tests, providing data on diagnostic 
test criteria, providing information on cost-effectiveness and cost-consequences, to 
improve the acceptance among clinicians, and to develop guidelines directing the clinical 
interpretation of test results. The latter is essential since for most pharmacogenetic tests a 
detailed knowledge of pharmacology is a prerequisite for application in clinical practice, 
and both physicians and pharmacists might find it difficult to interpret the clinical value 
of pharmacogenetic test results. Chapter 3 describes the initial development of such 
guidelines by the Dutch Pharmacogenetics Working Group. This multidisciplinary 
working group representing clinical pharmacists, physicians, clinical pharmacologists, 
clinical chemists, epidemiologists, and toxicologists was established in 2005 with 
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the objective to develop guidelines with pharmacogenetics-based therapeutic (dose) 
recommendations. After a systematic literature review that included 26 drugs therapeutic 
(dose) recommendations were composed for 17 drugs. The 26 drugs were substrates for 
CYP2D6 (n = 21), CYP2C19 (n = 1), CYP2C9 (n = 3), and UGT1A1 (n = 1). The 
guidelines do not call for prospective pharmacogenetic testing but are aimed at patients 
with a previously determined genotype. To assist drug prescribers and pharmacists the 
recommendations were included in an extensive electronic drug database (used by most 
computerized systems for drug prescription and automated medication surveillance in The 
Netherlands) since October 2006. In 2011 the number of pharmacogenetic guidelines 
is expanded from the initial 26 to 53 drugs and updates of the existing monographs are 
presented (Table 3.3). Assessed drugs were associated with genes coding for CYP2D6 (n 
= 25), CYP2C19 (n = 11), CYP2C9 (n = 7), thiopurine-S-methyltransferase (TPMT) 
(n = 3), dihydropyrimidine dehydrogenase (DPD) (n = 3), vitamin K epoxide reductase 
(VKORC1) (n = 2), uridine diphosphate glucuronosyltransferase-1A1 (UGT1A1), 
HLA-B44, HLA-B*5701, CYP3A5, and factor V Leiden (FVL) (all n = 1). Therapeutic 
(dose) recommendations were formulated for 39 (73.6%) of the drugs. In Chapter 4 the 
results of a pilot experiment to investigate the feasibility of pharmacogenetic screening in 
primary care with respect to patient willingness to participate, quality of DNA collection 
with saliva kits, genotyping, and dispensing data retrieved from the pharmacy are 
described. A sample of polypharmacy patients, age > 60 years that used at least one drug 
metabolized by CYP2D6 or CYP2C19 was randomly selected. DNA was collected with 
saliva kits and genotyped for CYP2D6 and CYP2C19 with the AmpliChip. Out of the 
93 invited patients, 54 patients (58.1%) provided informed consent. Nine saliva samples 
(16.7%) contained too little DNA. Call rates for CYP2D6 and CYP2C19 were 93.3% and 
100% respectively. The frequencies of genotype-predicted-phenotype were 2.4%, 38.1%, 
54.8%, and 4.8% for CYP2D6 poor-metabolizers (PM), intermediate-metabolizers 
(IM), extensive-metabolizers (EM), and ultrarapid-metabolizers (UM) respectively. For 
CYP2C19 genotype-predicted-phenotype frequencies were 2.2%, 15.6%, and 82.2% 
for PM, IM, and EM, respectively. From this study it is concluded that pharmacogenetic 
screening is feasible with regards to practical aspects and has potential clinical relevance 
for a primary care setting. 
Quality control of pharmacogenetic testing 
The application of pharmacogenetics in clinical practice may result in the adjustment of 
treatment of individual patients. Therefore, genotyping of patients in a routine clinical 
setting requires robust and reliable genotyping methods and good quality control is 
of great importance. In Chapter 5 we surveyed the use of quality control samples in 
pharmacogenetic studies published from 2005 to 2007 in the two most prominent 
pharmacogenetic journals. We found that 86% of papers in which samples were genotyped 
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did not use or define quality controls. Most studies duplicated 5–10% of the samples as 
a quality control. This may serve as an internal control, but can not be regarded as an 
independent quality control sample to assure the validity of the pharmacogenetic test. To 
develop standardized quality controls, we cloned TPMT*2,*3B/C; CYP2D6*3, *4, *6, 
*9, *41; CYP2C9*2, *3; and CYP2C19*2, *3 in plasmids. These plasmids can be used 
for different pharmacogenetic assays and enable pharmacogeneticists to use standardized 
genotype controls for diagnostic testing. 
A second quality related issue of importance for pharmacogenetics is the exclusion of 
SNPs because of poor genotyping. During one of our studies we experienced problems 
with genotyping rs757210, a SNP in the gene coding for hepatocyte nuclear factor 1β. 
Genotyping this SNP with a TaqMan assay failed to meet the pre-defined quality criteria of 
a call rate ≥ 95%. A literature search revealed that several studies reported similar problems 
in genotyping rs757210. In Chapter 6, the development of two alternative methods to 
genotype rs757210 is described. First we developed a pyrosequencing method, and since 
this methodology is not always available, also the feasibility of a high resolution melting 
method of small amplicons was investigated. The methods were tested in panels of type 
2 diabetes mellitus patients (n=258) and healthy blood donors (n = 183). Results were 
confirmed by Sanger sequencing. Results for pyrosequencing and high resolution melting 
were in 99.6% concordance. 
The influence of genetic variation on the response to sulfonylureas
The third part of this thesis is dedicated to the investigation of the influence of genetic 
variation on the response to SUs. SUs are part of the mainstay of treatment of type 2 
diabetes mellitus (T2DM) with oral antidiabetic drugs. We selected SU treatment as a 
case model to investigate the potential role of pharmacogenetics because most T2DM 
patients are treated in primary care. Secondly, there is significant interpatient variability 
in response to SUs, with approximately 10–20% of the patients experiencing primary 
failure. Thirdly, SUs are metabolized by the polymorphic enzyme CYP2C9 and this enzyme 
also plays an important role in the metabolism of many other drugs frequently used in 
primary care. Two allelic variants, CYP2C9*2 and CYP2C9*3, have been associated with 
a decreased metabolic capacity and elevated sulfonylurea serum levels in pharmacokinetic 
analyses performed in healthy individuals. In Chapter 7 we investigated the effect of the 
CYP2C9*2 and CYP2C9*3 alleles on prescribed SU dose and time-to-stable SU dose. A 
group of 207 incident sulfonylurea users treated in four university affiliated primary care 
centers was identified. No significant effects of the CYP2C9*2 and CYP2C9*3 alleles 
were found. However, a trend towards a lower stable glimepiride dose for carriers of the 
CYP2C9*3 allele was observed. We concluded that genotyping for the CYP2C9*2 and 
CYP2C9*3 alleles currently appears to have no clinical implications for dosing of SUs 
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in primary care patients with T2DM. In our search for genetic variation that might help 
to explain the interpatient variability in response to SUs we then hypothesized that a 
panel of 20 associated T2DM risk alleles might influence response to SU treatment. The 
rationale for this hypothesis was that the majority of the panel of T2DM risk associated 
SNPs is involved in the process of insulin release from the pancreatic beta-cells. Two SNPs, 
in the genes KCNJ11 and TCF7L2 had previously been correlated with variation in SU 
response. Furthermore, in subjects analyzed for genetic variation in the genes TCF7L2, 
PPARG, FTO, KCNJ11, NOTCH2, WFS1, CDKAL1, IGF2BP2, SLC30A8, JAZF1, and 
HHEX, it was reported that subjects with 12 or more T2DM risk alleles did not increase 
their insulin secretion to compensate for the increased insulin resistance as efficiently as 
those with 8 or less risk alleles. In Chapter 8 we analyzed the effect of the panel of 20 
repeatedly associated T2DM risk alleles on the response to SU treatment in 207 T2DM 
patients of the cohort described in Chapter 7. For each patient a genetic risk score was 
calculated based on the number of risk-alleles. With this score, patients were categorized 
into three predefined genetic risk groups. The effect of the genetic risk group on the 
achievement of stable SU dose, prescribed stable SU dose, and time to stable SU dose was 
analyzed. Patients with more than 17 T2DM risk alleles had a 1.7-fold reduced likelihood 
to achieve stable SU dose (p = 0.044). No significant effect of the number of T2DM 
risk alleles on prescribed dose was found. The patients with more than 17 T2DM risk 
alleles showed a marginally significant increased time to stable dose (hazard ratio: 0.81; 
95% confidence interval, 0.75–1.01, p = 0.058). We concluded that T2DM risk alleles 
are associated with response to SUs in primary care T2DM patients. This suggests that 
individualization of T2DM treatment according to genetic profile may be an opportunity 
to improve clinical outcome.
General discussion
In Chapter 9 the results presented in this thesis are discussed and a future perspective of 
the implementation of pharmacogenetics in clinical practice is outlined. Chapter 9.1 first 
discusses the translation of pharmacogenetics from concept to clinic. In the upcoming 
years, we foresee six important developments. First, dosing algorithms that include 
pharmacogenetic as well as more traditional clinical variables such as age, renal function 
and bodyweight will be developed. Secondly, pharmacogenetics will increasingly be applied 
to prevent idiosyncratic drug reactions such as the hypersensitivity reaction to abacavir. 
Thirdly, we will see a sharp increase in the number of available pharmacogenetic guidelines 
created by groups such as the Dutch Pharmacogenetics Working Group or the USA Clinical 
Pharmacogenetics Implementation Consortium. In addition, regulatory authorities such 
as the EMA and FDA will increasingly include pharmacogenetic information in drug 
labels. Fourthly, genetic variation that has previously been associated with disease will 
increasingly be associated with gene-drug interactions and vice versa. Fifthly, we will 
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see the beginning of the integration of gene–drug and drug–drug interactions. A sixth 
and final development will be the significant technological advancement and associated 
price drops of genotyping cost. As a result of these developments, pharmacogenetics will 
increasingly set foot inside routine clinical practice in the next 10 years. A major issue will 
be the required evidence base for initial clinical implementation of pharmacogenetics e.g. 
is a RCT required for each gene-drug interaction prior to clinical implementation? In some 
situations, other levels of evidence such as one or two confirmatory studies reproducing 
evidence from the initial exploratory study combined with a strong biological rationale 
for a gene-drug interaction may be sufficient to justify initial clinical implementation of 
pharmacogenetic testing. A second major issue is to what extent genomic diversity can 
explain variability in drug response. Pharmacoepigenomics might open a new era in the 
field of predicting drug response. 
In Chapter 9.2 the results from the two SU studies are discussed and a future outlook 
is presented. The finding that patients with a higher number of T2DM risk alleles 
show a different response to SUs provides some “proof of principle” that the complex 
background of T2DM may ultimately result in the identification of different genetic 
subgroups of T2DM patients that require different pharmacotherapy. Yet we are only 
on the beginning of the understanding of what genetic variation determines response 
to SUs and numerous challenges for future research remain. A major issue that can be 
anticipated in SU pharmacogenetics is that effect sizes of individual SNPs will be modest 
to small. In order to identify common SNPs with small to modest effect sizes, large 
cohorts with well characterized patients and outcome measures will be required. This 
presents a significant challenge since to date most SU pharmacogenetic studies have been 
of limited sample size. Once SNPs that predict response have been identified, underlying 
pharmacological pathways explaining the observed effects will have to be elucidated and 




De reactie op een geneesmiddel kan sterk verschillen tussen patiënten. Zo is wel gesuggereerd 
dat het percentage patiënten dat goed reageert op een behandeling met een geneesmiddel 
varieert van 25 tot 60 procent. Farmacogenetica onderzoekt in welke mate verschillen 
in het genetisch profiel van mensen een verklaring vormen voor de interindividuele 
verschillen in effectiviteit en bijwerkingen van geneesmiddelen. Het uiteindelijke doel van 
farmacogenetisch onderzoek is om te komen tot een geneesmiddelentherapie op maat 
voor de individuele patiënt. 
De gedachte dat de verschillen in de reactie op een geneesmiddel tussen mensen erfelijk 
kunnen zijn is voor het eerst beschreven in 1909. In 2003 werd het internationale 
humane genoomproject voltooid, waarbij voor het eerst de sequentie van het DNA 
tot in detail in kaart werd gebracht. Na de voltooiing van het humane genoomproject 
werd farmacogentica door velen gezien als een van de eerste praktische toepassingen die 
uit dit project zou voortvloeien. Deze ontwikkeling is echter veel minder snel gegaan 
dan verwacht. De mate waarin één kleine verandering in het DNA (SNP) in staat was 
om de reactie op een geneesmiddel te verklaren, bleek kleiner dan verwacht. Voor veel 
behandelaren is farmacogenetica (nog) geen routinematig toegepaste methode om 
farmacotherapie te individualiseren. Toch neemt het beschikbare wetenschappelijke 
bewijs voor toepassing van farmacogenetica dagelijks toe. Dit proefschrift, getiteld ‘Het 
toepasbaar maken van farmacogenetica in de eerstelijnsgezondheidszorg’, heeft als doel 
om de oorzaken voor de beperkte toepassing van farmacogenetica in kaart te brengen en 
om mogelijke oplossingen om deze oorzaken weg te nemen te verkennen. Het proefschrift 
bestaat uit vier delen. Het eerste deel bestaat uit een analyse van de mogelijke oorzaken 
voor de beperkte toepassing van farmacogenetica en draagt mogelijke oplossingen 
aan om de toepassing te verbeteren. Het tweede deel beschrijft onderzoek naar de 
kwaliteitsborging van farmacogenetische testen. Het derde deel beschrijft onderzoek 
naar de toepassingsmogelijkheden van farmacogenetica in de eerstelijnsgezondheidszorg, 
waarbij het effect van farmacogenetica op de respons op de behandeling van type 2 
diabetes met sulfonylureumderivaten als een model wordt gebruikt. Het vierde deel 
bevat een discussie van het in dit proefschrift beschreven werk en een beschouwing van 
toekomstige ontwikkelingen.
Farmacogenetica: van concept naar klinische praktijk
In hoofdstuk 2 worden zes barrières en bijbehorende oplossingen voor de klinische 
toepassing van farmacogenetica in kaart gebracht. De belangrijkste barrière is het beperkte 
wetenschappelijke bewijs dat het toepassen van farmacogenetica ook daadwerkelijk leidt 
tot een verbeterde behandeluitkomst voor de patiënt. Andere barrières zijn de selectie 
van klinisch relevante testen, het ontbreken van gegevens over de diagnostische waarde 
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van farmacogenetische testen, het ontbreken van studies naar de kosteneffectiviteit, 
het gebrek aan kennis van en scholing over farmacogenetica onder artsen, apothekers 
en patiënten, en het ontbreken van richtlijnen die helpen bij de interpretatie van een 
farmacogenetische test. Het ontwikkelen van dergelijke richtlijnen is essentieel omdat 
voor die interpretatie vaak gedetailleerde kennis van het werkingsmechanisme van 
geneesmiddelen nodig is. Hoofdstuk 3 beschrijft de ontwikkeling van dergelijke 
richtlijnen door de farmacogeneticawerkgroep. Deze multidisciplinaire werkgroep is in 
2005 opgericht door het geneesmiddelinformatiecentrum van de Koninklijke Nederlandse 
Maatschappij ter bevordering der Pharmacie met als doelstelling om arts en apotheker te 
helpen bij het in de praktijk toepassen van farmacogenetica. Na literatuuronderzoek werden 
in eerste instantie voor 17 van de 26 onderzochte geneesmiddelen adviezen opgesteld. 
De onderzochte geneesmiddelen waren substraat voor de enzymen CYP2D6 (n = 21), 
CYP2C19 (n = 1), CYP2C9 (n = 3), and UGT1A1 (n = 1). Adviezen bestonden uit 
dosisaanpassing, selectie van een alternatief middel, bloedspiegelbepaling, waarschuwing 
voor bijwerking, etc. De adviezen zijn geen oproep om prospectief te genotyperen, 
maar zijn bedoeld om de kennis van farmacogenetica toe te passen bij patiënten van 
wie het genotype om wat voor reden dan ook bekend is. Sinds oktober 2006 worden 
deze adviezen voor apothekers en voorschrijvers als onderdeel van de G-standaard (een 
elektronische bestand met informatie over geneesmiddelen) verspreid, waardoor deze 
elektronisch beschikbaar zijn tijdens het voorschrijven en bij de medicatiebewaking. In 
2011 werd het aantal richtlijnen uitgebreid van 26 naar 53 geneesmiddelen (Tabel 3.3). 
De onderzochte geneesmiddelen waren substraat voor CYP2D6 (n = 25), CYP2C19 (n 
= 11), CYP2C9 (n = 7), thiopurine-S-methyltransferase (n = 3), dihydropyrimidine 
dehydrogenase (n = 3), vitamin K epoxide reductase (n = 2), uridine diphosphate 
glucuronosyltransferase-1A1, HLA-B44, HLA-B*5701, CYP3A5, en factor V Leiden (allen 
n = 1). Voor 39 (73,6%) van de onderzochte geneesmiddelen werden dosisaanpassingen 
geadviseerd. 
Hoofdstuk 4 beschrijft de resultaten van een pilot-onderzoek naar de uitvoerbaarheid 
van een farmacogenetische screening in de eerste lijn. Hierbij is vooral gekeken naar 
praktische aspecten zoals de bereidwilligheid van patiënten om deel te nemen aan het 
onderzoek, de kwaliteit van het met speekselmonsters verzamelde DNA, kwaliteit van 
het genotyperen en de kwaliteit van de bij de apotheek verzamelde voorschrijfgegevens. 
Voor dit onderzoek werden patiënten van ouder dan 60 jaar die meer dan vijf 
geneesmiddelen gebruikten waarvan er minimaal één door het enzym CYP2D6 of het 
enzym CYP2C19 werd afgebroken geselecteerd. DNA werd verzameld met behulp 
van een speekselmonster. Het genotype voor CYP2D6 en CYP2C19 werd bepaald 
met de AmpliChip. In totaal werden 93 patiënten benaderd met de vraag of ze aan het 
onderzoek deel wilden nemen. Hiervan stemden er 54 (58,1%) in met deelname. Negen 
speekselmonsters bevatten te weinig DNA om het genotype vast te kunnen stellen. 
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Voor de resterende monsters slaagde het genotyperen in 93,3% van de monsters voor 
CYP2D6 en 100% van de monsters voor CYP2C19. Van de gegenotypeerde patiënten 
was 2,4% langzame metaboliseerder (PM), 38,1% had een vertraagd metabolisme 
(IM), 54,8% een normaal metabolisme (EM) en 4,8% was een snelle metaboliseerder 
(UM) voor CYP2D6. Voor CYP2C19 was dit 2,2% PM, 15,6% IM en 82,2% EM. 
Op basis van de resultaten in hoofdstuk 6 wordt geconcludeerd dat farmacogenetische 
screening in de eerste lijn uitvoerbaar is in, en mogelijk klinisch relevant is voor, de 
eerste lijn. 
De kwaliteitsborging van farmacogenetische testen 
Omdat de klinische toepassing van farmacogenetica mogelijk leidt tot aanpassingen aan 
de behandeling met geneesmiddelen van patiënten is het van belang om betrouwbare 
methoden te hebben om het genotype vast te stellen. Hiervoor is het van belang om 
goede kwaliteitscontrolemonsters te hebben. Hoofdstuk 5 beschrijft de resultaten 
van een onderzoek naar het gebruik van kwaliteitscontroles in farmacogenetische 
analysemethoden die waren toegepast in de periode 2005-2007 en gepubliceerd in 
twee toonaangevende farmacogenetische tijdschriften. Uit dit onderzoek bleek dat in 
86% van de onderzochte publicaties geen kwaliteitscontroles werden beschreven. De 
meeste onderzoekers voerden bij 5-10% van de monsters een duplobepaling uit als 
kwaliteitscontrole. Dit is op zich een goede interne controle, maar het is geen vervanging 
van een onafhankelijke kwaliteitscontrole om de validiteit van een farmacogenetische 
analysemethode vast te stellen. Door stukjes DNA met daarin de genetische varianten 
van TPMT*2, *3B/C; CYP2D6*3, *4, *6, *9, *41; CYP2C9*2, *3 en CYP2C19*2, *3 
in een plasmide te plakken is het gelukt om voor deze veel bepaalde genetische varianten 
gestandaardiseerde controles te maken. In hoofdstuk 6 wordt een tweede probleem 
met betrekking tot kwaliteitszorg beschreven, namelijk het uitsluiten van SNP’s in 
de analyse vanwege slechte resultaten van het genotyperen. Tijdens één van de in dit 
proefschrift beschreven onderzoeken ontstonden problemen met het genotyperen van 
rs75210, een SNP in het gen dat codeert voor HNF1β. Met de gebruikte TaqMan-
analyse lukte het niet om van meer dan 95% van de monsters het genotype te bepalen. 
Om dit probleem te verhelpen zijn twee alternatieve bepalingsmethoden ontwikkeld. 
Eerst werd een pyrosequencing-methode ontwikkeld en vervolgens een smeltmethode 
(“high resolution melting”) omdat in veel laboratoria de pyrosequencing-techniek 
niet beschikbaar is. Beide methoden werden getest op DNA van een groep van 258 
type 2 diabetes mellitus-patiënten en een groep van 183 gezonde bloeddonoren. De 
resultaten werden bevestigd met een ‘gouden standaard’-methode van genotyperen 
(Sanger sequencing) en waren in 99,6% van de gevallen gelijk tussen de verschillende 
methoden. 
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Het effect van genetische variatie op de respons op behandeling met sul-
fonyureumderivaten
Het derde deel van dit proefschrift beschrijft het onderzoek naar de invloed van 
genetische variatie op de respons op de behandeling met sulfonylureumderivaten. Deze 
geneesmiddelen worden toegepast bij de behandeling van patiënten met diabetes mellitus 
type 2 (T2DM). De dosering van sulfonylureumderivaten wordt per patiënt vastgesteld. 
Dit gebeurt door middel van dosistitratie waarbij iedere 2-4 weken op geleide van effect 
de dosering wordt opgehoogd. Bij circa 10-20% van de patiënten werkt behandeling met 
sulfonylureumderivaten onvoldoende (daling in nuchter bloedglucose < 1,1 mmol/L) 
en een vergelijkbaar percentage reageert beter dan gemiddeld. Deze behandeling is om 
drie redenen als model gekozen om een mogelijke rol van farmacogenetica in de eerste 
lijn te onderzoeken. Ten eerste worden de meeste T2DM-patiënten in de eerste lijn 
behandeld. Ten tweede vertoont circa 10-20% van de patiënten onvoldoende respons op 
de behandeling met sulfonylureumderivaten. Ten derde worden sulfonylureumderivaten 
afgebroken door het enzym CYP2C9, een enzym dat betrokken is bij het metabolisme 
van veel geneesmiddelen die in de eerste lijn worden toegepast. Van het gen dat codeert 
voor CYP2C9 zijn meer dan 25 variantallelen beschreven. Twee van deze varianten, 
CYP2C9*2 en CYP2C9*3, komen frequent voor in de Kaukasische populatie en coderen 
voor verminderd functioneel enzym. In onderzoek met gezonde vrijwilligers die een 
eenmalige dosis van een sulfonylureumderivaat kregen is aangetoond dat dragerschap 
van het CYP2C9*2 of CYP2C9*3 allel resulteert in een verminderde afbraak en dus een 
hogere blootstelling. Hoofdstuk 7 beschrijft een studie naar het effect van CYP2C9*2 en 
CYP2C9*3 op de hoogte van de voorgeschreven dosis waarop T2DM-patiënten stabiel 
werden ingesteld. Daarnaast werd ook gekeken naar het effect op de benodigde titratietijd 
tot het bereiken van deze stabiele dosis. In totaal werd DNA van 207 T2DM-patiënten 
verzameld. Er werd geen statistisch significant effect van het CYP2C9*2 en/of CYP2C9*3 
allel op de ingestelde dosis of de benodigde titratietijd gevonden. In de subgroep van 
glimepiride (één van de sulfonylureumderivaten) gebruikers werd wel een trend naar 
een lagere dosis voor dragers van een CYP2C9*3 allel waargenomen. Op basis van dit 
onderzoek werd geconcludeerd dat genotyperen voor CYP2C9*2 en CYP2C9*3 op dit 
moment geen meerwaarde heeft voor het doseren van sulfonylureumderivaten in de eerste 
lijn. Sinds 2007 is er door middel van genoombrede associatieonderzoeken steeds meer 
bekend geworden over erfelijke risicofactoren voor het ontwikkelen van T2DM. Uit deze 
onderzoeken komt een set van 20 risico-allelen naar voren die consequent geassocieerd 
zijn met een verhoogd risico op T2DM. De meerderheid van de allelen in deze set is 
geassocieerd met genen die een rol spelen bij de insuline-afgifte door de β-cellen in het 
pancreas. De genen KCNJ11 en TCF7L2 waren in eerdere onderzoeken ook geassocieerd 
met variatie in de respons op sulfonylureumderivaten. Ook was al beschreven dat 
individuen met 12 of meer risico-allelen voor de genen TCF7L2, PPARG, FTO, KCNJ11, 
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NOTCH2, WFS1, CDKAL1, IGF2BP2, SLC30A8, JAZF1 en HHEX minder goed in 
staat waren om hun insuline-afgifte aan te passen aan toenemende insulineresistentie 
in vergelijking met individuen met acht of minder risico-allelen. Deze gegevens leiden 
tot de hypothese dat patiënten met een groter aantal T2DM risico-allelen minder goed 
reageren op de behandeling met een sulfonylureumderivaat. Hoofdstuk 8 beschrijft 
een onderzoek naar het effect van het panel van 20 risico-allelen op de behandeling met 
sulfonylureumderivaten in het cohort van 207 T2DM-patiënten beschreven in hoofdstuk 
7. Per patiënt werd een genetische risicoscore berekend gebaseerd op het aantal T2DM 
risico-allelen. Met deze risicoscore werden patiënten ingedeeld in drie vooraf gedefinieerde 
risicogroepen. Vervolgens werd het effect van de genetische riscogroep op het bereiken 
van een stabiele dosering, de hoogte van de stabiele dosering en de benodigde titratietijd 
onderzocht. Patiënten met meer dan 17 risico-allelen hadden een 1,7 keer kleinere 
kans om stabiel ingesteld te worden op een sulfonylureumderivaat. Ook lijkt voor deze 
patiënten een langere titratietijd nodig, hoewel dit net niet statistisch significant was. 
Het aantal risico-allelen had geen relatie met de hoogte van de stabiele dosis. Op basis 
van deze studie werd geconcludeerd dat allelen die een verhoogd risico op T2DM geven 
ook geassocieerd zijn met de respons op de behandeling met sulfonylureumderivaten. 
Dit suggereert dat in de toekomst mogelijk de behandeling van T2DM kan worden 
verbeterd door rekening te houden met het individuele genetische profiel van de 
patiënt.
Algemene discussie
In hoofdstuk 9 worden de resultaten van het in dit proefschrift beschreven onderzoek 
besproken en wordt een toekomstvisie over de implementatie van farmacogenetica in de 
eerste lijn gepresenteerd. Hoofdstuk 9.1 beschrijft zes belangrijke ontwikkelingen voor 
de implementatie van farmacogenetica in de eerste lijn. De eerste ontwikkeling is dat 
er doseeralgoritmen ontwikkeld gaan worden die naast traditionele klinische variabelen 
zoals leeftijd, nierfunctie en gewicht ook rekening houden met farmacogenetica. De 
tweede ontwikkeling is dat farmacogenetica in toenemende mate zal worden toegepast 
ter verklaring en preventie van geneesmiddelengeïnduceerde bijwerkingen zoals de 
overgevoeligheidsreactie op abacavir. De derde ontwikkeling is een sterke toename van 
het aantal beschikbare richtlijnen voor het interpreteren en toepassen van de resultaten 
van een farmacogenetische test zoals deze ontwikkeld zijn door de Nederlandse 
farmacogeneticawerkgroep en het Amerikaanse Clinical Pharmacogenetics Implementation 
Consortium. Ook zullen registratieautoriteiten zoals de EMA en de FDA in toenemende 
mate informatie over farmacogenetica op laten nemen in de productinformatie van 
geneesmiddelen. Een vierde ontwikkeling is dat genetische variatie die was geassocieerd 
met ziekte zal worden geassocieerd met de respons op geneesmiddeltherapie en vice versa. 
Een vijfde ontwikkeling is het integreren van de kennis van gen–geneesmiddelinteracties 
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met geneesmiddel–geneesmiddelinteracties. Een zesde en laatste ontwikkeling is de 
enorme technologische vooruitgang en de bijbehorende prijsdaling die dit veroorzaakt 
op het gebied van genotyperen.
Het gevolg van deze zes ontwikkelingen is dat farmacogenetische kennis in de komende 10 
jaar steeds vaker klinisch zal worden toegepast. Een van de vraagstukken die beantwoord 
zal moeten worden is welke mate van bewijs nodig is voordat een farmacogenetische test 
klinisch toegepast kan worden. Is bijvoorbeeld altijd een gerandomiseerd dubbelblind 
onderzoek noodzakelijk, of voldoen andere vormen van bewijs? In sommige situaties 
zijn één of twee studies die eerdere resultaten bevestigen in combinatie met een goed 
onderbouwd onderliggend mechanisme voldoende voor klinische implementatie. Een 
tweede belangrijk vraagstuk is in welke mate genetische variatie verschillen in de respons 
op geneesmiddelen kan verklaren. Mogelijk gaat de farmacoepigenetica hier een belangrijke 
rol in spelen.
Hoofdstuk 9.2 bespreekt de resultaten van de twee onderzoeken naar het effect van 
genetische variatie op de respons op een behandeling met sulfonylureumderivaten. De 
bevinding dat patiënten met een groter aantal T2DM risico-allelen een andere respons 
op de behandeling met sulfonylureumderivaten vertonen is een “proof-of-principle” van 
het concept dat de multigenetische oorsprong van T2DM uiteindelijk kan leiden tot het 
identificeren van subgroepen patiënten met T2DM die een andere behandeling nodig 
hebben. Toch staan we nog slechts aan het begin van het ontrafelen van de invloed 
van genetische variatie op de respons op sulfonylureumderivaten. Een belangrijke 
uitdaging is dat de effecten van individuele SNP’s op de variatie in respons waarschijnlijk 
relatief klein zullen zijn. Om zulke effecten te kunnen vinden zijn grote groepen goed 
gedefinieerde patiënten nodig terwijl de meeste studies naar de farmacogenetica van 
sulfonylureumderivaten tot nu toe klein waren. Zodra SNP’s zijn gevonden die respons 
kunnen voorspellen en het onderliggende farmacologische mechanisme is opgehelderd, 
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